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Summary 
 
Buruli ulcer (BU) is a neglected tropical disease of the skin and subcutaneous tissue 
caused by Mycobacterium ulcerans. The disease has been reported from over 30 countries 
with most cases coming from West Africa. While it is commonly accepted that BU is not 
acquired by human-to-human transmission both the environmental reservoir of the 
pathogen and the mode of transmission to humans remain to be identified. Clinically BU 
presents with a wide range of forms which includes non-ulcerative lesions and ulcers with 
undermined edges. Much of the pathology of a M. ulcerans infection is believed to be 
caused by its unique ability to produce the macrolide toxin called mycolactone which 
causes tissue necrosis and local immunosuppression. BU can be diagnosed by microscopy, 
polymerase chain reaction (PCR), culturing and histology, however due to lack of access to 
laboratory facilities, cases are often diagnosed based on clinical symptoms only. 
Historically, BU was treated using wide scale excision, but since 2004 the WHO 
recommends the use of streptomycin and rifampicin daily for 8 weeks to treat the infection. 
In the framework of this PhD thesis we have established a new BU field research 
site in the Mapé Basin of Cameroon and studied various aspects of BU epidemiology, 
differential diagnosis and transmission at this location. As a basis for our research, we 
conducted an exhaustive house-by-house survey for BU, leprosy and yaws in the Bankim 
Health District. Following the survey we closely monitored and studied all BU cases 
detected in the region. By supporting local laboratory diagnosis with real time-PCR (RT-
PCR) and culturing, we were able to identify and describe a case of cutaneous tuberculosis 
which was initially diagnosed as BU. This patient highlighted the importance of further 
support to improve clinical differential diagnosis of BU in remote endemic areas. Eighty-
eight of all the RT-PCR confirmed BU cases identified in the Mapé Basin in the course of 
our research were studied in detail. By mapping the patients’ homes we were able to 
describe the distribution of BU in the area and to identify highly endemic communities. 
Based on the population age data collected in the survey we were also able to compute the 
age adjusted cumulative incidence rate of BU, revealing that children below the age of five 
were underrepresented among cases of BU. By analysing serological responses of patients 
and community members from BU endemic areas in the Mapé Basin and Ghana against an 
immunodominant antigen of M. ulcerans, we have observed a similar late onset of 
seroconversion, indicating that BU transmission intensifies when preschool children start 
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moving further away from home. To identify potential sites of M. ulcerans transmission, 
we screened sites of environmental contact at the homes and farms of laboratory confirmed 
BU patients for the presence of M. ulcerans DNA. In this analysis we identified three RT-
PCR positive permanent village water sites and by studying one of these sites 
longitudinally in great detail we obtained evidence that M. ulcerans can persist in 
underwater detritus. This niche of M. ulcerans may represent an environmental reservoir 
and a source of infection of the pathogen. To further elucidate BU transmission pathways 
we have generated a set of clinical isolates of M. ulcerans from the Mapé Basin for a 
phylogeographic analysis of the distribution of the currently circulating haplotypes of M. 
ulcerans based on whole genome sequencing. By the routine culturing from clinical 
specimens and the evaluation of different transport media and decontamination methods 
we were further able to develop an optimized protocol for the primary isolation of M. 
ulcerans after long term storage of samples. 
Our interdisciplinary research approach including biomedical and social science 
research elements, including future behavioural studies in young children, may eventually 
help to elucidate transmission and to improve control of BU. 
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Zusammenfassung 
 
Buruli Ulkus (BU), ist eine vernachlässigte Tropenkrankheit der Haut und des 
Unterhautgewebes welche durch Mycobacterium ulcerans verursacht wird. Die Krankheit 
ist in über 30 Länder nachgewiesen worden und die meisten Fälle stammen aus West 
Afrika. Während es allgemein akzeptiert ist, dass BU nicht direkt von Mensch zu Mensch 
übertragen wird, sind sowohl das Reservoir von M. ulcerans in der Umwelt wie auch der 
Übertragungsweg des Bakteriums zum Menschen noch nicht bekannt. Klinisch präsentiert 
sich BU mit einem weiten Spektrum an Krankheitsbildern und kann sowohl zu 
geschlossenen Läsionen wie auch zu offenen Ulzera mit den typischen unterminierten 
Wundrändern führen. Die Pathologie von BU wird vor allem durch die einzigartige 
Fähigkeit von M. ulcerans bestimmt, ein Makroloidtoxin namens Mycolactone zu 
produzieren, welches zu Nekrose und Immunsuppression führt. BU kann durch 
Mikroskopie, Polymerase-Kettenreaktion (PCR), das Kultivieren der Bakterien oder 
histopathologische Untersuchungen diagnostiziert werden. Auf Grund fehlenden Zugangs 
zu diagnostischen Laboratorien werden jedoch BU Fälle oft nur klinisch diagnostiziert. In 
der Vergangenheit wurde BU durch chirurgisches Entfernen der Läsionen behandelt. Seit 
2004 empfiehlt die Weltgesundheitsorganisation, dass BU mittels einer täglichen 
Kombinations-Chemotherapy bestehend aus Streptomycin und Rifampicin für acht 
Wochen behandelt werden soll. 
Im Rahmen dieser Doktorarbeit, haben wir einen neuen BU Forschungs-Standort 
im Kamerunischen Mapé Becken etabliert und epidemiologische und diagnostische 
Aspekte der Krankheit sowie den Übertragungsweg untersucht. Als Ausgangsbasis für 
diese Arbeiten haben wir einen vollumfassenden Survey für BU, Lepra und Frambösie in 
dem Bankim Gesundheitsdistrikt durchgeführt. In der Folge haben wir alle neuentdeckten 
BU Fälle aus der Region systematisch erfasst. Durch die Unterstützung lokaler 
Labordiagnostik mittels quantitativer-PCR (RT-PCR) und das Kultivieren des Erregers 
konnten wir einen Fall von Haut-Tuberkulose identifizieren, welcher zunächst klinisch und 
mikroskopisch als BU diagnostiziert wurde. Dieser Fall zeigt wie notwendig es ist die 
lokalen Kapazitäten der klinischen Diagnose für BU zu verbessern. Insgesamt haben wir 
88 RT-PCR positive BU Fälle, welche im Verlauf unserer Studie im Mapé Becken 
identifiziert wurden, im Detail untersucht. Wir haben die Häuser der Patienten 
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kartographiert und die Verteilung von BU in dem Gebiet beschreiben sowie 
hochendemische Regionen identifiziert. Basierend auf der Altersverteilung der 
Bevölkerung, welche wir in dem Survey erfasst haben, konnten wir die altersangeglichene 
kumulative Inzidenzrate von BU berechnen. Diese Analyse zeigte, dass unter fünf Jahre 
alte Kinder in der Altersverteilung der Patienten unterrepräsentiert sind. Unsere 
seroepidemiologischen Untersuchungen an Patienten und gesunden Personen aus BU 
endemischen Regionen Kameruns und Ghanas zeigten weiterhin, dass Kinder erst im Alter 
von etwa sechs Jahren vermehrt Immunantworten gegen M. ulcerans entwickeln. Dies 
deutet darauf hin, dass die Intensität der M. ulcerans Exposition zunimmt, wenn sich 
Kinder zunehmend weiter vom unmittelbaren Umfeld ihrer Elternhäuser entfernen. Um für 
die Ansteckung relevante Umweltreservoire zu identifizieren, haben wir die Anbauflächen 
sowie die von BU Patienten im Dorf und in der Nähe der Anbauflächen aufgesuchten 
Wasserstellen auf das Vorhandensein von M. ulcerans DNA untersucht. Hierbei konnten 
wir drei RT-PCR positive permanente Dorfwasserstellen identifizieren. Eine detaillierte 
longitudinale Analyse von einer dieser Wasserstellen deutete darauf hin, dass M. ulcerans 
in Unterwasser-Detritus persistieren kann. Diese ökologische Nische könnte eines der 
Reservoire von M. ulcerans darstellen. Um weitere Hinweise auf den Übertragungsweg 
von M. ulcerans zu erhalten, haben wir zusätzlich eine Stammsammlung von M. ulcerans 
Isolate aufgebaut. Die gewonnenen Isolate werden wir für phylogeographische und 
genomische Analysen zur räumlichen Verteilung der lokalen Haplotypen einsetzen. Durch 
das routinemässige Kultivieren von M. ulcerans aus klinischen Proben und das Evaluieren 
unterschiedlicher Transportmedien und Dekontaminationsmethoden konnten wir weiter ein 
optimiertes Protokoll für die Isolation von M. ulcerans aus klinischen Proben nach 
Langzeitlagerung entwickeln. 
Unsere interdisziplinäre Forschung mit biomedizinischen wie auch 
sozialwissenschaftlichen Elementen, sowie zukünftige Verhaltensstudien an kleinen 
Kindern, werden schlussendlich hoffentlich dazu beitragen, den Übertragungsweg von BU 
zu identifizieren und die Kontrolle der Krankheit zu verbessern. 
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The World Health Organisation’s (WHO) list of neglected tropical diseases (NTD) 
includes 13 conditions which are among the most frequent infections of the world’s 
poorest inhabitants. Buruli ulcer (BU) is together with leprosy and trachoma, one of the 
three bacterial infections included in this set of diseases [1,2]. Starting around the turn of 
the last millennium, in parallel to large scale international efforts to achieve the 
Millennium Development Goals and reduce the worldwide burden of malaria, human 
immunodeficiency virus infection / acquired immunodeficiency syndrome (HIV/AIDS) 
and tuberculosis, measures to tackle NTDs have also been scaled up. For BU specifically, 
major efforts to tackle the world wide burden of this disease were initiated by the WHO’s 
“Yamoussoukro Declaration on Buruli ulcer” in 1998 [3]. 
 
1.1 Epidemiology 
The first report of BU was published in 1948 by MacCallum et al. describing the 
disease based on six patients observed in Australia. In this initial publication, the disease 
causing organism, later named Mycobacterium ulcerans, was also isolated [4]. Despite the 
first report from Australia, the international name of BU originates from later reports 
which identified the Buruli county of Uganda as a hot-spot for the disease in the late 
1950’s [5]. Around the same time of this first report of cases from Uganda, cases were 
also reported from various other African countries including areas that now belong to 
Democratic Republic of the Congo, Republic of the Congo, Gabon, Nigeria and 
Cameroon [6]. Cases were further reported from South East Asian countries such as 
Malaysia, Indonesia and Papa New Guinea as well as Central and South American 
countries such as Mexico and French Guiana [5,6]. Currently disease incidence is highest 
in West Africa, specifically in Côte d'Ivoire, Benin and Ghana [7]. In South America and 
South East Asia on the other hand, there are today only sporadic reports of new cases 
[8,9]. As shown in Figure 1.1, BU has been reported from over 30 countries on four 
continents and has an important public health impact [10,11]. The disease is considered 
the third most common mycobacterial disease after tuberculosis and leprosy [7] and in 
2010 there were 4’888 cases notified worldwide [12]. Reports however suggest that this 
world wide case load may be a an underrepresentation of the true disease burden and BU 
may be more widely spread then what is currently known [7,12]. On the other hand 
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Portaels et al. also suggest that due to misdiagnosis (see below), some countries may also 
be over reporting cases [13]. 
In Cameroon, BU was first observed in 1969 in the Nyong area close to the towns 
of Ayos and Akonolinga [6]. Following this initial discovery of BU cases in southern 
Cameroon, other endemic areas, including the Bankim Health District (HD) in 2004 [14], 
have been discovered. Currently there are three major foci of BU in Cameroon; namely: 
Ayos/Akonalinga/Ngoantet, Bankim and Mbonge (A. Um Boock, personal 
communication). 
As illustrated by the distribution of BU cases in Cameroon, the occurrence of 
cases in the endemic countries tends to be very focalized and incidence rates can vary 
greatly inside countries. Reports of cases must therefore be evaluated at local level [13]. 
In the endemic countries, BU cases occur in particular close to wetlands or areas with 
stagnant water, in rural regions or in locations where the environment has been disturbed 
by man-made alterations [12,15]. In some of these foci, the number of cases of BU, may 
even exceed the number of leprosy or tuberculosis cases [13]. 
BU disease occurs mostly in children between the age of 5 and 15 [7,10]. Contrary 
to some initial reports [5] which suggested that there are differences between the number 
of women and man suffering from BU, in most BU endemic regions no significant gender 
differences in BU incidence have been observed [13]. Most of the BU lesions occur on the 
extremities with roughly 80% of lesions on the lower extremities [10]. Analysis of the 
lesion distribution have further shown that in adults lesions most often occur on the 
extremities whereas in children, the trunk, head and neck are also affected [13]. 
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Figure 1.1: Global distribution of BU cases in 2009. 
Figure adapted from Merritt et al. [10]. 
 
1.2 Causative agent 
The environmental pathogen M. ulcerans is believed to have evolved from 
Mycobacterium marinum which lives in diverse aquatic and intracellular environments 
and occasionally causes granulomatous skin lesions in human [16]. In the course of its 
divergence from M. marinum, with which M. ulcerans shares 98.3% average genomic 
DNA sequence identity, M. ulcerans has undergone some major changes. Specifically the 
species emerged by acquiring the virulence plasmid pMUM by horizontal gene transfer 
[15]. A further bottleneck in the evolution of M. ulcerans was the uptake and expansion of 
the insertion sequences IS2404 and IS2606. The spread of multiple copies of these IS 
elements over the chromosome has led to extensive pseudogene formation, genome 
reduction and genome rearrangement in M. ulcerans [15]. The reductive evolution is 
thought to have reduced the ability of M. ulcerans to grow under low oxygen conditions 
compared to M. marinum and its resistance to direct sunlight. These changes are believed 
to indicate that M. ulcerans has adapted to a new niche in the environment which is 
different from the one occupied by its ancestor [10,15]. 
Within M. ulcerans, reductive evolution has led to the emergence of three lineages 
[17]. Lineage 1 M. ulcerans are fish and frog pathogens that do not usually cause disease 
in humans. Lineage 2 is the ecovar causing human disease in Japan and South America 
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and lineage 3 M. ulcerans strains cause human disease in Australia and Africa [17]. 
Further genetic analyses of the diversity of M. ulcerans strains which cause human 
disease, found that the pathogen is highly clonal and high resolution typing methods are 
required to differentiate strains circulating in the same endemic area [7,18]. Furthermore, 
the monomorphism of M. ulcerans limit our ability to monitor the spread of the pathogen, 
although it has recently been shown that by single-nucleotide polymorphism (SNP) 
typing, strains originating from an area smaller then 1000km2 can be geographically 
clustered and separated into different haplotypes [18]. 
M. ulcerans, unlike all other mycobacteria, produces an immunosuppressive and 
necrotizing macrolide toxin called mycolactone. This toxin is responsible for most of the 
necrosis in the subcutaneous tissue in and around BU lesions [19]. Indeed, mycolactone 
alone has been shown to produce pathologies similar to those of M. ulcerans infections 
[19]. The toxin, which is secreted by M. ulcerans and diffuses into the infected tissue, has 
further been demonstrated to be essential for the virulence of M. ulcerans [10,12]. In 
addition to causing local tissue necrosis, mycolactone also has immunosuppressive 
properties and it is believed to kill infiltrating cells in human lesions [15,20]. M. ulcerans 
isolates from Africa produce the A/B form of the lipid toxin whereas Australian isolates 
produce the C form of the toxin and M. ulcerans from Asia produces the D form of 
mycolactone [7]. Strains of M. ulcerans from the various geographic regions that produce 
the different mycolactones differ in their virulence. In addition to the mycolactones 
produced by human pathogenic M. ulcerans, two additional chemical variants of the 
toxin, E and F, are produced by the fish and frog pathogens, which have previously also 
been referred to as M. liflandii and M. pseudoshottsii [15,20]. 
An additional noteworthy characteristic of M. ulcerans is its slow growth rate with 
an estimated generation time of 48 hours which greatly complicate the primary isolation 
of the pathogen (see below). Furthermore, M. ulcerans thrives in a cooler and fairly 
narrow temperature range from 28 to 34 ºC, which likely explains why mainly cooler 
tissues like the skin are infected by the pathogen [10,15]. 
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1.3 Reservoir and Transmission 
Based on the distribution of BU cases among Rwandan refugees in Uganda in the 
1960’s and early 1970’s researchers of the Uganda Buruli Group concluded that M. 
ulcerans was unlikely to be transmitted directly from person-to-person [5]. This opinion 
has mainly prevailed and it is now commonly accepted that infection occurs locally from 
an environmental source [21]. However to date the exact nature of the environmental 
reservoir and the mode of transmission of BU remain unknown and several hypothesis 
have been proposed [10].  
As early as the 1960’s and 1970’s it has been noticed that clusters of cases occur 
in close proximity to rivers and swampy areas but researchers also found that direct 
contact with large water bodies was not required for BU transmission [22]. More recent 
case control studies to identify risk factors for BU in various endemic areas, have 
repeatedly confirmed the association of BU cases with stagnant or slowly flowing water 
[10,22]. Associated with increased risk in proximity to water bodies, it has also been 
suggested that the incidence of BU increases after man-made alterations of the 
environment such as dam construction, deforestation, intensified agricultural use as well 
as other changes that increase the risk of flooding or the amount of wetlands [10]. Failure 
to wear protective clothing and pour wound care have also been reconfirmed as risk 
factors for BU in several studies [10]. Individual studies have identified other risk factors 
which were however not confirmed in different settings [10]. 
Based on the age distribution of cases, it has been suggested that transmission of 
BU likely does not take place at the homes of the patients [10]. Initial studies on the 
transmission suggested that the pathogen is inoculated directly from the environment into 
small skin lesions [23]. Such small skin trauma could go unnoticed by the patients. 
Further, such a mode of transmission would necessitate an environmental reservoir of the 
pathogen from where the bacteria would be picked up. To identify this source of the 
infection, numerous studies have attempted to detect the pathogen in soil, on plants and in 
water. Although M. ulcerans can be cultured from human lesions, culturing from 
environmental sources is very difficult due to overgrowth with other microorganisms 
[10]. Our current understanding of the distribution of M. ulcerans in the environment is 
therefore based on the detection of M. ulcerans DNA in the environment. Although M. 
ulcerans DNA could be detected at numerous samples such as soil, biofilm, detritus, and 
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water filtrates [10,24], a clear environmental reservoir could not be identified. 
Furthermore, published data on the distribution of M. ulcerans in the environment is at 
times contradictory [25]. While in some studies none of the samples from the physical 
environment were positive for M. ulcerans [26], in other studies samples collected both 
from endemic and non-endemic areas were positive [24]. Because of the detection of M. 
ulcerans DNA in aquatic insects [26], the potential roles of insect vectors are also being 
investigated [26]. Specifically water bugs are suspected to play a role in the transmission 
of BU [26]. The first isolation of an environmental strain of M. ulcerans from an insect 
provided further evidence for their involvement [27] and various field and laboratory 
studies have attempted to elucidate the implication of water bugs in BU transmission [13]. 
However based on the fact that these insects do not regularly bite humans and the lack of 
direct causal evidence of their involvement, the role of water bugs in BU transmission 
remains questionable [10]. In Australia, studies have also implicated mosquitos in the 
transmission to BU [28]. In addition to experimental evidence from endemic areas, much 
has also been speculated on the possible nature of an environmental reservoir of M. 
ulcerans [29]. Based on characteristics of M. ulcerans, it has been suggested that an 
eutrophic water body with high amount of sedimentation may favour M. ulcerans growth 
because of the reduced rate of dissolved oxygen and UV penetration [10,29]. On the other 
hand animals could also act as the reservoir of M. ulcerans [10]. In Southern Australia 
such a scenario, where possums are believed to greatly contribute to the environmental 
source of the pathogen, has been described [30]. In Africa no such animal reservoir has 
been identified to date [31]. 
Ultimately various modes of transmission of BU, depending on the 
epidemiological setting, are also possible [10]. Targeted studies in highly endemic 
communities, particularly looking at the behaviour of the local populations, are urgently 
required to fully understand the mode of transmission of BU [10]. Once the mode of 
transmission is known, preventive measures can be developed and implemented in the 
communities affected [12]. 
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1.4 Pathogenesis 
BU is a necrotizing skin disease that is believed to usually start with a painless 
nodule [7]. The incubation period of the disease is estimated at 2-3 months [7]. From the 
initial nodular phase, the disease may progress by the massive destruction of the 
subcutaneous adipose tissue to a non-ulcerative oedema or plaque (Figure 1.2). As the 
disease progresses further the epidermis may collapse and characteristic ulcers with 
undermined edges develop (see Figure 1.2) [15]. As lesions advance they can lead to 
extensive tissue destruction with large numbers of extracellular M. ulcerans and minimal 
inflammatory response [15]. Further characteristics of M. ulcerans infected skin tissue are 
the presence of dead fat cells, so called “fat cell ghosts”, and epidermal hyperplasia [13]. 
In certain patients if left untreated, BU lesions progress in size to cause extensive skin 
tissue damage and may encompass entire limbs or large portions of the trunk [12]. Even 
after treatment such large ulcers result in extensive scars and may lead to permanent 
disabilities [12]. In the past reports have suggested that BU lesions are comparatively 
clean [15]. However recent reports now shown that secondary infections of BU lesions are 
not uncommon and necessitate additional treatment [34,35]. 
In an estimated 10% of cases BU is also manifest with multiple lesions and in rare 
cases M. ulcerans infection leads to osteomyelitis [7]. Further studies are required, but it 
is believed that particularly patients co-infected with HIV suffer from more severe 
presentations of the disease [22]. 
In the active phase of the disease, there is extensive necrosis at the site of the 
lesion, little inflammation and no infiltrating immune response. The lack of an immune 
response along the active rim of the lesions is likely due to the secreted mycolactone 
which prevents any immune cells from reaching the M. ulcerans in the lesion. In this 
phase, lesions may contain large amounts of usually extracellular bacteria. As the lesion 
heals under antibiotic treatment, granulomatous inflammation and organized lymphoid 
aggregates develop and bacteria and bacterial debris are typically found intracellularly [7]. 
During this “organizing phase” there is extensive infiltration of lymphocytes, 
macrophages and Langhans’ giant cells which eventually leads to fibrosis [13]. 
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Figure 1.2: Clinical forms of BU. 
Typical presentations of a nodule (A), plaque (B), oedema (C) and large ulcer (D) are shown. 
Images are adapted from the WHO [36]. 
 
1.5 Diagnosis 
For BU laboratory diagnosis, there are currently four methods available. 
Microscopy can be used at the rural treatment centres to detect acid fast bacilli (AFB) 
after Ziehl-Neelsen straining. At reference laboratories, polymerase chain reaction (PCR) 
can be used to detect the M. ulcerans specific insertion sequence IS2404 or M. ulcerans 
can be cultured from clinical samples. Further at reference laboratories, tissue samples can 
be examined by histology to detect AFB. Based on its superiority in terms of sensitivity 
and specificity, PCR has become the gold standard of BU diagnosis [37]. However issues 
with false-positive results have recently been raised and strict quality control measures 
must be taken to ensure the accuracy of the obtained results (M. Eddyani et al., PLoSOne, 
submitted). To increase accuracy of the diagnosis it is further important that samples are 
collected from all around the lesion [38,39] and it is suggested that each site is sampled at 
least twice [7]. 
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In addition to supporting diagnosis, culturing of M. ulcerans is also used to asses 
treatment response and to monitor drug resistance [7,40]. Similarly, histology can be used 
to study the local immune response around the lesion and monitor the course of treatment 
[7,21,41]. Histopathology can further provide valuable insight into the state of the 
subcutaneous tissue of non-ulcerative lesions [41]. 
Because of difficulties with access to laboratory facilities, cases of BU in rural 
endemic areas are often diagnosed based only on clinical signs [15]. If performed by 
highly trained staff, the clinical diagnosis can achieve an accuracy of up to 95% [42]. 
However if performed by less specialized health care personnel, there are large 
discrepancies between clinical diagnosis and laboratory confirmation [7]. For the 
differential diagnosis, the nature of the edges of ulcerative lesions and the lack of fever as 
well as pain of small lesions, can be used as indications for BU [7]. Conditions such as 
tropical phagedenic ulcer, necrotising fasciitis, venous ulcer, diabetic ulcer, sickle-cell 
disease-related ulcers, yaws, cutaneous tuberculosis, leprosy, cutaneous leishmaniasis and 
malignant ulcer should be included in the differential diagnosis [2,43]. 
Because of these difficulties with the clinical diagnosis in routine settings, new 
point-of-care rapid diagnostic tests are urgently needed [2]. In particular a test to detect 
mycolactone in human lesions would be very specific and also allow for the monitoring of 
the viability of the infecting pathogen and thereby assessing treatment success [44]. 
 
1.6 Treatment 
Historically BU was treated by surgical removal of the lesions. Because of the 
local dispersion of M. ulcerans into the healthy skin surrounding the lesion [45], such 
surgery needed to include a margin of healthy tissue to try to reduce the rate of re-lapse. 
Despite this measure, surgical treatment still resulted in relapse rates of around 20% [7]. 
The resulting satellite lesions then required multiple interventions and led to prolonged 
hospital stays [46]. 
As early as in the 1970’s it was known that rifampicin can be used to treat small 
BU lesions [7]. However it was only in 2004, with experimental data in a mouse model 
and preliminary human data that the WHO started to suggest antibiotic therapy. 
Specifically current treatment guidelines recommend the use of 10mg/kg of oral 
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rifampicin and 15mg/kg of intramuscular streptomycin (S/R) daily for 8 weeks [7]. 
Although there were initial doubts [22], the use of S/R treatment appears to be well suited 
to treat BU and cases of recurrence are rare. Furthermore, toxic effects of S/R appear to be 
relatively rare [22]. Despite the efficacy of this antibiotic combination in killing the 
infecting pathogen, debridement and skin grafting is often required, particularly for larger 
lesion [22]. Because of the requirement of injections, efforts are on-going to establish a 
fully oral BU treatment with streptomycin replaced by clarithromycin [7]. With such a 
fully oral treatment regimen, blister packs with several days of treatment for the patient to 
take home, as for example used in the treatment of leprosy, could be implemented. 
However, wound care, which is increasingly being recognised as an important component 
in BU care, still requires major attention even with a fully oral treatment. Based on the 
temperature sensitivity of M. ulcerans, alternative treatment using heat is also being 
evaluated [47]. Furthermore, the development of a vaccine against BU is also on-going 
[12]. Early on in BU research it was shown that BCG has some potential to protect against 
osteomyelitis without an effect against cutaneous BU [13]. Further research is therefore 
required [12]. 
Even with adequate antibiotic treatment, large lesions may lead to disability and 
require physiotherapy to reduce the risk of permanent sequelae from joint contracture and 
poor scaring [2,7]. BU has been suggested to be able to self-heal in rare cases however 
often accompanied with deformities and functional limitations [22]. BU treatment may 
further lead to an immune system driven temporary worsening of the lesion or the 
development of secondary lesions. This phenomenon termed “paradoxical reaction”, can 
be resolved with simple wound care and changes to the treatment provided are 
unnecessary [21].  
 
1.7 Control 
In Cameroon, BU control is integrated with the control of leprosy, yaws and 
leishmaniasis into a national control program. This program collects epidemiological data 
about cases of BU from all around Cameroon and reports the statistics to the WHO. The 
program also advocates for the inclusion of BU into the training of future medical 
personnel (E. Njih Tabah, personal communication). However beyond these roles the 
National BU Control Program is limited by financial constraints and all remaining BU 
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control activities are conducted and in part financed (A. Um Boock, personal 
communication) by the African office of the Swiss NGO Fairmed. Philanthropic 
organizations play a key role in BU care in several African endemic countries [48]. In 
Cameroon, Fairmed coordinates and supports BU activities at all BU treatment centres 
except in Akonolinga, where the BU care facility is managed by Médecins sans Frontières 
(MSF). All Fairmed managed BU treatment centres are located at public health care 
facilities and are staffed by Ministry of Health employees. In addition to managing and 
distributing all drugs and other materials required for BU care, Fairmed trains, supervises 
and partially employs the staff working at the treatment facilities. In addition to treating 
cases, major health facilities in the endemic areas, which also act as BU reference 
facilities, supervise BU work in the surrounding health centres, where less severe cases of 
BU are treated as outpatients (A. Um Boock, personnel communication). For the Bankim 
endemic area, the Bankim district hospital coordinates BU activities in the Bankim health 
district and acts as a reference centre for cases coming from the surrounding districts. 
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1.8 Goal 
For this PhD thesis we set out to establish a new BU field research site in the 
Mapé Basin of Cameroon and investigate epidemiological and microbiological aspects of 
the disease. We further aimed to contribute to a better understanding of the transmission 
of M. ulcerans. 
  
1.9 Objectives 
1. To describe the epidemiology of BU in the Mapé Basin of Cameroon, including the 
geographic origin and age distribution of patients as well as the localisation of their 
lesions on their bodies, in detail. 
2. To study the onset of a serological response towards M. ulcerans in young children 
living in BU endemic areas in Cameroon and Ghana. 
3. To study the distribution of M. ulcerans DNA at sites of regular environmental contact 
of laboratory confirmed BU patients. 
4. To develop a protocol suitable for the primary isolation of M. ulcerans from clinical 
samples after long-term storage. 
5. To raise awareness of issues with the differential diagnosis of BU in rural African 
treatment facilities. 
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Chapter 2. Buruli Ulcer in the Mapé Basin of Cameroon 
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2.1 Abstract 
Buruli ulcer (BU), a neglected tropical disease of the skin, caused by 
Mycobacterium ulcerans, occurs most frequently in children in West Africa. Risk factors 
for BU include proximity to slow flowing water, poor wound care and not wearing 
protective clothing. Man-made alterations of the environment have been suggested to lead 
to increased BU incidence. M. ulcerans DNA has been detected in the environment, water 
bugs and recently also in mosquitoes. Despite these findings, the mode of transmission of 
BU remains poorly understood and both transmission by insects or direct inoculation from 
contaminated environment have been suggested. Here we investigated the BU 
epidemiology in the Mapé basin of Cameroon where the damming of the Mapé River 
since 1988 is believed to have increased the incidence of BU. Through a house-by-house 
survey in spring 2010, which also examined the local population for leprosy and yaws, 
and continued surveillance thereafter, we identified, till June 2012, altogether 88 RT-PCR 
positive cases of BU. We found that, the age adjusted cumulative incidence of BU was 
highest in young teenagers and in individuals above the age of 50 and that very young 
children (<5) were underrepresented among cases. BU lesions clustered around the ankles 
and at the back of the elbows. This pattern neither matches any of the published mosquito 
biting site patterns, nor the published distribution of small skin injuries in children, where 
lesions on the knees are much more frequent. The option of multiple modes of 
transmission should thus be considered. Analyzing the geographic distribution of cases in 
the Mapé Dam area revealed a closer association with the Mbam River than with the 
artificial lake. 
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2.2 Author Summary 
Buruli ulcer (BU) is an infectious disease caused by Mycobacterium ulcerans that 
is affecting mostly children in endemic areas of West Africa. Proximity to slow flowing 
water is a risk factor, but the exact mode of transmission of BU remains unclear. Man-
made environmental changes, such as sand mining, damming of rivers and irrigation have 
been implicated with increases in disease incidence. Here we report findings from a 
survey for BU and continued case detection thereafter in the Bankim Health District of 
Cameroon. In this area, the local population believed that the damming of the Mapé River 
has led to the emergence of BU. In 28 months we identified 88 laboratory confirmed cases 
of BU. Studying these cases, we found that the age adjusted cumulative incidence of BU 
in the elderly is similar to that in children and that the distribution pattern of BU lesions 
neither matches mosquito biting patterns nor the distribution of small skin injuries. 
Multiple modes of transmission should therefore be considered. Our data further showed 
that the patients appear to have closer contact to the local Mbam River than to the 
artificial Mapé dam reservoir. 
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2.3 Introduction 
Buruli ulcer (BU), a neglected tropical disease (NTD) of the skin, is caused by 
Mycobacterium ulcerans [1] and if untreated, can lead to disability. Worldwide, local BU 
incidence rates are highest in West Africa and Australia, where the classical lineage of M. 
ulcerans is found [2–4] and the disease occurs at different foci in the endemic countries. 
Both sexes can be affected by the disease and although individuals of all ages can get BU, 
most of the patients are less then 15 years old [5]. In Cameroon, BU was first described in 
1969 in the Nyong river valley where during a cross-sectional survey in 2001, a total of 
436 clinically diagnosed cases of active or inactive BU were found [6]. Since then, the 
Bankim Health District (HD) has been identified as an additional BU endemic area in 
Cameroon [7]. In this area, where our research has been carried out, the local population 
suspects that the creation of an artificial lake, by damming of the Mapé River in 1988, has 
led to an increase in BU incidence. Risk factors for BU include proximity to slow flowing 
water, poor wound care and not wearing protective clothing [8]. However, the exact mode 
of transmission has not yet been elucidated [9,10]. Clinically, BU presents with symptoms 
ranging from nodules, plaques and oedemas to ulcers [11]. The cytotoxic and 
immunosuppressive toxin, mycolactone, uniquely produced by M. ulcerans, is believed to 
account for most of the pathology of BU [12]. The severity of cases is classified into three 
categories, with ‘1’ being patients with small (≤ 5cm dimeter) lesions, ‘2’ patients with 
medium size lesions (5–15 cm) and ‘3’ being patients with large (> 15cm) lesions, 
multiple lesions or lesions at critical sites [13]. Many BU cases identified in rural areas 
are still diagnosed based on clinical symptoms only, although the use of laboratory 
diagnosis is highly recommended by the World Health Organization (WHO). In 2004, the 
WHO introduced the use of the combination of streptomycin and rifampicin given daily 
for 8 weeks as treatment [14]. However, surgery and wound management remain critical 
aspects of BU care [15,16]. 
During our investigations of BU in the Bankim HD, we also examined the local 
population for two other NTDs of the skin, namely yaws and leprosy. Yaws is caused by 
Treponema pallidum (T. pallidum) subspecies pertunu, and is transmitted through skin 
and mucous membrane contact [17,18]. After an initial single lesion, the disease 
progresses to secondary multiple lesions and in about 10% of cases it causes permanent 
disability [18]. Leprosy is caused by Mycobacterium leprae, which is believed to be 
transmitted by the respiratory route and can cause major disabilities through nerve 
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damage. Diagnosis of yaws and leprosy relies mainly on physical examinations [17,19] 
and treatment of both diseases is feasible with antibiotics [17,20]. 
The objectives of the present study were i) to conduct an exhaustive survey for 
BU, yaws and leprosy in the Bankim HD; ii) to continuously monitor the occurrence of 
BU in the Mapé Dam area; and iii) to examine the age distribution, geographic origin and 
distribution of lesions of the real-time polymerase chain reaction (RT-PCR) confirmed 
cases of BU to underpin future environmental and social science studies. 
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2.4 Materials and Methods 
Ethical Statement 
Approval for the survey and the subsequent continuous enrolment of cases was 
obtained from the Cameroon National Ethics Committee (N°041/CNE/DNM/09 and 
N°172/CNE/SE/2011) and the Ethics Committee of Basel (EKBB, reference no. 53/11). 
Participation in all aspects of the study was voluntary and all patients, independent of 
their study participation, were treated according to national treatment standards. All 
clinically confirmed cases who participated in the study provided written informed 
consent. 
 
Study Area 
The study was conducted in the Mapé Dam region of Cameroon (Figure 2.1) at 
two different geographical scales. The initial phase of the study was conducted in the 
Bankim HD which consists of seven Health Areas (HA): Atta; Songkolong, Somié, 
Nyamboya, Bandam, Bankim Urban and Bankim Rural. The health care infrastructure of 
the Bankim HD consists of one public district hospital, six primary and four private health 
centres (HC). All of these facilities employ two medical doctors and approximately 30 
nurses. For the later part of the study, bordering regions in the 4 HD surrounding the 
Bankim HD (Nwa HD, Malantouen HD, Mayo Darle HD, Yoke HD) were also included 
in the study area. The main environmental features of the area are the Mapé Dam and the 
Mbam River. 
 
Survey procedures 
In early 2010 (March 22 to April 19), we conducted an exhaustive cross-sectional 
house-by-house survey for BU, leprosy and yaws in the 88 villages of the Bankim HD 
(Figure 2.1). Eleven teams of three trained field workers, namely one local nurse and two 
local community relays, were employed to interview all inhabitants. Field workers were 
trained for two days on the use of the questionnaire and the clinical signs of the three 
diseases investigated. At the household level, demographic information of all inhabitants 
was collected and posters with photographs of the clinical presentations of the diseases 
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were shown. Households with suspected cases were re-visited by staff with extensive 
experience in the diagnosis of BU, leprosy and yaws. From clinically confirmed BU 
cases, samples were collected for laboratory confirmation as follows. Two or three dry 
swabs were collected from ulcerative lesions or a fine needle aspirate (FNA) was drawn 
from non-ulcerative lesions [21]. To facilitate handling of FNA samples, they were 
transferred onto a swab. 
 
Prospective BU surveillance 
Following the survey, we continued to monitor the occurrence of all new cases of 
BU in the Bankim HD by community and HC based case referral and regular supervision 
until the end of June 2012. For this, a health worker, trained and experienced in the 
diagnosis of BU, regularly visited all HC in the Bankim HD and areas of the adjacent 
Malantouen HD. During these visits, suspected cases who independently came forward or 
who were referred to the HC by community or family members, were evaluated and if 
clinically confirmed, asked to come for treatment. Before treatment, swabs or an FNA 
were collected for laboratory confirmation as described above. In addition to demographic 
and clinical information, the houses where the patients lived for at least a year before 
disease onset were mapped using a GPS device. From the GPS device, coordinates were 
only recorded once the GPS receiver showed an accuracy of below 10m. Details of the 
location of the lesions on the patient’s bodies were also collected and documented by 
photographs. Both clinically confirmed BU cases identified in the survey and during the 
continuous case detection were included in the cohort of patients investigated here. 
 
Laboratory Confirmation of BU Cases 
Samples were locally stored at 4ºC before transport to the laboratory where 
definite BU diagnosis was obtained by insertion sequence (IS) 2404 RT-PCR. Analysis 
was done according to the protocol developed by Fyfe et al. [22,23]. In brief, swabs were 
transferred into glass bottles containing glass beads with 2-5mL of PBS, and the bottle 
vortexed for 1.5 minutes. From 1mL of the solution, DNA was extracted and RT-PCR 
performed. DNA was amplified in a StepOnePlus Real-Time PCR System (Applied 
Biosystems) and data analyzed using the Applied Biosystems StepOne Software (2.2.2). 
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Analysis of lesion distribution 
Using published age specific relative body surface areas (RBSA) [24] and the 
number of patients in each of the age groups, the weighted average RBSAs of a model 
person (all ages), a model child (<15), and a model adult (≥15) were computed. If 
required to perform a Fisher's exact test, RBSA were converted to counts which add up to 
the observed number of lesions. The shape file used to analyze lesion localizations is 
found in Dataset S1. 
 
Statistical analysis 
Continuous variables were summarized as means and standard deviation or 
medians and interquartile ranges and categorical ones as counts and percentages. The 
Fisher’s exact or Chi-squared tests were used to compare categorical characteristics 
between groups and Student t-tests or Mann-Whitney U-test in the case of continuous 
variables. Multiple comparisons were adjusted for using a Bonferroni correction. The 
software, SAS (SAS Institute, Cary, USA; release 9.3), RStudio (RStudio, Boston, USA, 
version 0.95.262) and R (The R Foundation for Statistical Computing; version 2.15.1) 
were used to perform the statistical analysis. Geographic data and the localisation of 
lesions were analyzed with ArcGIS ArcMap (Economic and Social Research Institute, 
Redlands, USA; version 10.0). 
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2.5 Results 
Survey for BU, leprosy and yaws in the Bankim HD 
In the course of the survey, a total of 48 962 individuals in 9 344 households 
(Figure 2.1) were interviewed. The population of one village (approximately 550 people) 
refused to participate in the study. Assessing demographics and living conditions in the 
Bankim HD (Table 2.1), we found that the local population is very young with an average 
age of 19.3±17.0 (median = 14.0, interquartile range = 6.0 to 28.0), that 51.4% of the 
population are women and that overall, 61.2% of the population have attended school at 
some point in their lives. We further observed that Christianity is the most common 
(64.9%) religion and that, apart from the young members of society which are either 
students (32.2%) or children (23.5%), the most common professions in the district are 
farming (16.9%) and household work (17.4%). In terms of living conditions we found that 
there are on average 5.2 individuals living in each household and 26.8% of the households 
have a mosquito net. Further, our data showed that only 38.3% of the population have 
access to clean drinking water that comes at least from a fortified well and that the roofs 
and floors of the local houses are often very poorly constructed. Table 2.1 also shows that, 
the main local differences in the level of development in the HD exist between the six 
rural HA and the Bankim Urban HA (BA HA), which includes the town of Bankim 
(77.4% of the BA HA population) and nine small settlements around it. The higher level 
of development in the BA HA is reflected by the significantly higher percentage of people 
having gone to school at some point in their lives (p-value < 0.0001) or by the 
significantly better access to clean drinking water (p-value < 0.0001). Furthermore, in the 
BA HA the proportion of houses with better flooring (p-value < 0.0001) and walls (p-
value = 0.0037) is also significantly higher compared to the other HA. 
In the survey, we identified 32 cases of leprosy, 29 cases of yaws and 25 cases of BU 
based on clinical symptoms. With 32 cases of leprosy, the population-adjusted prevalence 
was at 6.5 cases per 10’000. The majority (70%) of the identified leprosy cases suffered 
from the multibacillary form of the disease and 22% of them were previously known but 
had abandoned their treatment and needed treatment re-initiation. Of the 29 yaws cases 
identified, 28% presented with the advanced symptom of hyperkeratosis and of the BU 
cases, 23% (6 cases) could be re-confirmed by RT-PCR. 
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Laboratory confirmation of BU 
In the five months after the survey (April 2010 to August 2010), only two new 
RT-PCR reconfirmed BU cases were identified (Figure 2.2). Following this lag, between 
September 2010 and June 2012 (22 months) there was a steady flow of about 2.5 new RT-
PCR confirmed BU cases per month from the Bankim HD. During this period, RT-PCR 
confirmed BU patients from the surrounding HDs (about 1.2 per month) also reported to 
BU treatment facilities in the Bankim HD. Overall, our study identified 157 clinically 
confirmed cases of BU of which 88 (56%) could be confirmed by RT-PCR. Of the non-
confirmed patients, 48 (31%) tested negative in RT-PCR and of 21 patients (13%) no 
samples were collected. Gender ratio, age distribution, average disease duration prior to 
consultation, and proportion of category 3 cases were comparable between the RT-PCR 
positive and negative patients. Only age differed significantly (p-value = 0.034) between 
the RT-PCR confirmed and the non-confirmed cases with the average age of the 
confirmed cases being 21.2 and that of the non-confirmed ones being 29.3. To ensure the 
reliability of our conclusions we focused the remaining analysis only on the 88 RT-PCR 
confirmed BU cases. Age distribution (p-value = 0.4754) and professions (p-value = 
0.5161) did not differ significantly between the population of the Bankim HD and the 
confirmed BU patients. The gender distribution among patients was moderately different 
(p-value = 0.061) from that of the overall population with a larger proportion of males 
among the confirmed BU cases. 
 
Spatial distribution of BU cases in the Mapé basin 
To better describe BU epidemiology in the Mapé basin we set out to identify the 
exact geographic origin of all 88 laboratory confirmed cases in our cohort. Based on 
information from the patients or their close relatives we were able to determine the HD of 
origin for 86 (98%) of the cases (Figure S2.1). For the remaining 2 cases we could only 
determine that they did not live in the Bankim HD for the year before the onset of 
symptoms, but we could not conclusively determine which HD they were from. Studying 
the distribution of cases by HD, we found that the proportion of category 1 cases among 
the patients originating from inside the Bankim HD (24/62) was significantly higher (p-
value = 0.039) compared to the cases from the surrounding HDs (5/26; Figure S2.1). For 
the 62 cases that originated from within the Bankim HD we were also able to determine 
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their HA of origin. Using the population data as collected by the survey, we were then 
able to calculate the cumulative incidence rate of BU per HA in the Bankim HD during 
our study. As shown in Figure 2.3A, the cumulative incidence rate of BU in the Bankim 
HD is highest in the BR HA (5.08/1’000). The cumulative incidence rate in this HA is 
significantly higher compared to all other HA in the HD (p-value < 0.001). Interestingly 
the cumulative incidence rate is also significantly higher in the southern HA (BR, BA, 
BD, NY) compared to the northern HA (AT, SO, SG) of the Bankim HD (p-value < 
0.001) (Figure 2.3A). Finally, for more detailed spatial analysis, the exact domiciles of 79 
(89.8%) of the confirmed BU cases were mapped (Figure 2.3B). For 7 of the remaining 
cases (Bankim HD: 3 from the Bandam HA, 1 from the Somié HA; surrounding HD: 1 
from the Malantouen HD, and 2 of unknown origin) we could not conclusively identify 
the exact house where they lived before the onset of BU. An additional two cases (1 each 
from the Nwa HD and Mayo Darle HD) are not considered in the analysis because they 
originated from outside of the Mapé basin. Based on the known exact origin of the cases 
that came from within the Bankim HD (n=58) and who were therefore identified by the 
same case finding strategy, a Kernel function was used to compute the density of BU in 
the Bankim HD (Figure 2.3B). This BU density map shows that most of the cases occur in 
the southern part of the Bankim HD, particularly along the Mbam River and in the area 
between the Mapé Dam reservoir and that river. The exact origins of 80.8% (21/26) of the 
BU cases from outside of the Bankim HD, indicate that the local BU focus expands 
outside of the Bankim HD, in particular westwards into the Malantouen HD (Figure 
2.3B). 
 
Age and gender distribution of cases 
The median age of the 88 RT-PCR confirmed cases was 12.5 (interquartile range= 
8.0 to 30.0). The age of patients ranged from 0.5 to 73, 52 out of 88 (59.1%) were 
children (age <15) and 11 (12.5%) were older than 50. The gender ratio of all cases was 
1.44 male / female. In children this ratio was 1.89, in the 15 to 50 year olds it was 0.79 
and in the above 50 year olds, it was 1.75. The age dependent variation in the gender ratio 
was not statistically significant (p-value = 0.20). 
With the ages of the 62 (70.5%) cases of BU which originated from within the 
Bankim HD and the population age distribution as collected in the survey (Figure 2.4A 
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and Table 2.1), we computed the age adjusted cumulative incidence rate of BU in the 
Bankim HD for the period of the study. As shown in Figure 2.4B, we observed a low age 
adjusted cumulative incidence rate of BU in individuals aged below four years. The rate 
then peaked in children aged between four and < 14 years of age, with the 12 to <14 year 
olds particularly affected (34.4 cases per 10’000 inhabitants). Interestingly, the age 
adjusted cumulative incidence rate peaks again in the over 50 year olds (27.0 cases per 
10’000 inhabitants; Figure 2.4B). 
 
Localisation of BU lesions  
In the laboratory confirmed BU patients studied here, 49/88 (55.7%) lesions 
occurred on the lower limbs, 27/88 (30.7%) on the upper limbs, 2/88 (2.3%) on the head 
and neck and 10/88 (11.4%) on the trunk. One of the trunk lesions occurred on the 
genitals. Two patients had multiple lesions and only the initial lesion was considered for 
analysis. The distribution of lesions differed significantly (p-value <0.001) from the 
relative body surface area (RBSA; Table S2.1). Interestingly, most of the lesions (52.3%) 
occurred in close proximity to joints with clusters around the ankles (19.2 %) and elbows 
(15.9 %; Figure 2.5A, 2.5B and Table S2.2). When analyzing the occurrence of lesions on 
the different body parts, we did not observe any statistically significant difference 
between lesions occurring on the right or left or front or back of the patients. However, 
when analyzing the occurrence of lesions on the joints, we did observe a statistically 
significant difference between the lesions on the front or back of the joints (p-value = 
0.012), in particular there was a significant difference between the occurrence of lesion on 
the front or back of the elbow (p-value = 0.005). No such difference was observed when 
analyzing the joint lesions on the right of left of the patients’ bodies. Analyzing the 
distribution of the lesions by body part, we found a moderately significant difference 
between males and females (p-value = 0.076) with the percentage of lesions on the trunk 
being significantly higher (p-value = 0.033) in males (Table S2.1). 
The distribution of lesions by body parts in children (Figure 2.5C and Table S2.1) 
was significantly different (p-value = 0.009) from the RBSA of children. Interestingly, 
only children (n=2) had lesions on the head and neck. Overall, the lesions appear more 
dispersed in children (Figure 2.5C and 5D). While, the difference in the general lesion 
distribution by body parts between adults and children (Table S2.1) was not statistically 
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significant (p-value = 0.154), there was a significant difference (p-value = 0.011) between 
the distribution of lesions at joints in children and adults. In particular, most joint lesions 
in adults occurred at the ankle (36.1%), whereas most joint lesions in children occurred at 
the elbow (19.2%). Finally in adults, lesions occurred mainly on the front and back of the 
feet and the distribution also differed significantly (p-value = 0.004) from what is 
expected based on the RBSA of adults (Figure 2.5C). 
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2.6 Discussion 
The 2011 Cameroon Demographic Health Survey (DHS) examined approximately 
22’000 adults (>14 years old) and found that the population is very young with roughly 
24% being 15-19 years old [25]. In the Bankim HD, we also observed a population that is 
strongly skewed towards young individuals and we found that living conditions and 
access to clean drinking water are very poor. Given the basic health infrastructure, these 
factors pose big challenges when addressing any health care related issues [26,27]. 
Although Cameroon has achieved nationwide leprosy elimination as defined by 
the WHO (< 1 case per 10’000 inhabitants) [28], our data showed that leprosy remains 
endemic in the Bankim HD. The substantial proportion of leprosy patients that had 
previously abandoned treatment further demonstrated that the oral treatment regimen 
requires better patient monitoring to achieve good compliance. In 2010 Cameroon 
reported 800 cases of yaws [29] and our survey confirmed that the Bankim HD is a yaws 
focus. Studies on the use of oral antibiotics have again raised hope for the eradication of 
yaws [30–32]. However, until eradication is possible, the focus of leprosy and yaws care 
should be early detection, complete cure and prevention of disabilities. To achieve this, 
front line medical staff needs to be trained on clinical diagnosis and efficient case 
management. 
Characteristics of BU and the remote areas where it occurs have been suggested to 
necessitate active case searches for early case detection [33,34]. Indeed, house-by-house 
surveys have helped to elucidate BU epidemiology in Ghana and Ivory Coast [35,36]. In 
Cameroon a study around the Nyong River, identified 135 PCR confirmed cases of BU 
[6]. In the survey described here, the number of RT-PCR confirmed BU cases identified 
was smaller than expected. However, the lag of new cases during the first months after the 
survey indicated that the survey identified the cases present at that time. It cannot be 
excluded however, that a proportion of BU patients seeks to avoid contact with the formal 
health system. By continuous case detection, also accounting for the trust needed for cases 
to come forward [37], we identified 157 clinically diagnosed cases of BU (from April 
2010 to June 2012). To increase validity of the findings [38,39], our analysis focused on 
the 88 (56.1%) RT-PCR confirmed cases among them. False negative RT-PCR results are 
unlikely since we analyzed multiple samples from each patient (data not shown). 
Although accurate BU clinical diagnosis is possible [40], misdiagnosis rates of up to 40% 
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have been reported emphasizing the pressing need for a point-of-care rapid diagnostic test 
[5,38,39,41–43]. 
Based on the number of BU cases in each of the HA in the Bankim HD and their 
respective populations, the BR HA was determined to have the highest cumulative 
incidence rate of BU in the Bankim HD. Furthermore, by detailed mapping of cases and 
through the use of a geographic information system (GIS), we identified hot-spots of BU 
transmission along the Mbam River. With only few cases living in the immediate 
proximity of only the Mapé Dam reservoir, our data does not support the suspected direct 
importance of this man-made lake. This does not exclude that environmental changes 
associated with the damming of the Mapé River may have had a more indirect effect on 
the spread of BU in the wider area. Whether the relatively large proportion of patients 
living in the town of Bankim (11/79 GPS mapped cases), contracted BU there, remains to 
be investigated. By also mapping cases from outside of the Bankim HD, we found that the 
local BU endemic area is larger then previously described [7]. Indeed it is possible that, 
because of the differences in case finding strategy inside and outside of the Bankim HD, 
our findings from outside the HD under represent the true degree of BU endemicity in the 
areas surrounding the Bankim HD. Further studies are therefore needed to investigate BU 
endemicity in the entire Mapé basin in more detail. Ongoing environmental and social 
science research at the identified hot-spots of disease is aiming to further elucidate the 
mode of transmission of BU. 
BU affects individuals of all ages [15,34] but in the African endemic regions most 
patients are children [9,44]. However, when adjusting for the population age distribution, 
studies in Benin [45] and in Australia [46] showed that 75 to 79 year olds or the ≥74 olds, 
respectively, have the highest risk of contracting BU. Our data similarly showed that the 
age adjusted risk of BU is as high in the > 50 year olds as in children, a trend possibly 
associated with immunosenescence, the gradual deterioration of the immune system 
associated with natural age advancement [46,47]. It is interesting to note that cases among 
very young (< 5) children, which make up an even larger part of society than the 5 – 10 
year olds, are relatively rare. This may indicate that compared to older children the very 
young children are less exposed to risk factors due to a smaller movement radius away 
from the house [10]. In the exposed individuals, host factors are likely to contribute to the 
degree of susceptibility [48]; seroepidemiological studies indicate that only a small 
proportion of exposed individuals develop clinical disease [49,50]. 
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Detection of M. ulcerans DNA-positive mosquitoes in an Australian BU focus 
[46] as well as identification of the failure to wear protective clothing as a risk factor and 
of the use of mosquito repellent as a protective factor for BU [8], support the hypothesis 
that insects are involved in M. ulcerans transmission [10]. Most biting arthropods 
selectively feed at specifics sites based on visual, physical or chemical cues such as 
distance of the ground, breath and skin temperature of the bait [51–55]. The resulting 
feeding patterns are often focused either on the feet and ankles or the head of the human 
subject [52]. Interestingly for vector transmitted parasitic diseases with local 
manifestations such as cutaneous leishmaniasis and filariasis, it has been found that the 
lesion distribution correlates with the biting sites of the responsible vectors [56,57]. BU 
lesions occur mostly on the lower limbs [15,45,58–60] and in adults, a focus on joints, 
specifically the elbows and ankles, has been reported [15,58]. Studies on the distribution 
of lesions also show that they are usually equally distributed between the left and right 
side of the body and compared to adults, children tend to have more lesions on the trunk 
[45,60]. Using GIS methodology we observed in this study that lesions cluster at specific 
locations on the limbs. We found that, particularly in adults, lesions occur mostly at 
locations where the skin is not commonly protected with clothing. As previously 
described, in females, which are more likely to cover their upper body with clothing, we 
found that there are less lesions on the trunk. In rural African villages children may often 
have their upper body exposed explaining the more dispersed distribution of their lesions. 
Detection of M. ulcerans DNA in the environment [10] and identification of poor 
wound care and failure to wear protective clothing as risk factors for BU [8] have lead 
investigators to speculate that transmission may alternatively occur by skin trauma and 
direct contact with M. ulcerans contaminated environment [10]. A study in Canadian 
children found that children 9 months and older have on average >3.5 recent skin injuries 
[61]. In 5 to 17 year olds injuries most often occur where the bones are close to the skin, 
i.e. at shins, knees, elbows and forearms. Injuries on the head were most common in 
children less then 5 years of age and lesions on genitals were rare in all ages [61]. While 
this study may have, due to differences in dress code and activities, limited relevance for 
Cameroonian children, it is remarkable that both BU lesions on the head in our cohort 
occurred in patients under the age of 5 [61]. While BU lesion distribution does not seem 
to correlate closely with the published distribution of insect bites, inoculation of skin 
injuries by a contaminated environmental source should lead, for example, to more lesions 
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on the knees. Based on these data, the option of multiple modes of transmission should be 
considered. 
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2.8 Tables 
Table 2.1 Sociodemographic characteristics of the Bankim Health District population. 
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Table S2.1: Lesion Distribution by Body Parts. 
 All Children (< 15 years old) Adults 
Lesion location* All (n=88) Male (n=52) Female (n=36) All (n=52) Male (n=34) Female (n=18) All (n=36) Male (n=18) Female (n=18) 
Head or neck 2 (2.3) 2 (3.8) 0 (0) 2 (3.8) 2 (5.9) 0 (0) 0 (0) 0 (0) 0 (0) 
Upper limbs 27 (30.7) 16 (30.8) 11 (30.6) 19 (36.5) 14 (41.2) 5 (27.8) 8 (22.2) 2 (11.1) 6 (33.3) 
Trunk 10 (11.4) 9 (17.3) 1 (2.8) 7 (13.5) 7 (20.6) 0 (0) 3 (8.3) 2 (11.1) 1 (5.6) 
Lower limbs 49 (55.7) 25 (48.1) 24 (66.7) 24 (46.2) 11 (32.4) 13 (72.2) 25 (69.4) 14 (77.8) 11 (61.1) 
* number of patients with lesion at the given location and percentage in parenthesis 
 
Table S2.2: Lesion on Joints. 
  All Children (< 15 years old) Adults 
Lesion Location * All (n=88) Male (n=52) Female (n=36) All (n=52) Male (n=34) Female (n=18) All (n=36) Male (n=18) Female (n=18) 
Ankle 17 (19.3) 10 (19.2) 7 (19.4) 4 (7.7) 1 (2.9) 3 (16.7) 13 (36.1) 9 (50.0) 4 (22.2) 
Elbow 14 (15.9) 9 (17.3) 5 (13.9) 10 (19.2) 7 (20.6) 3 (16.7) 4 (11.1) 2 (11.1) 2 (11.1) 
Hip 3 (3.4) 3 (5.8) 0 (0) 2 (3.8) 2 (5.9) 0 (0) 1 (2.8) 1 (5.6) 0 (0) 
Knee 3 (3.4) 3 (5.8) 0 (0) 3 (5.8) 3 (8.8) 0 (0) 0 (0) 0 (0) 0 (0) 
Shoulder 2 (2.3) 1 (1.9) 1 (2.8) 1 (1.9) 1 (2.9) 0 (0) 1 (2.8) 0 (0) 1 (5.6) 
Toe 1 (1.1) 0 (0) 1 (2.8) 0 (0) 0 (0) 0 (0) 1 (2.8) 0 (0) 1 (5.6) 
Wrist 2 (2.3) 2 (3.8) 0 (0) 2 (3.8) 2 (5.9) 0 (0) 0 (0) 0 (0) 0 (0) 
Not Joint 46 (52.3) 24 (46.2) 22 (61.1) 30 (57.7) 18 (52.9) 12 (66.7) 16 (44.4) 6 (33.3) 10 (55.6) 
* number of patients with lesion at the given location and percentage in parenthesis 
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2.9 Figures 
 
Figure 2.1: Environmental Features and Population of the Bankim HD. 
The Bankim HD is located in the South-Western corner of the Adamaoua Region of Cameroon and 
encompasses most of the Mapé basin. The main environmental features of the area are the Mapé Dam 
reservoir and the Mbam River. The Bankim HD consists of 7 HA (red crosses depict the location of 
the main HC in each of the HA; BR: Bankim Rural; BA: Bankim Urban; BD: Bandam; NY: 
Nyamboya; SO: Somié; SG: Songkolong; AT: Atta) and is surrounded by four other HD. In early 
2010 we conducted an exhaustive house-by-house survey and examined a total of 48’962 individuals 
in all HA of the district; population sizes of villages based on this survey are indicated by green 
circles. The village of Koumtchoum (black star; estimated population of 550) as a whole refused to 
participate in the survey and the village of Djaouro Tchi Arouna (470 inhabitants, located in the Somié 
HA between the HC of Somié and the town at the Nigerian border to the North-West of it) could not 
be mapped. 
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Figure 2.2: Identification of BU Cases in the Mapé Basin following the Survey. 
In the 27 months following the exhaustive survey all clinically diagnosed BU cases in the Bankim area 
were included in a cohort study. Cases are separated into the RT-PCR confirmed cases which occurred 
inside (black) and outside (grey) of the Bankim HD. RT-PCR negative and non-laboratory examined 
cases occurring anywhere in the Mapé basin during the same time period are also shown (white). 
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Figure 2.3: Geographic Distribution of BU in the Mapé Basin. 
Based on the HA of origin of the 62 BU cases who originated within the Bankim HD and the 
population data collected in the survey, we computed the per HA cumulative incidence rate of BU in 
the Bankim HD (A). For detailed analysis, the places of residence of 58 (black points) of the 62 cases 
from the Bankim HD were mapped using a GPS device (B). For the remaining 4 RT-PCR confirmed 
cases which occurred inside the Bankim HD (3 from the Bandam HA, 1 from the Somié HA) we could 
not identify their home. Using a Kernel function the density of BU in the Bankim HD was computed 
based on the mapped cases (red: highest BU density). Panel B further shows the places of residence of 
21 of the 26 RT-PCR confirmed cases of BU who originated from outside of the Bankim HD (brown 
points). For three of the remaining cases (1 from the Malantouen HD, and 2 of unknown origin) we 
could not identify their exact origin and two additional cases (1 each from the Nwa HD and Mayo 
Darle HD) are not shown because they originated from outside of the region shown on the map. 
 
 
 
 
 
Figure 2.4: Population Age Distribution and Age Adjusted Cumulative BU Incidence Rate in the 
Bankim HD. 
In the course of the exhaustive survey, data on the population age structure of the Bankim HD were 
collected (A). Using this age distribution and the ages of the RT-PCR confirmed BU cases which 
occurred inside of the Bankim HD (n=62), the age adjusted cumulative BU incidence rate (cases per 
1’000 inhabitants) for the duration of the study could be computed (B). 
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Figure 2.5: Lesion Localization. 
The localization of the lesions of all the RT-PCR confirmed BU patients (88) were mapped in detail 
and Kernel function was used to create a heat map of the lesion distribution (A). The localization of 
the lesions on the front and back and left (L) and right (R) of the patient’s bodies are shown. Studying 
the distribution of lesions, it was noted that they often occur at joints (B, example of two lesions on the 
ankle and one on the shoulder). Distribution of lesions in children (C, n=52) and adults (D, n=36) were 
also analyzed separately. 
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Figure S2.1: Disease Category by Health District. 
Most of the RT-PCR confirmed cases that were identified in the Bankim area originated from within 
the Bankim HD (n=62). However, patients from all of the surrounding HD also came to Bankim for 
BU treatment (Malantouen: 17; Nwa: 3; Yoko: 3; Mayo Drale: 1). The number of cases that occurred 
in each of the HD are classified by disease severity (red: category 3, orange: category 2, yellow: 
category 1). Two RT-PCR confirmed cases (both category 3, both from outside of the Bankim HD) 
could not be displayed because the location where the patient first showed symptoms of BU could not 
be conclusively determined. 
 
 
 
 
2.10 Supporting Information 
 
Dataset S1: Shape File for the Analysis of Lesion Distribution. 
The compressed folder contains the files of the body_FB shapefile which provides the outline of the 
front and the back of the human body which was used for the “mapping” and analysis of the lesion 
distribution. 
 
 
 
Checklist S1: STROBE Checklist 
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Chapter 3. Late onset of the serological response in BU 
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3.1 Abstract 
A survey for Buruli ulcer (BU) in the Mapé Basin of Cameroon has revealed that the 
age adjusted cumulative incidence rate of BU in individuals below the age of four is very low, 
indicating that compared to other age groups, very young children are less exposed to 
Mycobacterium ulcerans. Here we determined serum IgG titers against the 18KDa small heat 
shock protein of M. ulcerans in more than 900 individuals living in BU endemic sites of the 
Densu River Valley in Ghana and the Mapé Basin in Cameroon. While none of the sera 
collected from children below the age of four had a detectable IgG titer against the shsp, the 
majority of sera contained high levels of antibodies against a domain of the Plasmodium 
falciparum merozoite surface protein 1. These data suggest that exposure to M. ulcerans 
increases at an age when children start moving further away from their homes and have more 
intense environmental contacts, including contact to water bodies at the periphery of their 
villages. 
 
 
 
3.2 Author Summary 
Although the causative agent of Buruli ulcer, a mycobacterium designated as M. 
ulcerans, had already been identified in 1948, transmission pathways and environmental 
reservoirs are still poorly understood. It is commonly assumed that the highly focal 
occurrence of M. ulcerans infections in endemic countries of West and Central Africa is 
associated with certain aquatic habitats. In addition, recent studies have indicated that 
currently unknown host or pathogen factors may contribute to the degree of susceptibility. 
While BU has long been generalized as a disease mainly affecting children <15 years, a 
comprehensive survey for BU in the Mapé Dam Region of Cameroon, taking account of the 
population age distribution, has revealed that the risk of BU is as high in the >50 year olds as 
in children and that cases among infants are relatively rare. In accordance with these findings, 
data of the present sero-epidemiological investigation suggest that children <4 years are less 
exposed to M. ulcerans possibly due to age-related behavioural factors such as a limited 
movement radius from their homes. 
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3.3 Introduction 
The chronic skin infection Buruli ulcer (BU), cases of which have been reported from 
tropical and subtropical settings around the world, is caused by the emerging environmental 
pathogen Mycobacterium ulcerans. This species has diverged from the fish pathogen 
Mycobacterium marinum by evolving the ability to produce an immunosuppressive toxin, 
referred to as mycolactone, through the acquisition of a plasmid [1,2]. Over the course of the 
last few years other mycolactone-producing mycobacteria (MPM), have been identified in 
fish and frogs of widespread geographic origins and had been given diverse species names [3-
6]. However, recent genome analyses indicate that all MPM are genetically closely related 
and can be divided into three principal lineages, which should all be considered ecovars of M. 
ulcerans [7].  
Although DNA sequences of this agent could be detected in various aquatic 
environments of the affected countries, the disease is characterized by a highly focal 
occurrence [8-11]. Whether this circumstance can be attributed to host or pathogen factors is 
yet to be explored, as is the definite mode of M. ulcerans  transmission [12]. Recent findings 
in south-eastern Australia, which is the only non-tropical area with local BU endemic sites, 
suggest that mammals may represent environmental reservoirs and that mosquitoes may 
function as vectors of M. ulcerans [13,14]. In West and Central African BU endemic areas, 
where most of the cases occur, it is controversially discussed whether infection takes place 
through trauma of the skin or insect bites, but definite evidence for either mode of 
transmission is lacking. A recent survey for BU in the Mapé Basin of Cameroon has revealed 
that the distribution pattern of lesions neither matches any of the published mosquito biting 
patterns, nor distribution patterns of small skin injuries found in the literature. Hence, the 
option of multiple transmission routes should be considered [15].  
A further mystery contributing to the guesswork around M. ulcerans transmission is 
the close proximity of highly endemic and non-endemic sites as exemplified by adjacent 
communities located along the Densu River of Ghana. Interestingly, no significant difference 
in the exposure to M. ulcerans could be detected between residents of either BU endemic or 
BU non-endemic communities in this area when analysing their serum antibody titers against 
an immunodominant small heat shock protein (shsp) [11]. This preceding study, which has 
helped to identify a new low BU endemic site in the Volta Region of Ghana by screening 
blood sera of the local population for the presence of anti-shsp IgG titers, has shown that sero-
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epidemiology provides an attractive approach to monitor exposure of populations to M. 
ulcerans [11]. 
One drawback of this initial investigation was that all study participants from both the 
Densu River Basin as well as the Volta Region were older than 5 years of age. Hence, it is 
still not known at which age immune responses against M. ulcerans antigens start to emerge. 
While it has long been generalized that in African BU endemic areas children below the age 
of 15 are worst affected by the disease [16], data from the above mentioned BU survey in the 
Mapé Basin of Cameroon showed that children <5 years old were underrepresented among 
cases, even though this age group and the severely affected 5-10 year olds were equally 
represented in the population under study [15].  
In the present sero-epidemiological investigation anti-shsp IgG titers were determined 
in over 900 individuals from BU endemic sites in the Densu River Basin of Ghana as well as 
the Mapé Basin of Cameroon including more than 100 children <5 years of age. Results 
indicate that very young children are significantly less exposed to M. ulcerans than 
individuals of all other age groups, providing another cornerstone in the search for the mode 
of M. ulcerans transmission. 
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3.4 Materials and Methods 
Ethics statement 
Ethical clearance for the collection and testing of human blood samples from Ghana 
and Cameroon was obtained from the institutional review board of the Noguchi Memorial 
Institute for Medical Research (Federal-wide Assurance number FWA00001824) and the 
Cameroon National Ethics Committee (N°172/CNE/SE/201) as well as the Ethics Committee 
of Basel (EKBB, reference no. 53/11), respectively. Written informed consent was obtained 
from all individuals involved in the study. Parents or guardians provided written consent on 
behalf of all child participants. 
 
Study areas 
Study areas of the present serological investigation were located in two different BU 
endemic countries. In Cameroon serum samples were collected from all inhabitants of the BU 
endemic village of Mbandji 2 located in the Bankim Rural Health Area of the Bankim Health 
District. 
 
Study participants and human blood sera collection 
In Ghana, serum samples were collected from 101 laboratory confirmed BU patients 
(60 females and 41 males) as well as 404 age-, sex-, and home village-matched control 
individuals. Collected clinical data, wshich might have an impact on serological responses of 
the BU patients and/or the control individuals, included the clinical form of BU, disease 
category and number of lesions as well as the duration of lesions before treatment.  
In Cameroon, blood sera were taken from 406 inhabitants of Mbandji2 with a nearly 
equal gender distribution. Re-sampling of 80 blood donors was carried out one year after the 
first blood collection. Demographic data as well as information on previous mycobacterial 
infections were recorded for all participants. While the majority of individuals had no history 
of mycobacterial infections, eight study participants reported to have had tuberculosis (2), 
leprosy (1) or BU (5). 
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The age distribution of study participants from Ghana and Cameroon is shown in 
Figure 3.1A and 3.1B, respectively. 
 
ELISA 
96-well Nunc-Immuno Maxisorp plates (Thermo Scientific) were coated with 0.25 g 
recombinant M. ulcerans 18 kDa shsp per well in 100 l phosphate-buffered saline (PBS) and 
incubated over night at 4°C. Plates were washed four times with washing buffer (dH2O, 2.5% 
Tween20) before being incubated with blocking buffer 1 (5% skim milk in PBS) for 2 hours 
at room temperature (RT). After washing as described above, 50 µl of 1:100 diluted human 
blood sera in blocking buffer 2 (1% skim milk in PBS) was added to each well and incubated 
for 2 hours at RT. Following a further washing step, 50 µl of 1:8000 diluted goat anti-human 
IgG (γ-chain specific) coupled to horseradish Peroxidase (HRP, SouthernBiotech) in blocking 
buffer 2 was added to each well and incubated for 1.5 hours at RT. Plates were washed and 50 
µl TMB Microwell Peroxidase Substrate (KPL) was added per well. The reaction was stopped 
after 5 minutes using 0.16M sulfuric acid. The absorbance was measured at 450 nm in a 
Tecan Sunrise microplate reader.  
 
Western Blot analysis 
15µg of recombinant M. ulcerans 18kDa shsp or 5µg of a Plasmodium falciparum 
MSP-1 protein domain (amino acids 34-469 of PfK1) were separated on NuPAGE Novex 4-
12% Bis-Tris ZOOM Gels with 1.0mm IPG well (Invitrogen) using NuPAGE MES SDS 
Running Buffer (Invitrogen) under reducing conditions. After electrophoresis the proteins 
were transferred onto nitrocellulose membranes using an iBlot Gel Transfer Device 
(Invitrogen). Membranes were blocked with 5% skim milk in PBS containing 0.1% Tween20 
(PBS-T) and cut into thin strips. Membrane strips were then incubated with human blood sera 
at a 1:1000 dilution in PBS-T for 2 hours at RT. Strips were repeatedly washed with 0.3M 
PBS containing 1% Tween20 and after that incubated with 1:20000 diluted goat anti-human 
IgG (γ-chain specific) coupled to HRP (SouthernBiotech) for 1 hour at RT. After a second 
washing step, bands were visualized by chemiluminescence using ECL Western Blotting 
substrate (Pierce). 
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Data analysis 
ELISA results were analyzed using GraphPad Prism software version 6.0 (GraphPad 
Software, San Diego California USA). Results are presented as box plots with a line for the 
median, edges for the 25th and 75th percentiles and traditional Tukey whiskers showing 1.5 
times the interquartile distance. Dots on the graph represent individual points that lie outside 
that range. Differences between data sets were assessed by a Mann-Whitney and Dunn`s 
multiple comparison test. 
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3.5 Results 
M. ulcerans 18 kDa shsp specific serum IgG responses in BU patients and control 
individuals living in the BU endemic Densu River Valley of Ghana 
M. ulcerans 18 kDa shsp specific IgG titers were determined by ELISA in 101 BU 
patient sera as well as 404 sera from control individuals living in different communities of the 
BU endemic Densu River Valley in Ghana. Each serum sample was tested twice in two 
independent experiments (Figure S3.1, R=0.039 between duplicate experiments). No 
statistically significant difference (p=0.3315) could be detected by comparing ELISA OD 
values of the two cohorts (Figure 3.2A). While sero-responders were identified in all age 
groups >5 years, the vast majority of sera from both BU patients and control individuals had 
no detectable anti-18 kDa shsp titer. Interestingly, none of the sera from very young children 
(<5 years) exhibited a significant titer (Figure 3.2B). No relationship between ELISA OD 
values and clinical parameters of the BU patients (clinical form/category/duration/number of 
lesions) could be detected for both patients and controls, which can partly be explained by 
small sample sizes of the different categories (data not shown). Results for a subset of sera 
tested negative, moderately positive and highly positive by ELISA were reconfirmed by 
Western blot analysis, showing good agreement between ELISA OD values and Western Blot 
band intensities (Figure S3.2). 
 
Age distribution of 18 kDa shsp specific serum IgG responses among individuals living 
in the Mapè Basin of Cameroon 
We analysed 486 serum samples collected in Mbandji 2 located in the Mapé Basin of 
Cameroon, including 96 sera from children aged <5 years for the presence of IgG titers 
against the M. ulcerans 18 kDa shsp. In accordance with results from Ghana, individuals with 
high antibody titers were detected in all age groups >5 years, while none of the very young 
children showed any IgG titre above the background response (Figure 3.3). In order to 
reconfirm these data qualitatively and to be able to determine the age at which individuals 
start to mount immune responses against M. ulcerans, we tested all sera sampled from 
children below the age of seven by Western Blot analysis. While no specific bands 
representing IgG antibodies against the 18 kDa shsp, were detected for sera from children <4 
years of age, sero-responders were found in all tested age groups >4 years. Since very week 
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IgG titers were recorded for some of the sera from four year olds, the approximate age of a 
possible seroconversion may be situated between three and five years (Figure 3.4). Accurate 
performance of the Western Blot analyses was confirmed by including a control serum 
(ELISA OD = 0.963) between each of the age groups. Analysis of the five most ELISA 
positive sera from older children aged between seven and twelve years showed strong 
Western Blot band intensities for some of the sera (Figure S3.3).  
 
Analysis of serum IgG responses against a domain of the Plasmodium falciparum MSP 1 
protein among infants living in the Mapè Basin of Cameroon 
In order to assess the exposure of infant study participants living in the Mapé Basin to 
the mosquito transmitted parasite P. falciparum, IgG titers against an immunodominant 
domain of the malaria merozoite surface protein 1 (MSP 1) were determined by Western Blot 
analysis. In contrast to the striking lack of antibody titers against the 18 kDa shsp in children 
<4 years old, serum IgG responses against the MSP 1 domain were detected in all age groups 
tested. Strong band intensities were obtained for the majority of sera collected from children 
between one and seven years of age as well as for one of the infants <1 years old (Figure 3.5).  
 
Serial analysis of anti-18 kDa shsp IgG titers among 80 residents of Mbandji 2 
One year after the first serum collection in Mbandji2, 80 of the 406 study participants 
were re-sampled in order to analyse the stability of anti-18 kDa shsp serum IgG levels over 
time. While only minimal changes in antibody titers against the shsp were recorded overall, 
more individuals had a decreased serum IgG level after one year (Figure 3.6A). The most 
distinct changes, characterized by a high decrease of antibody titers between the two 
samplings, occurred in young adults, although no significant correlation between age and the 
change in OD could be observed (Figure 3.6B). 
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3.6 Discussion 
A high degree of antigenic cross-reactivity among mycobacterial species complicates 
investigations on M. ulcerans-specific humoral immune responses. Nevertheless, the 
immunodominant 18 kDa shsp was shown to be a suitable serological marker for exposure to 
M. ulcerans. In one of our previous studies we observed the presence of antibody titers 
against this antigen in about 30% of healthy individuals living in BU endemic and non-
endemic communities in the Densu River Basin of Ghana, indicating that infection with M. 
ulcerans may lead only in a proportion of exposed individuals to active disease [11]. Diverse 
outcome of infection with other mycobacteria such as M. tuberculosis and M. leprae has been 
associated with different host and pathogen factors. While only one study has investigated a 
possible association between BU and host genetics [17], various behavioural factors that may 
lead to increased susceptibility to the disease have been reported, with poor wound care, 
failure to wear protective clothing, and living or working near water bodies being the most 
common risk factors identified [18]. While the generalization persists that children <15 are 
most affected by the disease [16], a recent survey for BU in the Mapé Basin has revealed that 
the risk of BU is as high in individuals above the age of 50 as in young teenagers and that 
very young children are underrepresented among cases when adjusting for the population age 
distribution [15]. Data of our previous sero-epidemiological investigation focusing on the 
detection of serum IgG titers against the 18 kDa shsp suggested that individuals of all age 
groups >5 are equally exposed to M. ulcerans [11]. However, results of the present study, 
including more than 100 serum samples from children <5, show that none of the tested sera 
had an IgG titer against the shsp above the background level. Hence, children are likely to be 
considerably less exposed to the pathogen, which may be explained by certain behavioural 
factors connected with prevention from risk factors such as a smaller movement radius from 
the house.  
Results of a case-control study carried out in a BU endemic region of south-eastern 
Australia indicated reduced odds of having BU for individuals who frequently used insect 
repellent and increased odds for those who were bitten by mosquitoes [19], which are 
associated with the transmission of M. ulcerans in this region. In African settings, the highly 
focal transmission of different M. ulcerans haplotypes in a BU endemic region [10,20,21] as 
well as the distribution pattern of BU lesions on the body, described for cases in the Mapé 
Basin of Cameroon [15], speak against an exclusive role of mosquito vectors in transmission. 
Further evidence for this assumption was supplied in this study by comparing antibody levels 
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against the M. ulcerans antigen to the titres against an immunodominant protein of the malaria 
parasite P. falciparum in very young children. In contrast to the absence of serum IgG against 
the M. ulcerans shsp, the majority of the children’s sera contained high anti-MSP 1 domain 
IgG levels, indicating exposure to the mosquito transmitted malaria parasite already at a very 
young age. Hence, the option of different transmission routes in African and Australian 
settings should be considered. A sero-epidemiological investigation in south-eastern Australia 
as well as a BU endemic site in far north Queensland is planned to compare the exposure to 
M. ulcerans in different settings. 
No significant difference could be observed by comparing antibody titers against the 
shsp between a BU patient- and control cohort. However, these results may be explained by 
the diverse group of BU patients recruited, including healed and active cases as well as cases 
with different clinical form, category and number of lesions. Due to the small sample size, no 
statistics could be applied to assess a relation between antibody levels and these different 
factors.  
While the conducted sero-epidemiological investigations provided a good insight into 
the exposure to M. ulcerans in BU endemic areas at the population level, it reflects only a 
snapshot in time for the individual. Until today, mechanisms for the control of M. ulcerans 
infection are poorly understood. However, the fact that a considerable proportion of exposed, 
but healthy individuals develop specific humoral responses against M. ulcerans antigens 
together with the observations that BU can heal spontaneously [22] and that secondary M. 
ulcerans infection foci developing after successful treatment of the initial lesion heal without 
further treatment [23], suggests the existence of protective immunity. Although it is generally 
assumed that cell-mediated immunity plays an important role, antibodies could provide 
additional protection against the predominantly extracellular pathogen. More information on 
humoral immune responses against M. ulcerans could be obtained by serial analyses of serum 
samples from the same individual over time. Within the framework of our analyses, blood 
was re-collected from a limited number of participants one year after the first sampling. 
Results of this pilot study showed that antibody titers against the shsp were relatively stable in 
most of the individuals, while only a few distinct changes between the two samplings were 
observed. Interestingly, the absolute differences of the two serial ELISA OD values seemed to 
vary by age, with most pronounced changes in young adults - an age where the incidence of 
BU is believed to be the lowest [15]. Hence, we can only speculate that in this age group, 
enough pre-immunity has developed for the immune system to react, thereby preventing the 
development of the disease. However, due to the small cohort size of this pilot study, these 
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observations were not significant by tests of the homogeneity of variances. A future analysis 
of serially collected sera from individuals living in the Densu River Basin of Ghana over a 
two year period is expected to provide a better understanding of how the immune system 
functions to combat M. ulcerans infections. This may help to improve prevention and 
treatment strategies for BU. 
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3.7 Figures 
 
Figure 3.1. Age distribution of study participants. 
A Blood sera were collected from 101 Ghanaian BU patients (black) and 404 control individuals 
(grey) of the different age groups shown. B In Cameroon, serum samples were collected from 406 
individuals of which 80 were re-sampled after one year. The graph consists of all 486 data points. 
 
 
Figure 3.2. Anti-18kDa shsp IgG titers in sera from Ghanaian BU patients and control 
individuals. 
A Box plots showing OD values of sera (1:100 diluted)  tested from Ghanaian BU patients (n=101) 
and control individuals (n=404) in an 18 kDa shsp ELISA. No statistical difference between cohorts 
was observed. B The distribution of OD values for BU patients (red) and control individuals (black) is 
shown for different age groups. No IgG titres above the background level were observed for children 
below the age of 5 years. 
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Figure 3.3. Anti-18kDa shsp IgG titers in sera from inhabitants of Mbandji 2. 
OD values of serum samples (1:100 diluted) from inhabitants of Mbandji2 tested in an 18 kDa shsp 
ELISA are visualized for different age groups as box plots. No IgG titers above the background level 
were observed for children below the age of five. 
 
 
Figure 3.4. Western Blot analysis of specific anti- 18 kDa shsp IgG responses in children. 
Sera collected from children living in Mbandji 2 were tested for the presence of specific anti-18 kDa 
shsp IgG titers by Western Blot analysis. No specific bands were detected for very young children 
below the age of four. An ELISA positive control serum (OD=0.963) was included between each of 
the age groups tested (+). 
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Figure 3.5. Western Blot analysis of specific anti-P. falciparum MSP 1 IgG responses in children. 
Serum IgG responses against a domain of the P. falciparum MSP 1 protein were analysed in sera from 
children living in Mbandji2 by Western Blot analysis. Specific bands were detected in the majority of 
individuals of all tested age groups >1 year. 
 
 
Figure 3.6. Anti-18kDa shsp IgG titers of serially collected serum samples. 
A IgG titers against the 18 kDa shsp were determined in serial serum samples collected from 80 
individuals. Minimal changes in antibody levels were observed and most individuals showed a 
decreased titer after one year. B Absolute differences in OD values between the two samplings are 
shown by age. A few distinct changes in antibody titers occured in young adults although there was no 
significant correlation between ∆OD and age. 
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Figure S3.1. Duplicate ELISA testing of sera. 
All serum samples collected from individuals living in the BU endemic Densu River Basin of Ghana 
were tested twice (analysis 1 and analysis 2) with a high correlation between duplicate experiments 
(R=0.039). 
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Figure S3.2. Reconfirmatory Western Blot of randomly chosen Ghanaian sera. 
A subset of sera tested moderately positive (OD=0.58-0.64), negative (OD=0.1) and highly positive 
(OD=1.0-1.2) by ELISA were tested by Western blot analysis. Specific bands were detected for 
ELISA positive sera, while no signal was obtained for ELISA negative sera.   
 
 
 
 
Figure S3.3. Western Blot showing specific anti-18kDa shsp IgG responses in older children.  
The five most ELISA positive sera of each age group between seven and twelve were tested for the 
presence of specific anti-18 kDa shsp IgG responses by Western Blot analysis. Strong band intensities 
were observed for most of the sera. 
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Chapter 4. Environmental Persistence of M. ulcerans 
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4.1 Abstract 
Buruli ulcer (BU), a neglected tropical disease of the skin and subcutaneous tissue, is 
caused by Mycobacterium ulcerans and is the third most common mycobacterial disease after 
tuberculosis and leprosy. While there is a strong association of the occurrence of the disease 
with stagnant or slow flowing water bodies, the exact mode of transmission of BU is not 
clear. M. ulcerans has emerged from the environmental fish pathogen M. marinum by 
acquisition of a virulence plasmid encoding the enzymes required for the production of the 
cytotoxic macrolide toxin mycolactone, which is a key factor in the pathogenesis of BU. 
Comparative genomic studies have further shown extensive pseudogene formation and 
downsizing of the M. ulcerans genome, indicative for an adaptation to a more stable 
ecological niche. This has raised the question whether this pathogen is still present in water-
associated environmental reservoirs. Here we show persistence of M. ulcerans specific DNA 
sequences over a period of more than two years at a water contact sites of BU patients in an 
endemic village of Cameroon. At defined positions in a shallow water hole used by the 
villagers for washing and bathing, hypertrophic detritus remained consistently positive for M. 
ulcerans DNA. The observed mean Ct difference of 1.45 between the RT-PCR for the 
insertion sequences IS2606 and IS2404 indicated that lineage 3 M. ulcerans, which cause 
human disease, persisted in this environment after successful treatment of all local patients. 
Underwater detritus may therefore represent a reservoir of M. ulcerans for direct infection of 
skin lesions or vector-associated transmission. 
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4.2 Introduction 
Buruli ulcer (BU) is a neglected tropical disease of the skin and subcutaneous tissue 
caused by the environmental pathogen Mycobacterium ulcerans. The disease, which can 
affect all age groups and both sexes, has been reported in over 30 countries but is most 
frequent in West Africa. Typically, BU presents with ulcers with undermined edges but 
clinical manifestations also include nodules, oedema and plaques. Lesions can encompass 
entire limbs if patients report late for treatment [1]. The WHO recommends that all cases 
should be laboratory confirmed by microscopy, polymerase chain reaction (PCR), primary 
culturing or histology [2]. However, because of the limited access to laboratory facilities in 
BU endemic areas, cases are often diagnosed based only on clinical signs and there is a 
pressing need for a simple, sensitive and specific point-of-care diagnostic test [3]. 
Historically, BU was treated using wide scale excision of the lesions. Since 2004, the WHO 
recommends a combination therapy of daily streptomycin and rifampicin for 8 weeks as the 
standard treatment for BU [1]. 
The major risk factor for BU is proximity to stagnant or slow flowing water, but other 
factors such as poor wound care, and failure to wear protective clothing have also been 
identified in case-control studies [4]. It has further been reported, that man-made 
modifications of the environment may increase the incidence of BU [4]. Despite relentless 
efforts, both the reservoir and the exact mode of transmission of BU remain a mystery. 
Numerous investigations of the environment have attempted to identify the source of the 
pathogen with so far only limited success. Studies in Ghana and Benin, have examined 
environmental samples for the presence of the M. ulcerans insertion sequence (IS) 2404. 
Some of these studies have identified many IS2404 positive sites and found positive samples 
in both BU endemic and non-endemic areas [5]. On the other hand, a study from Ghana has 
reported that only very few samples were real time PCR (RT-PCR) positive [6]. These 
difficulties to conclusively identify the environmental reservoir of M. ulcerans and the fact 
that investigations on its genome have revealed that the pathogen has undergone substantial 
niche adaptation[7,8], have led investigators to look for animal reservoirs [4,7]. While to date 
no such reservoir has been detected in Africa, possums have been identified as an animal 
reservoir in the southern Australian BU endemic area [9]. The mode of transmission from an 
animal or environmental reservoir to human patients also remains to be elucidated. Both 
insect bites, from mosquitos or water bugs, and direct inoculation of bacteria into the skin 
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from an environmental reservoir after skin trauma have been suspected to be relevant for 
transmission [4] and several parallel modes of transmission may need to be considered [10]. 
The objective of the current study was to longitudinally monitor environmental contact 
sites of laboratory confirmed BU patients for the persistence of M. ulcerans DNA. 
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4.3 Materials and Methods 
Ethical statement 
Approval for this study was obtained from the Cameroon National Ethics Committee 
(N°041/CNE/DNM/09 and N°172/CNE/SE/2011) and the Ethics Committee of Basel (EKBB, 
reference no. 53/11). Participation was voluntary and all patients, independent of their study 
participation, were treated according to national treatment guidelines. All cases who 
participated in the study or their legal guardian provided written informed consent. 
 
Study area, patient inclusion and patient confirmation 
All RT-PCR confirmed cases identified in the Mapé Basin of Cameroon [10] between 
the beginning of December 2009 and the end of November 2011, were eligible for inclusion 
in this study. For definitive BU diagnosis, clinical samples were collected, DNA extracted and 
IS2404 RT-PCR performed as previously described [10–12]. Environmental sampling was 
performed between February 2011 and June 2013. 
The main water bodies of the study area are the Mapé Dam and the Mbam River [10]. 
The region experiences two rainy seasons, a short one from mid-March to mid-May and a 
long one from mid-June to the end of September, with the rest of the year being dry. 
 
Selection of environmental sampling locations and sampling procedures 
Patients selected for in-depth investigation were interviewed to determine where they 
lived for the year before the onset of BU. Homes of as many non-participating RT-PCR 
confirmed cases as possible were also identified and mapped. If participating patients had a 
home both in their village and at their farm, an interview was used to determine where they 
spent more time. After achieving an accuracy of less than 10m, a GPS receiver was used to 
map the patient’s home. Together with the patient, a close friend or relative, sites of regular 
environmental contact of the patient were then visited. The investigated and mapped sites 
included the patient’s farm(s) and the location(s) where she/he obtained water while at home 
(VW: village water site) or at the farm(s) (FW: farm water site). Sites used to obtain water for 
drinking, cooking, bathing, cloth washing and dish washing were visited. At all sites, soil and 
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plant material was collected. At the water contact sites, a water sample was also collected. 
Samples collected at the farms were dry soil and plants growing on dry grounds. Plant and 
soil samples from the water contact sites, were collected from either in the water, at the 
water’s edge or in the moist area around the water site. 
Additionally, animal fecal samples were collected in the highly BU endemic village of 
Mbandji 2. Samples were collected around the homes of laboratory confirmed BU patients 
and included the feces of chicken, ducks, pigs, goats and sheep. 
At two water contact sites located in Mbandji 2 (VW12 and VW13) we performed 
repeated and in-depth sampling over a period of more than two years (Supplementary Table 
4.1). In addition to the samples collected at the initial time point (t=0) as described above, 
samples were collected from VW12 and VW13 at seven additional time points (t=2.1, 4.8, 
7.7, 10.5, 15.3, 20.3 and 27.4 months). At the two initial time points, samples were collected 
from 3 sampling points at each VW site. At the remaining time points, samples were collected 
at 21-22 sampling points around VW12, with 3-5 sample replicates at each point. At the same 
time points, VW13 was sampled at 14-16 points with 1-3 sample replicates collected at each 
sampling point. Details of the sampling points and the number of replicates collected at each 
sampling point and at each time point are given in Figure 4.4, Supplementary Figure S4.1 and 
Supplementary Table S4.1. All samples, with the exception of points 7 and 13, which were 
plants on dry soil, were collected from inside the water or at the water’s edge (Figure 4.4 and 
Supplementary Figure S4.1). 
At the last follow-up time point (t=27.4 months), further soil samples from inside the 
water were collected around the log at site VW12. At each sampling point 3-5 replicates of 
the same type of sample were collected. At several sampling points on either side of the log, 
samples were repeatedly collected in the course of a few days (Figure 4.5). At sampling point 
55, additional samples of various natures were collected. 
All environmental samples were stored at 4ºC until analysis. 
 
Environmental DNA Extraction and RT-PCR 
From the environmental samples, DNA was extracted and RT-PCR performed as 
previously described [11,12]. Briefly, approximately 200µL of each soil, plant and fecal 
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sample was transferred to a lysing tube and DNA extracted using the Fast DNA Spin Kit for 
Soil (MP Biomedicals, product number 116560-200) and a Precellys24 homogenizer (Bervet 
Bertin Technologies). For water samples, 1mL was transferred to a lysing tube, the tubes 
centrifuged for 10 min (14’000 rpm), the supernatant removed and the samples then processed 
like the other samples. All samples were at least once extracted by the above method. Some 
samples were also processed once by homogenizing them in lysing matrix E tubes in the 
presence of the MT buffer (MP Biomedicals) and Phosphate Buffered Saline (MP 
Biomedicals), pelleting debris (10 min at 14’000 rpm) and then extracting DNA from the 
supernatant with the QIASymphony (Qiagen) and the QIAsymphony DSP Virus/Pathogen 
Midi Kit (Qiagen, product number 937055). For each extraction, a reagent control was 
included. 
Extracted DNA (1µL of 100µL) was run twice in the IS2404 RT-PCR assays as 
previously described [11,12]. In the IS2404 RT-PCR, an internal positive control (IPC, 
Applied Biosystems) was included. Samples which were inhibited were diluted 1/5 and 1/10 
and analyzed again. In each RT-PCR run both negative and positive controls were included. If 
a sample was positive in at least one of the IS2404 RT-PCR assays, DNA was extracted from 
a second aliquot of the same environmental sample. If again at least one of two parallel 
IS2404 RT-PCR assays was positive, the corresponding environmental sample was 
considered positive for IS2404. DNA extracted from these samples (1 µL and 5 µL) was then 
subjected to IS2606 and keto reductase (KR) RT-PCR as previously described [11,12]. If the 
extracts of a particular sample, were at least once positive for these two additional targets, the 
sample was considered positive for M. ulcerans DNA. All IS2404 positive samples that were 
not positive for both of the other targets were not considered to contain M. ulcerans DNA and 
were not included in the analysis. All RT-PCR assays were performed in a StepOne Plus 
Real-Time PCR System (Applied Biosystems) and analyzed using the StepOne Software 
(v2.2.2; Applied Biosystems). Samples extracted using the QIASymphony as well as samples 
analyzed on site in Cameroon, were RT-PCR tested for the presence of IS2404 by a 
Mastercycler Realplex 4 ep Gardient S (Eppendorf) and the data analyzed by Mastercycler ep 
Realplex (version 2.2). 
 
Statistical Data Analysis 
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Statistical data analysis was performed using R (The R Foundation for Statistical 
Computing; version 2.15.1) and RStudio (RStudio, Boston, USA; version 0.95.262). Maps 
were drawn in ArcGIS ArcMap (Economic and Social Research Institute, Redlands, USA; 
version 10.0). 
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4.4 Results 
Screening of environmental contact sites of BU patients for the presence of M. ulcerans 
DNA 
From December 2009 to November 2011, 67 RT-PCR confirmed cases of BU were 
identified in the Mapé Basin of Cameroon. Of these patients, 46 were selected for in-depth 
environmental contact analysis based on their origin in the southern part of the Mapé Basin 
and their availability to participate in the study. The homes and farms as well as the VW and 
FW sites of the patients were mapped (Figures 4.1A and 4.1B). The median direct distance 
between the homes and farms was 1.5 km (interquartile range = 0.6 km to 5.3 km). While 
some patients lived permanently at their farm, others travelled more than 15 km to get from 
their home to their farm (Table 4.1). As shown in Figures 4.1A and 4.1B, many of the BU 
patients in the southern Mapé Basin moved south and east towards the Mbam River for their 
farming activities. 
Environmental samples (171 soil, 153 plant and 109 water samples) were collected at 
the farms (n=49), FW (n=43) and VW (n=48) sites shown in Figure 4.1A. Of the soil and 
plant samples, 108/171 and 109/153 respectively, were collected in or around water. The 
remaining samples were collected from dry grounds. All environmental contact sites are 
numbered in Table 4.1; sites used by several patients are indicated by the same number. 
Additionally, pig, goat, sheep, chicken and duck fecal samples (n=24) were collected at 14 
locations in the BU endemic village of Mbandji 2 (Figure 4.1B). 
All environmental and fecal samples were tested by RT-PCR for the presence of the 
M. ulcerans specific IS2404 DNA sequence. Three VW sites (VW12, VW31 and VW54) and 
one duck fecal sample (F07) tested positive (Figures 4.1A and 4.1B). At locations VW31 
(Figure 4.1C) and VW54 (Figure 4.1D), soil samples collected in the moist area around the 
water wells were positive. Both of these water sites were used by one BU patient each (Table 
4.1). Water from VW31 was reported to be used for bathing and washing of clothing and 
water from VW54 was used for all purposes including drinking. At site VW12, used by three 
of the patients living in the village of Mbandji 2, both a soil and a plant sample collected at 
the water’s edge, tested positive. Further details on the results of a longitudinal study at 
VW12 are provided below.  
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Persisting RT-PCR positivity of hypertrophic detritus after successful treatment of the 
identified local BU patients 
As shown in Figures 4.1B and 4.2A, six BU patients were notified during the study 
period in Mbandji 2, which is situated between the Mapé Dam and the Mbam River (Figure 
4.1E). The locations of the homes of these patients are shown in Figure 4.2B and 
characteristics of the patients, which are not related to each other, are listed in Table 4.2. 
Patients 06, 13, and 34, aged 9, 5 and 57, respectively, all used the RT-PCR positive VW12 
site (Figure 4.2B and Table 4.1). Furthermore, the only positive faecal sample (F07; from a 
duck) was collected in close proximity of the home of patient 13 (Figure 4.2B). The other 
three patients from Mbandji 2 used primarily four other VW sites (Table 4.2, Figure 4.2B).  
To better characterize IS2404 RT-PCR positivity in Mbandji 2, we performed detailed 
longitudinal analyses of VW12 and the close-by IS2404 negative site VW13 (Figure 4.1B and 
2B). VW12 was a permanent small water body with a wooden log lying in it (Figure 4.3A). 
The water was shallow and flowed slowly from the left to the right. For most of the log, the 
left and right side of the water were not connected under the log; however at some points 
water could pass underneath the log. On the right side the vegetation was denser and a layer 
of detritus was accumulating. In contrast, the compacted ground on the left was not covered 
with detritus. Site VW12 was used by the local population – including patients 06, 13 and 34 
(Table 4.1 and 4.2) – to wash clothing and for bathing. For these activities, locals stood in the 
water on the left side of the log. The father of patient 13 also reported that his daughter went 
to this site to play. In contrast, VW13 was used by the local population – including again 
patients 06, 13 and 34 – to obtain drinking water as well as water for cooking and bathing. In 
the front section of VW13, where there were planks of wood (Figure 4.3B), water emerged 
from several springs. 
We collected and analysed environmental samples at eight time points over a period of 
27.4 months at both VW12 (n=635) and VW13 (n=217) (Supplementary Table S4.1). 
Particularly at location VW12, substantial seasonal alterations of the environment over the 
study period were observed (Figure 4.3A and 4.3B). None of the 217 samples collected at 
VW13 tested positive in the IS2404 RT-PCR and only one of 108 samples taken from the 
sand pits to the north-west of VW12 tested positive (Figure 4.4B and 4.4C, Supplementary 
Figure S4.1 and Supplementary Table S4.1). In contrast, at 7/8 sampling time points, positive 
samples were obtained from at least one of the six positive sampling points identified at 
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VW12 (Fig. 4). In particular underwater soil samples collected at sampling point 37 were 
positive at 5/6 time points tested (Figures 4.4A and 4.4B). The average IS2404 RT-PCR Ct 
values of the positive samples varied between 34.0 and 38.4 (Figure 4.4B). As shown in 
Figure 4.4C, at the initial sampling time point, there was still one active case of BU (patient 
34) using VW12 and there were still a total of three active BU cases in the entire village of 
Mbandji 2. However, from the third sampling time point on, no active BU case was using 
VW12 and from the fourth time point on, no active BU case was present in the entire village 
of Mbandji 2 (Figure 4.4C). Taken together IS2404 RT-PCR positivity at the VW12site thus 
persisted for more than one year after successful treatment of all BU patients identified in the 
village of Mbandji 2 (Figure 4.4). 
Having identified the deposit on the right hand side of the log lying in VW12 as an 
IS2404 hotspot (Figure 4.4C), we analysed the soil all around the log in more detail. While 
compacted and sandy ground was found on the left, the ground was covered with hypertrophic 
detritus on the right hand side of the log (Figure 4.5A). At the eighth sampling time point we 
collected three replicates of soil samples every 1.14m at a total of 14 sampling points all 
around the log (Figure 4.5B). Using on site RT-PCR, we identified sampling point 55 (Figure 
4.5C) as being positive (data not shown) and then sampled this location as well as other points 
around the log repeatedly over the next 12 days (Figure 4.5C). All samples were analysed 
once back in the lab. While all 59 samples collected on the left hand side and at the back of 
the log were negative, 9/62 samples from the right side of the log were positive. Positive 
samples were identified at sampling point 55 and the neighbouring point 56 (Figure 4.5C) 
with an average IS2404 Ct value of 35.8 for all nine positive samples (Figure 4.5C) 
Additional sample types, including plants, roots or samples from the surface of the log, 
collected at sampling point 55 all tested negative (data not shown). 
All the above mentioned IS2404 positive samples also tested positive in the IS2606 
and the KR RT-PCR and the mean Ct difference (∆Ct) between IS2606 and IS2404 (IS2606-
IS2404) of the samples was 1.45 (95% confidence interval from 1.10 to 1.80). This ∆Ct 
indicated that the obtained PCR signal is not related to lineage 1 M. ulcerans bacteria, which 
are fish and frog pathogens and harbor only a few copies of IS2606, but that the PCR signal 
likely originates from lineage 3 bacteria, which are found in human lesions and contain 63-98 
copies of IS2606 per genome [7]. 
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4.5 Discussion 
In African BU endemic areas, both the nature of the environmental reservoirs of M. 
ulcerans and the mode of transmission to humans have so far remained unclear. The physical 
environment, e.g. biofilms, and organisms such as amoeba, insects, fish and frogs have all 
been proposed as possible reservoirs for the pathogen [4]. Investigations in Southern Australia 
have identified mammals, specifically possums, as a local reservoir of M. ulcerans [9]. 
However, no such mammalian source of the pathogen has been detected in Africa thus far 
[13]. As for the transmission to humans, hypotheses include insect vectors and direct 
inoculation from the environment via small skin lesions. Parallel modes of transmission may, 
depending on the environmental and epidemiological setting, be relevant [4,10]. A recent 
review on BU transmission, found that more evidence is needed to conclude that insects are 
involved in M. ulcerans transmission [4]. Interestingly, M. marinum, the closest relative and 
ancestor of M. ulcerans, occasionally causes human infection by inoculation through small 
skin lesions which are often not remembered by the patient because of the long incubation 
period [14]. 
Although BU may occur at all ages, the relative risk for children below the age of fife 
to develop the disease is lower than for older children [10,15]. This appears to apply across 
different endemic areas in Africa and may indicate that exposure to M. ulcerans is increasing, 
once children are taking up new activities away from their homes [10,16]. Such activities 
could include going to the farm to work or to water sources for household activities, to collect 
water or to play. With this in mind and since proximity to water bodies undoubtedly is a risk 
factor for BU [4], we set out to systematically test environmental, and in particular water, 
contact sites of laboratory confirmed BU patient. Specifically we collected plant, soil and 
water samples at the farms as well as village and farm water sites of patients and tested them 
for the presence of M. ulcerans DNA.  
Due to the abundance of other and faster growing microorganisms in the environment, 
routine cultivation of M. ulcerans from environmental samples has mostly failed [17] and to 
date only a single M. ulcerans isolate from a water-strider, has been reported [18]. Attempts 
to culture from our samples were not successful also because of the overgrowth by other 
mycobacteria. By PCR using pan-mycobacterial and hsp65 primers [19,20] and DNA 
sequencing, we detected species such as M. shimoidei, M. psychrotolerans and M. chubuense 
in our preparations (data not shown). Because of these difficulties, RT-PCR for IS2404 is 
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commonly used to detect M. ulcerans in the environment. We applied most stringent quality 
control procedures with internal positive controls in each sample as well as negative and 
positive controls in each RT-PCR reaction. Further, we only considered an environmental 
sample positive if it was positive in two separate DNA extractions. With this approach we are 
confident that the positive samples truly contain M. ulcerans DNA. We can however not 
exclude, particularly given the heterogeneity of the environmental samples, that some positive 
samples may be missed. Although IS2404 is considered a specific marker for M. ulcerans 
[21], the existence of IS2404 positive M. ulcerans ecotypes (lineage 1) that are largely 
avirulent for humans complicates interpretation of RT-PCR data and requires that samples are 
also tested for the presence of IS2606 and that the difference between the IS2606 and the 
IS2404 Ct value is analyzed [7,11]. Because M. ulcerans ecotypes that cause human disease 
in Africa and Australia (lineage 3) harbor a higher number of IS2606 sequences then those of 
linage 1, the ecovars can be separated based on the IS2606 to IS2404 ∆CT [7]. All 41 IS2404 
positive environmental samples collected in the course of this study also tested positive for 
IS2606 with a mean IS2606 to IS2404 ∆Ct of 1.45. This ∆Ct is well below the ∆Ct of 7 to 8 
of the for humans non-pathogenic lineages 1 M. ulcerans strains [11]. Two of the IS2404 and 
IS2606 positive samples, both not included in the M. ulcerans DNA positive samples 
discussed in this paper, were negative for the RT-PCR of the lower copy number virulence 
plasmid associated KR sequence. 
Our screening of environmental contact sites of laboratory confirmed BU patients 
revealed that they travel considerable distances to get to their farms and some of the patients 
further reported to spend several months there. Molecular typing studies of disease isolates 
may help to identify if the patients were infected close to their homes or farms [22]. 
By testing environmental samples, we identified two M. ulcerans DNA positive water 
wells (VW31 and VW54) in two different villages. In a third village we identified an M. 
ulcerans positive duck fecal sample (F07) and a positive open permanent water site (VW12). 
While this rate of environmental positivity is similar to what has been found in a study from 
Ghana [6], positivity was much higher in another study also conducted in Ghana [23]. It is 
interesting to note that all three positive sites were permanent as opposed to seasonal water 
sources. Obtaining water from such water sources has previously been shown to increase the 
risk for BU [24]. The positive duck fecal sample, merits further investigation to determine 
how waterfowl may contribute to the reservoir of M. ulcerans. 
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At VW31 and VW54 we did not investigate the local scenario any further and cannot 
exclude the possibility that these sites were contaminated with M. ulcerans DNA from the 
lesions of patients living close to the wells. However at VW12, located in Mbandji 2, we 
observed persistence of M. ulcerans DNA in underwater detritus for more than one year after 
successful treatment of the last BU patient. Continuous presence and case detection in the 
village allowed us to detect all local cases and it is therefore unlikely that the source of the 
environmental positivity was from bacteria recently spread from a human lesion. 
Interestingly, the more sandy ground on the left of the log at WV12 was never RT-PCR 
positive for M. ulcerans DNA and even on the right side of the log the distribution of M. 
ulcerans DNA was highly focalized (Figures 4.4 and 4.5), with samples taken from sites just a 
few meters apart giving different results. The persistent of RT-PCR positivity in the detritus is 
a strong indication that this micro-environment may represent a niche environment to which 
M. ulcerans has adapted in the course of evolution from the more generalist M. marinum 
[7,25].  
The previously described age distribution of BU patients in the Mapé Basin [10] and 
the here described findings of M. ulcerans DNA at a village water sites, lead to the hypothesis 
that around the age of four, when children are beginning to be sent to fetch water, both 
exposure to M. ulcerans and the risk of contracting BU increases because of direct contact 
with the environmental source of the pathogen. Our data further suggest that, the detritus at 
the water site could represent a reservoir from where infection could take place through either 
direct contamination of skin lesions or through contamination or colonization of insect 
vectors.  
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4.7 Tables 
Table 4.1: Environmental contact sites of laboratory confirmed BU patients tested for M. ulcerans DNA. 
Patient ID Village Water (VW) *** Farm (F) *** Farm Water (FW) *** Distance Home – F (km) 
01 VW01, VW02, VW03 F not visited FW01, FW02 NA 
02 VW04, VW05 F01 NA * 0.63 
03 VW06, VW07 F02 FW03 12.14 
04 VW08, VW09 F03 FW04, FW05 14.31 
05 VW10, VW11 F04 FW06 5.62 
06 VW12#, VW13 F05, F06 FW07 7.54; 6.19 
07 VW14, VW15, VW16 F07, F08 NA * 0.34; 0.65 
08 VW17 F09 FW08 0.69 
09 VW18, VW19 F10 FW09, FW10 3.03 
10 VW20, VW21 F11 FW11 2.27 
11 VW22 F12 FW12 1.08 
12 VW23, VW24 F13, F14, F15 FW13 5.37; 5.26; 1.40 
13 VW12#, VW13 F16 FW not visited 2.87 
14 VW25 F17 FW14 1.57 
15 VW26 F18 FW15, FW16 3.20 
16 VW27, VW28 F19 FW17, FW18 11.96 
17 VW29 F20 FW19, FW20 3.51 
18 VW30 F21 FW21 0.55 
19 VW31# F22 FW22 12.62 
20 VW32 F23 NA * 0 
21 VW not visited F24 FW23 0 
22 VW33 F25, F26 FW24 0.89;1.20 
23 VW34, VW35 F27 FW25 2.00 
24 VW36, VW37 F not visited FW not visited NA 
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25 VW38 F28 FW not visited 5.66 
26 VW39 F29 FW26, FW27 1.48 
27 VW40, VW41 F30 FW28, FW29 7.32 
28 VW42, VW43 F31 FW30, FW31, FW32, FW33 4.40 
29 VW44, VW45, VW46 F32 ** FW34 3.60 
30 VW47 F33 FW35 15.35 
31 VW48 F34 NA * 0.30 
32 VW49 F35 NA * 0.99 
33 VW50 F36 FW36 1.83 
34 VW12#, VW13 F16 FW not visited 2.98 
35 VW51 F37, F38 NA * 0.08; 0.21 
36 VW52, VW53 F39 NA * 0.38 
37 VW54# F40 NA * 0.24 
38 VW55 F41 FW37 1.31 
39 VW56, VW57 F42 NA * 0.59 
40 VW58, VW59 F43, F44 FW38, FW39 1.13; 0.84 
41 VW52, VW53 F45 NA * 0.79 
42 VW60 F46 NA * 0 
43 VW61 F47 NA * 0.02 
44 VW not visited F48 FW40, FW41, FW42 5.91 
45 VW62 F49 FW43 13.52 
46 VW48 F50 NA * 0.17 
NA: not applicable 
* Water carried to farm from home 
** Location not tested by RT-PCR 
*** VW, F and FW sites are individually numbered; sites which are shared between patients are identified by the same number 
# Positive for M. ulcerans DNA 
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Table 4.2: Laboratory confirmed BU patients in Mbandji 2 during the course of the study. 
Patient ID Age Gender Clinical Form Category Disease Start Date* Discovery Date Treatment Start VW used by the patient  
06 9 M nodule 1 unknown 13.04.2010 24.07.2010 VW12 and VW13 
13 5 F plaque 2 11.09.2010 06.11.2010 10.11.2010 VW12 and VW13 
15 2 M ulcer 3 26.10.2010 30.11.2010 03.12.2010 VW 26 
33 11 M ulcer 2 10.03.2011 05.05.2011 10.05.2011 VW 50 
34 57 M ulcer 1 01.03.2011 10.05.2011 12.05.2011 VW12 and VW13 
40 42 M ulcer 3 06.09.2009 07.08.2011 07.08.2011 VW 58 and 59 
* Calculated based on information provided by the patient 
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Supplementary Table S4.1: Number of environmental samples collected at each sampling point 
of VW12 and VW13 at all sampling time points. 
Sampling 
Point* 
Sample 
Type t = 0 
t = 2.1 
months 
t = 4.8 
months 
t = 7.7 
months 
t = 10.5 
months 
t = 15.3 
months 
t = 20.3 
months 
t = 27.4 
months 
1 water NA NA 1 3 3 3 3 3 
2 soil NA NA 1 3 3 3 3 3 
3 plant NA NA 1 3 3 2 3 3 
4 plant NA NA 1 3 3 3 3 3 
5 water 1 NA 1 3 3 3 3 2 
6 plant 1 NA 1 3 3 3 3 3 
7 plant NA NA 1 3 3 3 3 3 
8 soil NA NA 1 3 3 3 3 3 
9 soil NA NA NA NA 3 3 3 3 
10 plant NA NA 1 3 NA NA NA NA 
11 water NA NA 1 3 3 3 3 3 
12 soil NA NA 1 3 3 3 3 3 
13 plant NA NA 1 3 3 3 3 3 
14 water NA NA 1 3 NA NA 3 3 
15 soil 1 NA NA 3 NA NA NA NA 
16 plant NA NA NA NA 3 2 3 3 
17 soil NA NA 5 3 3 3 3 3 
18 water NA NA 4 3 NA 3 3 3 
19 plant NA NA 5 3 3 3 3 3 
20 plant NA NA 5 3 3 3 3 3 
21 water NA NA 4 3 3 3 NA 2 
22 soil NA NA 5 NA 3 3 3 3 
23 water 1 1 NA 5 NA NA 5 NA 
24 soil NA NA 5 NA 5 5 NA 5 
25 soil 2 1 4 5 5 5 5 5 
26 water NA NA NA 5 NA NA NA NA 
27 plant 2 3 5 NA 5 5 5 5 
28 soil NA NA 5 NA 5 5 5 5 
29 plant NA NA NA 5 NA NA NA NA 
30 water NA NA 5 5 5 5 5 3 
31 soil NA NA 5 5 5 5 5 5 
32 plant NA NA 5 5 5 5 5 5 
33 plant NA NA 5 5 5 5 4 5 
34 water NA NA 4 5 5 5 5 5 
35 plant NA NA 5 5 5 4 5 5 
36 plant NA NA 5 4 5 5 5 NA 
37 soil NA NA 5 5 5 5 5 5 
38 water NA NA 5 5 5 5 5 5 
39 plant NA NA 5 5 5 5 5 NA 
40 plant NA NA 5 5 5 5 5 5 
41 plant NA NA 5 5 5 5 5 5 
42 plant NA NA 5 5 5 5 NA 5 
43 plant NA NA 5 5 5 5 4 5 
* Sampling points 1 to 16 are at VW13 and 17 to 43 are at VW12. 
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4.8 Figures 
 
Figure 4.1: Environmental contact network of laboratory confirmed BU patients from the 
southern Mapé Basin. 
Panel A and B (detailed view of the village of Mbandji 2) show the houses where the 46 laboratory 
confirmed BU patients in our study lived (black points), the farm(s) where they worked (green points) 
and the locations where they obtained their water (blue points) during the year before the onset of BU 
symptoms. The home of each patient is connected with their farm(s) as applicable. Homes of 17 of the 
21 non-participating laboratory confirmed BU patients are shown in grey. At the farms and water 
contact sites, soil (n=171), plant (n=153) and water (n=109) samples were collected. Furthermore, in 
Mbandji 2 (B), animal faecal samples were collected around patients’ houses (brown points). All 
samples were tested for the presence of M. ulcerans DNA and three village water sites were found to 
be positive (red points; VW12, VW31 and VW54). Further, at site F07 a positive duck faecal sample 
(red point) was collected. Photographs of locations VW31, VW54 and F07 are shown in C, D and E, 
respectively. Finally Panel B also shows a negative water contact site (VW13) which was studied in 
detail.   
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Figure 4.2: Water contact sites in Mbandji 2 which were investigated in detail. 
Based on the high case number and the identification of two environmental sites which were positive 
for M. ulcerans DNA, water contact sites in Mbandji 2 were analysed in detail. The town is located 
between the Mapé Dam and the Mbam River (A). Panel B shows the locations of the homes of the 6 
patients from Mbandji 2 in our study (black points) and each of the homes is connected with the 
village water site(s) used by the respective patient. Faecal sampling sites are also shown (brown 
points). Locations which tested positive for M. ulcerans DNA are highlighted in red (B). A positive 
(VW12) as well as a close by negative (VW13) village water sites were studied in more detail. Images 
are based on a 0.5m resolution WorldView-2 image take on March 12th 2011. 
 
 
Figure 4.3: Alterations of the environment at locations VW12 and WV13 at the sampling time 
points. 
Photographs of locations VW12 (A) and VW13 (B) are shown at selected environmental sampling 
time points. 
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Figure 4.4: Persistence of M. ulcerans at a village water site of BU patients. 
Panel A shows a diagram of the water hole at VW12A from where samples were collected at eight 
time points over a period of 27.4 months. Soil sampling points are shown as brown crosses, water 
sampling points as blue crosses and plant sampling points as green crosses. Supplementary Table S4.1 
shows how many samples were collected at each sampling point and each time point. All samples 
were tested for the presence of M. ulcerans DNA by RT-PCR. At 7 sampling time points, M. ulcerans 
RT-PCR positive samples were identified at VW12 (B with positive sampling points identified by the 
larger coloured circles and C). Panel C (line colours correspond to the circle colours in panel B) 
further shows the rate of positivity of the collected sample replicates as well as the average Ct value 
for the IS2404 RT-PCR performed on the positive samples. Finally, panel C shows the number of 
active BU cases in the village of Mbandji 2 (black line) and the number of active BU cases using 
VW12 (red line) at the environmental sampling time points. 
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Figure 4.5: In-depth analysis of soil surrounding the log at VW12. 
Panel A shows the nature of the soil on the right and the left hand side of the log. To better understand 
positivity of samples at location VW12, we performed sampling all along the log on either side (B; 
brown crosses indicate sampling points). Selected locations were re-sampled over the next 12 days as 
indicated in panel C. Panel C further shows the rate of positivity among the replicates collected at each 
sampling time point and the average Ct value of the IS2404 RT-PCR performed. 
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Supplementary Figure S4.1: Sampling points at VW13 and the sand pits at VW12. 
Diagram of VW13 and the sand pits close to VW12 with the sampling sites; soil sampling points are 
shown as brown crosses, water sampling points as blue crosses and plant sampling points as green 
crosses. For details on the main water site of VW12 (transparent part) see Figure 4.4. 
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Chapter 5. Culturing of M. ulcerans After Long-Term Storage 
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5.1 Introduction 
Buruli ulcer (BU), a neglected tropical disease of the skin, has been reported from over 
30 countries worldwide with most cases occurring in West Africa. Clinically BU, which is 
caused by Mycobacterium ulcerans (MU), presents with both non-ulcerative lesions, such as 
nodules, plaques and oedema as well as ulcers and the major burden of disease falls on 
children between 5 and 15 years of age (1, 2). Despite years of research, both the reservoir 
and the mode of transmission of the environmental pathogen remain unknown (1). Currently 
available methods for laboratory diagnosis of BU are microscopy, polymerase chain reaction 
(PCR) for the MU specific insertion sequence 2404 (IS2404) or primary culturing. Based on 
the high sensitivity and specificity, the IS2404 PCR is considered the gold standard in BU 
diagnosis (2). Historically, BU was treated with surgery and tissue samples could easily be 
obtained for laboratory diagnosis. Since the introduction of streptomycin and rifampicin (SR) 
combination therapy in 2004 by the WHO, samples for laboratory testing are obtained by fine 
needle aspiration (FNA) from closed lesions and cotton swabs from ulcers (3). 
Although primary culturing of MU can provide a definitive BU diagnosis, this method 
is strongly limited by the fact that colonies take 8-12 weeks to appear and even under optimal 
conditions it is not positive for all BU cases (4, 5). Culturing can therefore not be used for 
routine laboratory diagnosis of BU but as an auxiliary to other diagnostic methods and for 
studies on treatment efficiency, transmission and the development of drug resistances, 
primary isolation of MU remains crucial (6, 7). Because of the slow growth rate of the 
pathogen, primary culturing requires decontamination of clinical samples prior to culture 
inoculation to prevent the overgrowth with other microorganisms (5). Palomino and Portaels 
have shown that decontamination by the commonly used Protroff (NaOH) or reverse Petroff 
(HCl) methods or using oxalic acid (OA), all have a detrimental effect on the viability of 
cultured MU (5, 8, 9). The same study also found that PANTA, a mixture of the antibiotics - 
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Polymyxin B, Amphotericin B, Nalidixic acid, Trimethoprim and Azlocillin - did not have an 
inhibitory effect on the growth of MU and can therefore potentially be used to prevent the 
growth of other microorganisms (9). Once decontaminated, MU can be recovered by 
inoculation on Löwenstein-Jensen (LJ) media and incubation at temperatures between 30 and 
33ºC. 
Two studies have previously shown that culturing from cotton swabs or FNA after 
short term transport in a semi-solid medium is feasible (10, 11). Eddyani et al. found that 
culture positivity using FNA was 17.6% which was not significantly different from the culture 
positivity from tissue samples (11). In the more recent study, Yeboah-Manu et al. evaluated 
the effect of decontamination by the Petroff method, OA or a combination of both on samples 
collected by cotton swabs. Processing samples within 24 hours, the two decontamination 
methods were found to be equivalent in terms of MU recovery but decontamination by OA 
showed a reduced rate of contamination and this was therefore declared as the preferred 
method (10). 
For the current study we set out to determine the best procedure for the cultivation of 
MU from remote endemic areas after long term storage. Specifically, the objectives of the 
current study were to: (i) determine which transport medium, decontamination method or 
other factors decrease the chance of contamination of MU primary cultures and (ii) investigate 
which of the same factors can increase the chance of MU primary isolation. The method 
devised here is suitable for the establishment of an MU strain collection for research purposes 
following long term storage of samples coming from remote BU endemic areas. 
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5.2 Materials and Methods 
Ethical statement and patient recruitment 
Samples were collected from patients recruited in the Mapé Basin of Cameroon (12) 
between April 2010 and 2012 as well as from patients recruited for a BU clinical trial in 
southern Cameroon during the same period. Ethical clearance for the collection of samples 
was obtained from the Cameroon National Ethics Committee (N°041/CNE/DNM/09, 
N°006/CNE/SE/2010, and N°172/CNE/SE/2011) and the Ethics Committee of Basel (EKBB, 
reference no. 53/11). Participation was voluntary and all patients who participated in the study 
or their legal guardian provided written informed consent. 
 
Sample collection, storage and transport 
Prior to the start of treatment several FNA or cotton swabs were collected from each 
patient. To facilitate handling, FNA were transferred onto a cotton swab immediately after 
collection. Samples were stored dry, in 7H9 or in Amies (VWR International) transport 
medium. Sterile 7H9 (Difco Middlebrook, Becton Dickinson and Company) transport 
medium was home made to contain 0.5% Agar-Agar (Merck), 0.2% glycerol (Sigma), 2% 
PANTA (Becton Dickinson and Company) and 10% OADC Enrichment (Becton Dickinson 
and Company) (13). Locally the collected samples were stored at 4ºC whenever possible. At 
4-6 month intervals, samples were transported to the laboratory at ambient temperature. Once 
in the laboratory, swabs were stored again at 4ºC. 
 
PCR, decontamination and primary inoculation 
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For DNA extraction, swabs were transferred to glass bottles containing glass beads 
with 2-5mL of sterile PBS and the bottle vortexed for 1.5 minutes. From 1mL of the solution 
DNA was extracted as described by Lavender and Fyfe (14). To reduce the probability of 
false negative results, extracts were analyzed twice by IS2404 real-time PCR (RT-PCR) as 
previously described (14). 
Decontamination of 1mL of wound exudate in PBS was performed with 1mL of 1M 
NaOH for 10 minutes (NaOH_10min) or 20 minutes (NaOH_20min) or with 1mL of 5% OA 
for 30 minutes (OA_30min) or 1 hour (OA_1h) at room temperature with occasional 
vortexing. Decontaminated extracts were neutralized with 20mL of sterile PBS, the 
decontaminated bacteria pelleted by centrifugation for 30 minutes at 3’000g, the supernatant 
decanted and the pellet re-suspended in a minimal volume of sterile PBS. Of the re-suspended 
pellet, 0.1mL was transferred to LJ (with glycerol; Becton Dickinson and Company) and/or 
LJ supplemented with 2% PANTA (LJ_PANTA). 
 
Culture processing and M. ulcerans identification 
All inoculated cultures were stored at 30ºC until growth could be observed. Slants 
were regularly examined and discarded if contamination, i.e. overgrowth with other faster 
growing microorganisms, was detected. Inoculations where no growth was observed were 
kept for a minimum of 25 weeks before discarding. Suspected MU growth was confirmed by 
colony PCR using primers MU154 (5’-ggcagttacttcactgcaca-3’) and MU155 (5’-
cggtgatcaagcgttcacga-3’) and amplification for 32 cycles of 30 seconds at 94°C, 30 seconds at 
60°C and 1 minute at 72°C. PCR products were resolved in a 1.5% agarose gel. 
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Statistical analysis 
To identify factors that affect the rate of contamination and MU recovery in MU 
primary culturing, three statistical analyses, one with all inoculations and two with subsets, 
were performed. The first analysis identified differences between inoculations that did not 
contaminate versus those that did result in contamination (non-contamination vs. 
contamination). The data set used for this analysis included both RT-PCR positive and 
negative swabs and inoculations with any of the three possible outcomes; MU growth, 
contamination with another microorganism or no growth. Swabs with a negative RT-PCR 
result in this data set were assigned a Ct value of 76.80 (reciprocal of the midpoint between 
zero and the minimum of 1/Ct). In the second analysis, a subset of inoculations was analyzed 
to identify factors that affect MU growth (MU growth vs. no growth). All inoculations with 
no realistic probability of resulting in MU growth, i.e. contaminated inoculations and 
inoculations from swabs that were RT-PCR negative were excluded for this analysis. Finally 
in the third analysis, we studied factors that affect the recovery of MU if some inoculations 
resulted in contamination (MU growth vs. contamination or no growth). This subset included 
all inoculations originating from positive swabs independent of their outcome, i.e. also 
including swabs for which growth may have been undetectable because of overgrowth from 
other microorganism. Workflows of the swabs included in the three data sets are shown in 
Figure 5.1 and the combinations of decontamination methods performed are listed in 
Supplementary Table S5.1. 
For the identification of factors that contribute to the outcomes studied, generalized 
linear mixed models with patient identification and identification of each individual swab as 
random effects were used. Factors included in the one to one analysis were: transport 
medium, decontamination method, inoculated media, swab RT-PCR Ct value, per patient RT-
PCR result, time from sampling to inoculation and the duration of the disease before 
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diagnosis. Factors that individually had a p-value of the association of less than 0.2 were 
included in the multivariate analyses. The software SAS (SAS Institute, Cary, USA; release 
9.3), RStudio (RStudio, Boston, USA, version 0.95.262) and R (The R Foundation for 
Statistical Computing; version 2.15.1) were used to perform the analysis. 
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5.3 Results 
Factors affecting the rate of contamination of MU primary cultures 
Of the 443 swabs in the analysis for factors affecting the rate of contamination of MU 
primary cultures, 302 were RT-PCR positive with an average Ct value of 28.09 (Figure 5.1A). 
Of the 1125 inoculations from these swabs (Figure 5.1A), 7.82% resulted in MU growth, 
52.53% yielded no growth and 39.46% resulted in contamination, i.e. overgrowth with other 
faster growing microorganisms. The median time to contamination was 5.0 (IQR = 4.0 to 
11.0) days (Table 5.1). One-to-one analyses were used to identify factors that should be 
included in the multivariate analysis (Supplementary Table S5.2). When studying the 
combined effect of factor on the rate of contamination of MU cultures, we found that the 
transport medium had an overall significant (p-value: 0.006) effect on the probability of 
contamination. Specifically, dry swabs had a significantly increased probability of non-
contamination with an odds ratio (OR) of 57.68; meaning swabs transported dry had 57.68 
times less chance of contamination compared to swabs transported in Amies (Table 5.2). We 
found no significant difference in terms of the rate of contamination between swabs 
transported in 7H9 or Amiens. As also shown in Table 5.2 we found that there is no overall 
significant difference (p-value: 0.266) in the rate of contamination between the four 
decontamination methods evaluated here. The inoculated culture medium on the other hand 
significantly (p-value: <0.001) influences the rate of contamination, with cultures on LJ 
having a 3.79 (1/0.264) times higher probability of contamination than cultures inoculated 
onto LJ_PANTA. The multivariate analysis further showed that there is a significant (p-value: 
0.007) interaction between transport medium and the inoculated media (Table 5.2). On the 
other hand, both an increase in the Ct value of the swab (p-value: 0.236) and the time from 
sampling to inoculation (p-value: 0.606) did not have a significant effect on the rate of the 
contamination of the cultures (Table 5.2). Overall this analysis to identify conditions that are 
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best to prevent contamination of MU primary culture, therefor suggest that swabs should be 
stored dry, any of the evaluated decontamination methods can be used, cultures should be 
inoculated into LJ_PANTA and neither the Ct value of the IS2404 RT-PCR nor the time from 
sampling to inoculation had any effect on the rate of contamination. 
 
Factors affecting the rate of MU recovery in primary culturing 
To identify factors that affect the recovery of MU, 440 inoculations from 220 swabs 
originating from 66 patients were analyzed. The average Ct value of the swabs was 27.86. Of 
all the inoculations included in the analysis, 20.00% (88/440) resulted in MU growth and the 
rest yielded no growth. The median time to growth was 67.0 (IQR = 55.0 to 105.2) days 
(Table 5.1). Because it was not possible to determine if the contaminated inoculations could 
have resulted in MU growth, those inoculations were not included in this analysis (Materials 
and Methods; Table 5.1). One-to-one analyses were again used to identify factors that should 
be included in the multivariate analysis (Supplementary Table S5.3). In the multivariate 
analysis, we found that the transport medium had an overall significant effect (p-value: 
<0.001) on the probability of MU growth (Table 5.3). Specifically, swabs transported dry had 
a significantly reduced chance of MU growth with only 0.023 times the chance of MU growth 
compared to samples transported in Amies (Table 5.3). Between swabs transported in Amies 
or 7H9 we did not detect any significant difference, although transport in Amies had a 
tendency to increase the chance of MU recovery (OR: 0.304; Table 5.3). Interestingly, in the 
multivariate analysis there was no significant difference in the chance of MU recovery 
between the decontamination methods evaluated (p-value: 0.519) and inoculation on either LJ 
or LJ_PANTA (p-value: 0.216). However, With an increase of the Ct value by one unit, the 
probability of MU growth was reduced by 12.1% (p-value: 0.044; Table 5.3) and with every 
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10 extra days of storage between sampling and inoculation, the probability of MU growth 
decreased significantly (p-value: 0.001) by 45.9%. Our analysis further detected a moderately 
significant (p-value: 0.074) interaction between the transport time and the transport medium, 
with Amies having the best chance of MU growth for an increase in transport time by 10 
days. Overall, the analysis to evaluate factors that affect the recovery of MU therefore found 
that either storage in Amies or 7H9 are significantly better than keeping samples dry, the 
decontamination methods tested have an equivalent effect on the growth of MU and the MU 
recovery is not affected by inoculation of samples onto media containing PANTA. On the 
other hand, the analysis showed that both a one unit increase in the Ct value of the IS2404 
RT-PCR and a 10 day increase in the storage time of the samples had a significant negative 
effect on the rate of MU recovery. 
 
MU recovery versus no growth or contamination 
For the identification of factors that affect MU recovery in a scenario where some 
cultures contaminate, 302 swabs from 72 patients with an average Ct value of 28.09 were 
analyzed. As shown in Table 5.1, 12.57% of the 700 inoculations in this analysis resulted in 
MU growth, 37.14% of the inoculations were contaminated and 50.29% did not result in any 
growth. The observed culture positivity corresponds to a per patient culture positivity of 
43.06%. Analysis of these inoculations in a multivariate analysis with all factors that had a 
statistically significant effect on culture contamination or MU growth showed, that transport 
medium had a significant effect (p-value: 0.019) on the recovery of MU from primary 
cultures. Specifically, swabs transported in Amies showed the best recovery rate of MU, 
although not significantly better (95% CI of OR: 0.269 - 1.415) than 7H9. As also seen in the 
analysis of non-contamination (Table 5.2) and MU growth (Table 5.3), the decontamination 
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methods evaluated here, did not significantly vary in their effect on the chance of MU growth 
(p-value: 0.295; Table 5.4). On the other hand the use of the inoculated media had a 
significant (p-value: 0.003) impact on the chance of MU growth, with the use of LJ as 
opposed to LJ_PANTA reducing the probability of MU growth by 65.5%. As further shown 
in Table 5.4, a one unit increase in the Ct value away from the mean Ct value of the 
inoculated swabs (mean=28.09) decreased the chance of MU recovery by 10.8% (p-value: 
0.011). Furthermore, consistent with the analysis of factors effecting M. ulcerans growth, the 
days from storage sampling to inoculation were again found to significantly (p-value: 0.006) 
affect the chance of MU recovery, with a decrease in the chance of MU recovery by 19.1% 
for every 10 extra days of storage compared to the mean per swab storage time of 80.2 days 
(Table 5.4, Figure 5.2). As shown in Figure 5.2, the predicted portability of M. ulcerans 
recovery decreases from 58% to 25% within 70 days of transport. Overall the analysis of the 
sample set consisting of only RT-PCR positive swabs but including all possible outcomes of 
the inoculations, showed that either of the moist transport medium increase the chance of MU 
recovery compared to samples kept dry, none of the decontamination methods is preferred 
and MU culturing is favored on LJ which are supplemented with PANTA. Further the 
analysis showed that both a one unite increase in the Ct value of the IS2404 RT-PCR and a 10 
day increase in the storage time of the samples, negatively impacted the chance of MU 
growth.  
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5.4 Discussion 
In the present study we evaluated the effect of various factors on the rate of MU 
recovery. For this we examined three sets of inoculations to identify factors that reduce the 
rate of contamination of the primary cultures, to determine which factors increase the rate of 
MU recovery in a scenario where none of the cultures contaminate and to evaluate the effect 
of factors on MU recovery in a real-life set of inoculations where there is some “undetectable 
growth” due to the contamination of cultures. 
In a study on 1273 IS2404 PCR positive biopsies which were stored for up to 26 
weeks in semi-solid transport medium, Eddyani et al. were able to achieve a culture positivity 
rate of 45.2% and thereby showed that the establishment of an MU strain collection from 
remote BU endemic areas from tissue samples is possible (13). Other studies using either 
tissue biopsies or cotton swabs and FNA and shorter transport time have also reported culture 
positivity rates around 50% with the rest of the cases, although clinically typical and PCR 
confirmed, remaining culture negative (5, 10, 11, 15, 16). With a per patient culture positivity 
rate of 43.1% in our study, we have therefore achieved, from cotton swabs and after long 
transport, MU recovery rates similar to what is reported in the literature. To increase MU 
recovery rates, Yeboah-Manu et al. have suggested that the collection of multiple samples per 
patient, which is feasible with the now routinely used and non-invasive sampling by cotton 
swabs and FNA, could increase the rate of MU recovery. Considering the third data set in our 
study (Figure 5.1C), we collected 4 (IQR = 2 to 6) swabs from most patients. This repeated 
sampling did indeed affected the rate of the recovery of MU in that there was a significant 
difference (p-value 0.003) between the number of samples collected from the culture positive 
(median: 5; IQR: 3 to 6 swabs) versus the culture negative (median: 2; IQR: 1 to 5 swabs) 
patients. To increase the chance of culture positivity, we have also ensured that lesion 
exudates are collected from all around ulcers. Even though BU lesions can be painless if there 
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is no secondary infection (17), and although it has been reported that the collection of FNA 
does not cause much discomfort for the patients (18), there is a limit to the number of samples 
that can be collected from a patient on one day. We recommend the collection of 5 samples 
per patient which should be tolerable and alternatively could be spread over 1-2 days. 
In both our analyses for MU growth and for contamination of cultures, there was no 
significant difference between swabs transported in 7H9 or Amies medium. However, based 
on the reduced costs of Amies transport medium per swab compared to the 7H9 medium 
(approximately 0.7 USD per Amies swab and 2.8USD per 7H9 swab with PANTA and 
OADC), we recommend the use of Amies medium for the transport of swabs collected from 
BU patients. 
In our analysis, the number of days for which samples were stored did not 
significantly affect the rate of contamination of the inoculated cultures but longer storage did 
significantly reduce the rate of MU recovery (Tables 5.3 and 5.4, Figure 5.2). This is 
potentially contrary to previous reports of culturing from tissue biopsies which found that that 
storage time did not affect the rate of MU recovery (13). Viability of MU may be supported if 
transported in a tissue biopsy, however given the similarity in the MU recovery rate of the 
above mentioned study and our results presented here, the reason for no-growth of MU from 
certain patients should be further investigated. 
As can be expected, the CT value of the IS2404 RT-PCR had a significant effect on 
the rate of MU recovery (Tables 5.3 and 5.4). On the other hand neither the qualitative nor the 
quantitative RT-PCR result of the swab or the BU status of the patient had a significant effect 
on the rate of contamination of the primary cultures in the one-by-one or the multivariate 
analysis (Table 5.2 and Supplementary Table S5.2). In line with a recent report on secondary 
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infections of BU lesion (17), this finding does not support previous claims that BU lesion are 
less prone to contamination with secondary microorganism compared to other lesions. 
In our analysis there was further no significant difference between the four 
decontamination methods evaluated, although in the univariate analysis for MU growth, 
NaOH for 10 minutes appeared to outperform the other decontamination options with 
borderline significance (p-value: 0.076, Supplementary Table 5.3). Because of the lack of 
difference between the decontamination methods and since 10min NaOH is the quickest 
decontamination method, we suggest this one be used. In a previous study on a small set of 
swabs that were processed within 24 hours, OA for 20 minutes was found to be most suitable 
based on its reduced rate of contamination (10). As shown by our analysis and also the lack of 
effect on MU recovery in the previous study (10), either decontamination method should 
allow for MU recovery. It must however also be noted that all decontamination methods have 
a strong negative effect on the viability of MU (9). As for the medium to inoculate, 
LJ_PANTA has a significantly (p-value: <0.001) reduced the rate of contamination (Table 
5.2) and at the same time the mix of antibiotics does not significantly (p-value: 0.216) 
influence the probability of MU growth (Table 5.3). In fact, our analysis of MU growth vs. 
contamination or no growth including only RT-PCR positive swabs (Figure 5.1C), showed 
that the use of LJ_PANTA had a significant positive effect (p-value: 0.003) on the rate of 
recovery of M. ulcerans. This is similar to what has been found by Yeboah-Manu et al. where 
MU recovery was also significantly improved (p-value < 0.001) on LJ_PANTA compared to 
LJ alone (10). 
By evaluating a small set of swabs, Yeboah-Manu et al. have previously been able to 
show that culturing from dry cotton swabs is feasible (10). In our study we confirmed have 
been able to confirm this finding. However the chance of M. ulcerans recovery is reduced by 
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68.9% compared to swabs transported in Amies (Table 5.4) and in our analysis dray swabs 
only achieved a per patient culture positivity rate of 13.1%. 
In conclusion primary culturing of MU from cotton swabs after long term storage is 
possible. Based on our findings we suggest that samples should be transported in Amies 
medium, that they should be decontaminated in 0.5M NaOH for 10 minutes and that cultures 
should be inoculated onto LJ supplemented with 2% PANTA. As shown in the model 
presented in Figure 5.2, from inoculations of swabs with a RT-PCR Ct value of 27.8, that 
were transported in Amies medium, decontaminated using NaOH for 10 minutes and 
inoculated into LJ with PANTA, a probability of MU growth of 60% can be expected if 
samples were not stored at all. If the sane samples are stored for 50 or 100 days the predicted 
probability decreases to 42% and 12% respectively. Furthermore, multiple samples 
(approximately 5) should be collected from each patient and only the PCR positive swabs 
should be inoculated for culturing. 
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5.6 Tables 
 
Table 5.1: Outcomes of M. ulcerans primary culturing 
Attribute Non-Contamination 
vs. contamination 
#
 
MU growth vs. 
no growth 
##
 
MU growth vs. contamination 
or no growth 
##
 
M. ulcerans growth per inoculation (%) 88 (7.82) 88 (20.00) 88 (12.57) 
M. ulcerans growth per patient (%) 31 (32.63) 31 (46.97) 31 (43.06) 
Contamination (%) 446 (39.46) - 260 (37.14) 
No growth (%) 591 (52.53) 352 (80.00) 352 (50.29) 
Days to primary outcome* 5.0 (4.0; 11.0) 67.0 (55.0; 105.2) 67.0 (55.0; 105.2) 
# Analysis of 1125 inoculations from 95 patients with contamination as the primary outcome. 
## Analysis of 440 inoculations from 66 patients with MU growth as the primary outcome. 
### Analysis of 700 inoculations from 72 patients with MU growth as the primary outcome. 
* Median with IQR in parentheses. 
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Table 5.2: Association
§
 between non-contamination and all factors of interest. 
Factor Value of factor Odds ratio
§
 95% CI odds ratio Overall effect (p-value) 
Transport medium
§§
 7H9 1.579 0.632 - 3.944 0.008 
 dry 57.675 23.704 - 140.334  
  Amiens (ref. level)  1.000   
Decontamination medium OA_1h 0.715 0.362 - 1.412 0.266 
 OA_30min 0.540 0.260 - 1.122  
 NaOH_20min 0.879 0.383 - 2.016  
 NaOH_10min (ref. level) 1.000   
Inoculation media
§§
 LJ 0.264 0.162 - 0.429 <0.001 
 LJ_PANTA (ref. level) 1.000   
Swab RT-PCR Ct value for an increase in 1 unit CT 0.992 0.978 - 1.006 0.236 
Time from sampling to inoculation for an increase in 10 day   0.606 
Interaction of transport medium  when 7H9§§§ 0.982 0.824 - 1.171 0.007 
and days from sampling to  when dry§§§ 1.167 1.032 - 1.321  
inoculation when A (ref. level) 0.799 0.643 - 0.993  
§ Adjusted for random effects of the patient and swab identification. 
§§ Interaction (p-value: <0.001) between transport medium and inoculation media was observed. 
§§§ for an increase in 10 days from mean of days from sampling to inoculation. 
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Table 5.3: Association
§
 between MU growth and all factors of interest with a relevant effect  
Factor Value of factor Odds ratio
§
 
95% CI odds 
ratio 
Overall effect 
p-value 
Transport medium 7H9 0.304 0.046 - 2.026 <0.001 
 dry 0.023 0.004 - 0.143  
  Amiens (ref. level)  1.000   
Decontamination medium OA_1h 0.414 0.102 - 1.683 0.519 
 OA_30min 0.697 0.127 - 3.837  
  NaOH_20min 1.242 0.204 - 7.546  
  NaOH_10min (ref. level) 1.000   
Inoculation media LJ 0.478 0.148 - 1.545 0.216 
 LJ_PANTA (ref. level) 1.000   
Swab RT-PCR CT value for an increase in 1 unit CT1 0.879 0.775 - 0.996 0.044 
Time from sampling to inoculation for an increase in 10 days   0.001 
Interaction of transport medium when 7H9§§ 0.531 0.320 - 0.881 0.074 
and Days from sampling to when dry§§ 0.880 0.704 - 1.099  
inoculation when A (ref. level) 0.541 0.347 - 0.844  
§ Adjusted for random effects of the patient and swab identification. 
§§ for an increase in 10 days from mean of days from sampling to inoculation. 
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Table 5.4: Model describing the association
§
 between MU growth and all factors of interest with a relevant effect  
Factor Value of factor Odds ratio
§
 95% CI odds ratio 
Overall effect 
p-value 
Transport medium 7H9 0.617 0.269 - 1.415 0.019 
 dry 0.248 0.094 - 0.655  
  Amiens (ref. level)  1.000   
Decontamination medium OA_1h 0.440 0.182 - 1.062 0.295 
 OA_30min 0.529 0.203 - 1.375  
  NaOH_20min 0.739 0.236 - 2.313  
  NaOH_10min (ref. level) 1.000   
Inoculation media LJ 0.345 0.169 - 0.703 0.003 
 LJ_PANTA (ref. level) 1.000   
Swab RT-PCR CT value for an increase in 1 unit CT1 0.892 0.818 - 0.974 0.011 
Time from sampling to inoculation for an increase in 10 days 0.809 0.695 - 0.941 0.006 
§ Adjusted for random effects of the patient and swab identification. 
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Supplementary Table S5.1: Parallel decontaminations performed on the samples included in the analyses 
Combination of parallel 
decontamination methods 
Non-contamination 
vs. contamination 
MU growth vs. 
no growth 
MU growth vs. contamination 
or no growth 
NaOH_10 and OA_30min 19 3 13 
NaOH_10 and OA_1h 87 44 86 
NaOH_20 and OA_30min 61 25 33 
OA_1h and OA_30min 70 23 32 
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Supplementary Table S5.2: Association
§
 between Non-contamination and each of the factors of interest. 
Factor Value of factor Odds ratio
§
 95% CI odds ratio Overall effect (p-value) 
Transport Medium 7H9 0.840 0.462 - 1.527 <0.001 
 dry 24.314 13.268 - 44.555  
  Amiens (ref. level)  1.000   
Decontamination medium OA_1h 0.853 0.465 - 1.567 0.021 
 OA_30min 0.749 0.396 - 1.414  
 NaOH_20min 1.777 0.860 - 3.673  
 NaOH_10min (ref. level) 1.000   
Inoculation media LJ 0.441 0.307 - 0.634 <0.001 
 LJ_PANTA (ref. level) 1.000   
Swab RT-PCR Ct value for an increase in 1 unit CT 0.990 0.978 - 1.002 0.119 
Patient RT-PCR result negative 0.799 0.379 - 1.682 0.554 
 positive (ref. level) 1.000   
Time from sampling to inoculation for an increase in 10 day 1.402 1.282 - 1.534 <0.001 
Weeks before diagnosis* for an increase by 1 week 0.992 0.976 - 1.007 0.285 
§ Adjusted for random effects of the patient and swab identification. 
* Information as reported by the patient. 
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Supplementary Table S5.3: Association
§
 between MU growth and each of the factors of interest. 
Factor Value of factor Odds ratio
§
 95% CI odds ratio 
Overall effect 
p-value 
Transport medium 7H9 0.343 0.099 - 1.192 <0.001 
 dry 0.004 0.001 - 0.015  
  Amiens (ref. level) 1.000   
Decontamination medium OA_1h 0.373 0.135 - 1.032 0.076 
 OA_30min 0.396 0.136 - 1.157  
 NaOH_20min 0.229 0.071 - 0.734  
  NaOH_10min (ref. level) 1.000   
Inoculation media LJ 0.510 0.239 - 1.089 0.082 
 LJ_PANTA (ref. level) 1.000   
Swab RT-PCR Ct value for an increase in 1 unit CT 0.947 0.868 - 1.033 0.216 
Time from sampling to inoculation for an increase in 10 day 0.621 0.522 - 0.738 <0.001 
Number of days of treatment before 
sampling 
for an increase in 1 day 1.033 0.965 - 1.106 0.343 
Weeks before diagnosis* 1 week 1.002 0.976 - 1.029 0.865 
§ Adjusted for random effects of the patient and swab identification. 
* Information as reported by the patient. 
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5.7 Figures 
 
Figure 5.1: Workflow of swabs included in the statistical analysis. 
The complete set of MU primary culturing inoculations was used to identify factors that affect the rate 
of contamination (non-contamination vs. contamination; A) of M. ulcerans primary cultures. A subset 
of the inoculations was used to identify factors that influence the growth of MU in the absence of any 
contaminated inoculations (MU growth vs. no growth; B) and a second subset was used to identify 
factors that affect MU growth if some of the inoculations resulted in contamination (MU growth vs. 
contamination or no growth; C). The number of swabs collected as well as the transport media and 
storage time are shown. Further, the number of RT-PCR positive swabs with their average Ct value are 
given and the numbers of decontaminations as well as inoculations performed are shown. Finally the 
number of total inoculations in each of the data sets is indicated. 
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Figure 5.2: Predicted Probabilities for M. ulcerans Growth. 
Based on the MU growth vs. no growth or contamination model we predicted the probability of MU 
growth as a function of transport time is samples are transported with the transport media indicated, 
decontaminated using NaOH for 10 minutes, inoculated onto LJ supplemented with PANTA and if the 
Ct value of the RT-PCR was 27.8. Mean predicted probability of MU growth and 95% confidence 
intervals are shown. 
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Chapter 6. Cutaneous TB in a BU Area 
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6.1 Presentation of Case 
A 27-year-old male farmer presented himself to an integrated health centre in the 
Bankim health district of the Adamaoua region of Cameroon with two ulcerative lesions with 
undermined edges on the upper chest and neck as well as enlarged and indurated lymph nodes 
of the neck (see Figure 6.1). He had not sought any traditional treatment and indicated that the 
condition had been ongoing for one month. Given the known high prevalence of 
Mycobacterium ulcerans (M. ulcerans) disease (Buruli ulcer) in the Bankim health district 
[1], ulcer exudates were examined for acid-fast bacilli by Ziehl-Neelsen (ZN) staining at the 
local health centre and tested positive. Based on the positive ZN stain, a diagnosis of Buruli 
ulcer (BU) was made and the treatment recommended for BU by the World Health 
Organization (WHO) [2], daily rifampicin (600 mg p.o.) and streptomycin (1 g i.m.) for 56 
days, was administered to the patient. Additional swabs of ulcer exudates were analyzed using 
the M. ulcerans–specific IS2404 quantitative polymerase chain reaction (qPCR) assay [3]. All 
four swabs obtained from the patient tested negative. Exudate swabs were also used for the 
initiation of a culture on Löwensein-Jensen medium after decontamination with 2.5% oxalic 
acid for 30 minutes at room temperature. After 8.5 weeks of incubation at 30ºC, the optimal 
growth temperature of M. ulcerans, mycobacterial growth was observed. The cultured 
mycobacteria were ZN positive, but negative in the M. ulcerans–specific IS2404 qPCR. PCR 
amplification [4] and DNA sequencing of the rifampicin resistance determining region 
(RRDR) of the rpoB gene identified the strain as belonging to the M. tuberculosis complex; 
no rifampicin resistance conferring mutation in the RRDR was found. A qPCR identifying a 
single-nucleotide (A to C) change at position 2’154’724 further characterized the cultivated 
strain as belonging to Lineage 4 (Euro-American Linage) of M. tuberculosis [5]. 
Spoligotyping and analysis using the SITVITWEB database revealed that the strain belonged 
to the "T-family" [6] of M. tuberculosis, a spoligotype of Lineage 4 which encompasses all 
strains that are difficult to classify into other spoligotype families. While the strain therefore 
does not belong to the “Cameroon Family” of TB, the obtained spoligo type has previously 
been reported to occur in Cameroon [6]. 
Based on this laboratory diagnosis of an M. tuberculosis infection, the patient was re-
examined 186 days after completion of the BU treatment. At this point, the ulcers had fully 
scarred (see Figure 6.1). However, the lymph nodes of the neck remained enlarged and 
indurated. A chest X-ray provided no evidence for pulmonary tuberculosis (TB), and the 
patient tested negative for human immunodeficiency virus (HIV) infection. Given the 
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laboratory results and the clinical presentation, the patient was retrospectively diagnosed as a 
case of cutaneous TB [7]. Given the insufficiency of the BU treatment to cure TB, the patient 
was started on the full regimen of the standard TB treatment recommended by the Cameroon 
National TB Control Program: two months of isoniazid, rifampicin, ethambutol, and 
pyrazinamide followed by four months of isoniazid and rifampicin. 
 
6.2 Case Discussion 
Ethical approval (clearance N° 041/CNE/DNM/09, 19/06/2009) to analyze patient 
specimens was obtained from the National Ethics Committee of Cameroon, registered under 
the N° IRB00001954. Written informed consent from the patient was obtained before 
specimens were used for reconfirmation of clinical diagnosis and detailed laboratory analysis. 
BU disease presents with a variety of clinical manifestations including nonulcerative 
forms such as movable subcutaneous nodules, plaques, and oedema, which may eventually 
progress to ulcerative lesions with characteristic undermined edges. Without treatment, ulcers 
may enlarge considerably and involve entire limbs or large areas of the trunk [8]. It is 
believed that mycolactone, the macrolide toxin produced by M. ulcerans, largely contributes 
to the pathogenesis of BU disease [9]. The diversity in clinical presentation renders clinical 
diagnosis difficult. Of the four currently available methods for laboratory reconfirmation of 
BU [8], only one, ZN microscopy, is suitable as a point-of-care diagnostic test in the African 
endemic areas, which are usually remote and rural. However, its sensitivity is limited [10,11]. 
Cultivation of the slow-growing mycobacteria, histopathology, and PCR-based detection of 
M. ulcerans DNA can only be performed in central reference laboratories. 
Given its wide range of clinical presentations, the differential diagnosis of cutaneous 
tuberculosis, which makes up 1%–2% of all TB cases worldwide [7,12], is also difficult. Both 
infectious and noninfectious diseases of the skin need to be considered when examining a 
potential case of cutaneous TB [13]. For a definite diagnosis, histological examination, PCR, 
or optimally isolation of M. tuberculosis is required. All of these diagnostic methods again 
require sophisticated reference laboratories [7,12]. Once diagnosed, patients can be treated 
with the regiment that is also used to treat pulmonary TB [7]. It is remarkable that a clinical 
manifestation very similar to that of BU disease was observed in the case presented here, 
although M. tuberculosis does not produce a potent macrolide toxin. 
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For patients from BU-endemic regions, ZN microscopy is usually accepted as 
reconfirmation of the clinical diagnosis and, to reduce costs, it has been suggested that only 
ZN negative swabs should be sent to a reference laboratory for analysis by PCR [11]. While 
the vast majority of ZN positive samples are also PCR positive, sensitivity of PCR is much 
higher than microscopy and many ZN negative samples still turn out PCR positive [11]. In 
BU-endemic areas as remote as the Bankim health district, clinical diagnosis by local medical 
staff is often considered sufficient for treatment decision. It has been shown that if clinical 
diagnosis is performed by highly trained and experienced staff, more than 90% of suspected 
cases can be reconfirmed by PCR [14]. However in regions where health care staff does not 
regularly encounter BU cases, a large proportion of suspected BU cases cannot be confirmed 
by laboratory tests [15]. Clinical overdiagnosis on one side, and true BU cases missed by 
relying only on ZN microscopy on the other side, can lead to over- or undertreatment of 
patients, respectively. It is therefore recommended that all BU cases should be laboratory 
confirmed [15]. If the decision is made to send only ZN negative swabs for confirmation to a 
reference laboratory, training of health care staff in BU differential diagnosis becomes even 
more important. Furthermore, such training should include the clinical presentation of other 
skin diseases, including other mycobacterial diseases. As demonstrated by the case presented 
here, lymphadenopathy—not a typical sign of BU—should lead to a more detailed clinical 
examination. 
Overall, the case of a misdiagnosed patient with cutaneous TB in a BU-endemic area 
presented here further underscores the need for a simple, highly sensitive, and specific point-
of-care diagnostic test for BU.  
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6.3 Learning Points 
• Clinical diagnosis of Buruli ulcer should be supplemented with laboratory 
examinations. 
• Microscopy, the only point-of-care laboratory test currently available, does not 
differentiate between Buruli ulcer and infections by other mycobacteria. 
• Clinical presentation of other mycobacterial diseases should be included when training 
staff on the differential diagnosis of Buruli ulcer. 
• There is a pressing need for a sensitive and specific point-of-care laboratory test for 
Buruli ulcer. 
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6.5 Figure 
 
Figure 6.1. Clinical evolution of TB patient discovered in BU-endemic area. A 27-year-old male 
presented to an integrated health centre in a BU-endemic area in Cameroon with multiple lesions on 
the neck and upper chest. After acid-fast bacilli were observed in the wound exudates, the patient was 
diagnosed with BU and treated according to WHO guidelines. Figure 6.1A shows the patient on day 
17 of BU treatment. The lesions healed following eight weeks of rifampicin/streptomycin combination 
therapy. Figure 6.1B and 6.1C show the patient 86 and 178 days after completion of BU treatment, 
respectively. Further laboratory analysis on the original wound exudates showed that the patient was 
suffering from TB as opposed to BU, and the appropriate long-term TB treatment was administered. 
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7.1 General remarks 
Although BU was first formally described in 1948 in Australia [1], where it is called 
Daintree or Bairnsdale ulcer, the internationally used name of the disease originates from an 
area of the Mengo district of Uganda which was called Buruli (today the area is called 
Nakasongola). Twenty-eight of the 40 first BU cases from Uganda were discovered in this 
area in 1958 [2,3]. Much of what is known about the disease today, such as major risk factors, 
clinical and histopathological aspects of lesions and characteristics of the pathogen were 
initially discovered in the course of research conducted in the 1960’s and 1970’s [3,4]. 
Modern day BU research was then initiated by the launch of the WHO lead “Yamoussoukro 
Declaration on Buruli ulcer” in 1998 [5]. This new era in BU research is illustrated by a stark 
raise in the number of search results for “Mycobacterium ulcerans“ in the MEDLINE 
database (http://www.ncbi.nlm.nih.gov/pubmed/) a few years afterwards (Figure 7.1). 
However despite continued research, BU remains mysterious with major aspects of both its 
pathology and transmission unknown. Specifically the unidentified reservoir, the unknown 
mode of transmission, the elusive natural history which leads to the different clinical forms 
and the only partially characterized mode of action of mycolactone all remain to be 
elucidated. In addition to these research questions, numerous aspects of BU care, such as early 
case detection, differential diagnosis, documentation of the patients, and treatment beyond 
antibiotics, remain to be optimized. 
 
Figure 7.1: MEDLINE search results for “Mycobacterium ulcerans“ between 1951 and 2012. 
Search was performed on 02. September 2013 and only publications published until the end of 
2012 were included. 
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Within the scope of this PhD thesis we have established a new BU research site in the 
Mapé Basin, an emerging BU focus in a remote area of Cameroon [6]. With a survey in the 
entire Bankim Health District (HD) in 2010 and continuous surveillance thereafter, we studied 
the epidemiology of BU in the area in great detail (Chapter 2). The thereby gained 
understanding of the local scenario formed the basis for both completed and on-going 
biomedical (Chapters 3, 5 and 6 and Appendix 1) as well as environmental (Chapter 4) 
studies. On the next few pages, the relevance of our findings and observations for BU 
research and control will be discussed. 
 
7.2 BU control and treatment in the Bankim HD: current status and 
possible improvements 
A major concern in BU control is that patients should receive their treatment as early 
as possible to prevent lengthy hospital stays and debilitating deformities. Major efforts are 
therefore needed for early case detection [7]. Given the observation that many BU cases 
report very late, it is speculated that there are cases in remote communities that are not 
discovered by the health care system [8]. This is of course hard to proof or dismiss with 
evidence, although in some studies exhaustive surveys have identified a substantial number of 
new BU cases [9]. In the course of our work, we conducted an exhaustive house-by-house 
survey in early 2010 (Chapter 2). Despite including all communities in the Bankim HD, even 
the very remote ones that can only be reached by motorcycle, boat or foot and examining over 
49'000 individuals, only 6 new cases of laboratory confirmed BU were discovered. In the 
future, surveys should be conducted only in selected communities chosen based on 
epidemiological data. Recently such a targeted two day survey on the western shore of the 
Mapé dam in the Malantouen HD, has identified 3 clinically confirmed BU cases that are 
currently receiving treatment and awaiting PCR confirmation (A. Um Boock, personal 
communication). Additional targeted surveys, for example along the Mbam River in the south 
eastern corner of the Bankim HD or in the area just to the south of the same river may also 
help to discover new cases with fairly little effort. Despite the small number of cases 
identified in our exhaustive survey, there is no evidence to suggest that BU cases were 
missed. As a matter of fact, not considering the identified cases of yaws (n=29) and leprosy 
(n=32), several other cases of – at times very severe – skin conditions were discovered in the 
survey. Furthermore, following the survey, there was a steady flow of new cases of BU 
discovered by passive case finding indicating that in the area around Bankim the community 
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appears to have well accepted the local BU control program and the personnel working for it. 
In addition to the passive case finding, two strategies are used to support continuous case 
detection. Firstly, health care providers engage with all actors in BU care, including 
traditional healers, and encouraging them to refer any case they encounter to a treatment 
facility. Secondly, the local population is sensitized using a health promotion video 
accompanied by the clinical evaluation of any skin lesions. These approaches to supplement 
case finding are likely to be more resource efficient compared to the very time, staff and 
money intensive exhaustive surveys. The impact of these strategies is currently being 
evaluated (F. Mou, personal communication). Sensitization in schools, local markets, 
churches or other places where communities – including those individuals that usually live in 
very remote areas – gather may further help to identify BU cases early. 
In addition to improving case finding, tackling issues that lead to treatment seeking 
delays may also lead to earlier case detection. Both traditional and worldly concerns should be 
considered as causes of such delays. In addition to causing unnecessary procrastination of 
modern treatment, traditional treatments, such as topically applied herbal remedies or heat, 
may lead to severe burns of the skin and can substantially worsen the state of the lesions. 
Believing in a spiritual origin of the BU lesions may cause patients to seek care with a 
traditional healer. Financial constraints and convenience may also lead to the involvement of 
traditional healers. Given the remoteness of many of the communities in which BU occurs, 
the distance to the modern health care facility may be large and a traditional healer may, on 
the other hand, be working in the patient’s village. However, some of the patients encountered 
at traditional healers in the course of this thesis, also travelled considerable distances to reach 
a healer with a reputation of treating BU. Potential costs of the modern treatment (see below), 
may further cause patients to consult traditional healers where services can be paid with 
natural goods or labour and where patients can get complementary housing and food. 
Traditional treatment has been shown to be involved in 50% of the treatment itineraries of a 
small cohort of BU patients in the Democratic Republic of Congo [10]. The same study did 
however also relativized the role of traditional healers by finding that it was more the staff at 
modern health care facilities – by wrong diagnosis – that caused treatment delays [10]. In the 
Bankim area traditional healers appear to play an important role in BU care and a system of 
collaboration, where they are given a few days to treat spiritual aspects of the disease and are 
then encouraged to refer suspected BU cases to the health care system, may represent a win-
win-win situation. With this approach, the patients get their traditional believe concerns 
addressed, the traditional healer increases her/his credibility in the community by 
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collaboration with the local medical facility and the health care system receives the patient 
without much delay. Such an unconventional interaction between care providers is currently 
being evaluated in Bankim and showing some promising results (F. Mou and A. Um Boock, 
personnel communication). On the other hand, there may also be patients that don’t want to 
come for modern treatment and BU control programs should focus on applying cost-effective 
measures to identify and treat those patients that are willing to accept antibiotic treatment. 
Even though antibiotic treatment and wound care is provided for free to BU patients, there are 
several factors that may lead to direct as well as opportunity costs that could cause patients to 
delay or later abandon treatment. These costs accrue because BU patients must come to 
treatment facilities daily for an injection during the antibiotic treatment and thereafter for 
wound care. Concerns include issues such as the inability of a caretaker of a child patient to 
leave behind other obligations and dependents and to relocate to the hospital or rent an 
apartment close to the treatment facility. The cost of daily transport by motorcycle taxi to the 
treatment centre could also deter patients. Being displaced for several weeks to receive 
treatment may further mean that meals must be bought which may exceed the financial 
capacities of patients. Appropriate counselling and measures to address these issues will 
hopefully allow the patients to come for treatment early and minimize the number of cases 
that abandon treatment. Specifically the provision of housing and food for patients that 
require such support may allow them to complete treatment. Attached to such support, it may 
also be possible to create a more extended care structure within which patients can provide 
psychosocial support to each other and the care for young patients can be shared if her / his 
caretaker has other obligations. Such a structure of extended support is currently also being 
evaluated in Bankim and results of its impact are pending (F. Mou and A. Um Boock, 
personal communication). 
Some cases of BU that do not receive any modern medical treatment are speculated to 
be able to heal spontaneously or after only traditional treatment [11]. In the course of our 
work one patient that healed without modern treatment was identified. The 9 year old patient 
was first discovered in early 2011 (Figures 7.2A and 7.2B) at which time, he was RT-PCR 
and culture positive and the patient's parents accepted only traditional treatment. Seen again in 
late 2013, the ulcer on the elbow healed completely without any other complications and, to 
our knowledge, without receiving any modern BU treatment (Figure 7.2C). Such clean cases 
of healing without modern medical treatment are likely to be rare. 
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Figure 7.2: Case of spontaneous healing seen in Bankim HD. 
RT-PCR and culture confirmed case of BU first discovered in March 2011 when the patient was 
seen twice (A and B) and only accepted traditional treatment (B). According to medical records 
the lesion scared completely by the end of July 2011. An image of the scar taken in late 2013 is 
shown in Panel C. According to our knowledge this patient did not receive any modern BU 
treatment. 
 
Once a patient is registered at a treatment facility, it is of great importance for public 
health and research purposes that she / he is thoroughly documented. The relevance of this 
documentation may not be inherently apparent for the front line health care worker that is 
primarily concerned with the treatment of the individual patient. However only with detailed 
and reliable information about recent cases can the local BU scenario be truthfully described 
and useful conclusions drawn. With considerable efforts, we have established both an 
electronic and paper based data capturing system in the Mapé Basin and thereby greatly 
increase the quality of the available data. One aspect that required special attention in our 
setting was the village and health district of origin of the patients. Initially patients from 
outside of the Bankim HD were record as being from "outside Bankim" without any further 
details. For other patients, village names were not standardized, the village of the closest 
health centre as opposed to the village where the patient lived was recorded and insufficient 
effort was made to question the patient about where she/he lived before the start of treatment, 
i.e. not where they moved to for better access to treatment. Only after correcting these issues, 
were we able to identify small villages along the Mbam with several cases and BU endemic 
villages in the Malantouen HD. Given the crucial role of the collected information in research 
and public health, it is therefore of great importance that front line health care worker are 
trained to diligently document all cases. 
In addition to the effective antibiotic treatment, wound care is essential for adequate 
clinical management of BU cases. The material and staff-time required for this care 
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contributes substantially to the costs of BU treatment. Although leaders of the African 
endemic countries have agreed in the “Yamoussoukro Declaration on Buruli ulcer” [5] that 
treatment of BU should be free, in particular wound management leads in many settings to 
considerable costs for the patients. Further, unlike for the amount of drugs, it is difficult for 
planners to predict how much wound care material will be required per case of BU. This 
makes the control program vulnerable to fraudulent claims and a stringent control system 
must be put into place. Measures to reduce cost such as sterilizing wound care material locally 
without being able to monitor the success of the process or by getting patients to wash their 
own bandages, a common practise at many treatment centres, may in the long run not result in 
any cost savings but in contrary lead to extra treatment cost due to delays in wound healing 
[12]. In addition to the necessary material, wound care also requires a suitable and sterile 
environment to perform wound cleaning and dressing. This dedicated area must provide 
enough space and be sufficiently equipped to handle the – at times – very large and 
contaminated wounds. There must also be a system of organizing the patients so that they can 
be efficiently, one after the other, taken care off. Once again medical and organizational 
training and supervision of front line health care workers and supervising staff is crucial to 
ensure appropriate care. Only recently has the WHO started to develop and implement 
standardized guidelines on how BU wounds – depending on factors such as their size or the 
presence of any secondary infection – should be cared for. Furthermore, procedures have to 
be implemented to safely dispose of the dirty wound care material. In the course of our 
environmental sampling, we tested two environmental samples from outside of the wound 
dressing room at the Bankim district hospital by IS2404 RT-PCR and one of the samples was 
positive (unpublished data). Such a contamination of the environment may increase the risk of 
infection and must be avoided by appropriately handling of waste material. Locally adopted 
solutions, for example by using bleach as a disinfectant, can minimize risks from used wound 
care material. Overall efforts required to provide basic wound care at rural health care 
facilities, such as the Bankim district hospital or any of the health centres in the area, are not 
trivial and should not be underestimated. Even seemingly simple aspects such as the logistics 
of transporting wound care material to the peripheral health centres must be well organized so 
that situations where staff in the periphery is forced to improvise can be avoided. With the 
prospect of an only oral treatment for BU by replacing streptomycin with clarithromycin [13], 
wound care will remain very important and standards must be maintained. Blister packs of 
antibiotics that are given to patients asking them to come back only once they are finished – 
as it is commonly done for leprosy patients – leads to the danger that wound care will be 
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neglected. Such negligence will unnecessarily prolong the wound healing process even 
further. Overall, ccurrent capacities in the Mapé Basin are only barely able to deal with the 
challenges of the large wounds and the wound care currently received by BU patients must be 
substantially improved. Excluding the option of creating a parallel health care system where 
the provision of wound care material for BU patients and the required expertise to treat the 
wounds are provided by a vertical structure, the necessary improvements to wound care 
would require investments in the health care system overall. BU control programs should not 
solely bear the cost of such changes since in addition to BU patients, all other patients with 
open wounds – caused by accidents, infections or chronic diseases – would profit from 
strengthened wound care expertise. However to get a rural African health care facility, such as 
the Bankim district hospital, to invest into wound care may be very difficult and local BU 
control measures may need to create the necessary hygienic conditions for appropriate wound 
care alone and preferably allow all patients with open wounds to profit from the established 
wound management system. 
In addition to wound care, debridement of BU lesions is often required and large 
ulcers will not heal without surgery and skin grafting. This is illustrated in Figure 7.3 which 
shows a patient with a large open lesion discovered in Bankim in late 2009. Following 
antibiotic treatment for only 45 days, the patient returned to the village without any additional 
care. Her case was photo-documented in 2010, 2011 and for the last time in mid-2013 (Figure 
7.3). Lesions of this size will require a skin graft which this particular patient is receiving 
now. It must be mentioned, that likely multiple factors, including the patient refusing any 
additional treatment after spending a long time at the health centre and the patient changing 
residence several times, contributed to the delay of this patient’s skin graft. Offering wound 
debridement and surgery to patients in a timely fashion, possibly even during antibiotic 
treatment, is therefore crucial also for treatment adherence and to make the patients feel that 
their wound is healing. Conducting the necessary surgical interventions and skin grafting 
however requires even more sophisticated setups and additional equipment compared to 
simple wound care. Sufficiently trained staff and aseptic conditions are further required to 
provide the services and to keep the rate of graft rejection or other complications low. 
Creating such conditions in a health care facility like the Bankim district hospital, which 
suffers from regular power cuts and does not have access to running water, is complicated. 
Furthermore, surgeries will lead to additional and again difficult to plan costs. Detailed 
documentation of cases, which includes information such as how many days of wound care a 
patient received and if there was any surgery performed, may support planning for wound 
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care and surgical needs. Correlating the amounts of wound care material required - estimated 
based on the number of days of wound care received - and the need for surgery with factors 
such as disease category, should allow for quite detailed budgeting and overall planning. 
 
Figure 7.3: Case illustrating that large ulcer will not heal without skin grafting. 
Case was first discovered in late 2009, when the patient received antibiotic treatment. She was 
first photo documented in February 2010 (A) and after receiving antibiotic treatment left for the 
village. The patient was seen again in June 2011 (B) and in June 2013 (C) after which she is now 
receiving a skin graft. 
 
An additional aspect of BU care that is often neglected, is the pain caused by the 
dressing and cleaning of the lesions and the lesions themself. Reviews commonly state that 
BU lesions are painless [14], and this is likely true for nodules and possibly even for small 
plaques, oedemas and small ulcers. However, particularly lesions with secondary infections 
are painful [12]. Furthermore, large ulcers appear to be very painful based on the responses of 
the patients to wound care. Because pain medication is only rarely provided at the hospital, 
patients in Bankim have locally been reported to go to neighbourhood pharmacies or to 
traditional healers to get pain relieve medication. Even worse, patients may decide to abandon 
treatment if the pain becomes unbearable. All of this is highly undesirable for BU control and 
measures should be taken to provide the necessary pain management for the patients. To 
achieve this, staff at treatment facilities must be trained on the use of the appropriate 
analgesics and the drugs must be made available. 
There are several additional issues and concerns that must be considered when 
treating BU patients. One such issue is the fact that especially large BU lesion are prone to 
secondary infections which can lead to a delay in wound healing [12] and may require 
additional antibiotic treatment [12,15]. As illustrated by a tetanus infection in a Bankim BU 
case in 2012, secondary infections of BU wounds may even be life threatening. In the past it 
has been speculated that BU lesions are less susceptible to secondary infections compared to 
other lesions [12]. However, in our studies on the cultivation of M. ulcerans from swab 
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samples, we did not find a statistically significant correlation between the amount of M. 
ulcerans DNA and the frequency of contamination with other microorganisms (Chapter 5).  
Given the fact that lesions often occur on the joints (Chapter 2), prevention of 
disability (POD) is an additional important aspect of BU care. Especially after long treatment 
delays, contractures are frequently observed and can require lengthy physiotherapy to regain 
full functionality [16]. To be able to provide POD care, staff requires training and some basic 
equipment. Furthermore, POD is fairly time consuming and a larger treatment centre may 
require staff that is fully dedicated to this. A further insufficiently explored aspect of BU 
treatment is the care for patients with HIV and M. ulcerans co-infections, who are reported to 
often suffer from more severe forms of BU [17]. Although co-infections may be rare the rate 
of HIV infections in BU patients has been suggested to be above that of the general 
population (V. Yana Tijé, personal communication). However reference HIV rates used for 
such comparisons may not be fully reliable. In our cohort of 88 RT-PCR confirmed BU cases 
studied in great detail (Chapter 2), of the 41 tested patients five (12.2%) were co-infected 
(unpublished data). Guidelines for the management of BU/HIV co-infection are currently 
being prepared by the Global Buruli Ulcer Initiative of WHO. The success of BU care may 
further depend on the nutritional status of the patient, a factor that has been shown to 
influence wound healing [18]. Supplying appropriate meals for the patients would provide 
them with the essential nutrients that promote wound healing and as discussed above such 
support may also reduce treatment seeking delay and prevent some of the patients from 
terminating treatment prematurely. Finally, cases of BU should be followed-up for at least one 
year after the end of treatment. Such follow-ups will identify cases of relapse which may 
indicate the presence of drug resistance. New lesions discovered during follow-up may be 
caused by an immune reaction which would most likely resolve with adequate wound care or 
by re-infection that would need a new round of treatment [19]. Further, with BU lesions often 
encompassing joints, BU scars can be quite fragile and break open upon physical trauma. To 
prevent this, patients must be educated on the appropriate care for the scar, such as use of 
palm oil to keep the scar tissue soft. Furthermore, wound care must be provided if a patient 
comes back to the treatment facility with a re-opened scar. Follow-up visits are further 
important to detect any long-term side-effects of the drug treatment. Although it is reported 
that BU patients appear to be less susceptible to adverse effects of the drugs compared to 
other populations [13], this may also be an impression related to the lack of systematic and 
prolonged observation of the patients. Re-finding cases for follow-ups can however be 
complicated by the fact that some local communities are very mobile and contacting 
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individuals in very remote communities or having them adhere to scheduled appointments is 
difficult. Locally adopted approaches such as having the contact details of someone in the 
same village or a family member or friend that lives closer to the road may help to re-find 
patients or allow for messages to be passed to the patient telling them that they should come 
for a check-up. Having patients come to the facility with their transport reimbursed should be 
preferred over having health care workers, who require a per diem and have numerous other 
tasks, go out and find the patient with the possibility that the patient will not be at home.  
 
7.3 Diagnosis of BU for research and public health purposes 
The four currently available methods for laboratory diagnosis of BU are microscopy 
to detect acid fast bacteria (AFB) after Ziehl-Neelsen straining, PCR based detection of the M. 
ulcerans specific insertion sequence IS2404, culturing of M. ulcerans or identification of BU 
typical alterations of the skin by histology. A major difference between the first three and the 
last one of the methods is, that the first ones can be performed on samples obtained by 
minimally- or non-invasive collection of wound exudates by FNA or from below the 
undermined edges of the ulcer with a cotton swab. Histology on the other hand necessitates a 
tissue biopsy which can either be obtained specifically for this purpose or in the course of 
wound debridement or surgery. Microscopy, the only method that can be performed locally at 
health facilities in the periphery, is highly insensitive, with positivity rates between 40 and 
78% being reported in the literature [20], and not 100% specific. A possible concern with a 
positive microscopy results is illustrated by the case of cutaneous TB presented in Chapter 6. 
Even though such cases may be rare, they have also been found in other BU endemic sites (D. 
Yeboah-Manu, personal communication). Culturing which can provide definitive BU 
diagnosis, is also far from 100% sensitive and more importantly takes a very long time. In our 
hands (Chapter 5) clinical isolates of M. ulcerans took between 6 and 25 weeks to grow on 
Löwenstein-Jensen medium. One cause for the low sensitivity of culturing is the overgrowth 
of the primary inoculations with other microorganisms, thereby depriving M. ulcerans of a 
possibility to grow (Chapter 5). Measures to prevent such contamination, e.g. by using dry 
swabs (Chapter 5) or decontaminating wound exudate [21], negatively impact the recovery of 
M. ulcerans. In our study aiming to optimize culturing, we have shown that transport with a 
simpler and cheaper transport medium called Amies, which is non-nutritious, may be better 
than the currently used medium (Chapter 5). As for the effect of the long term storage of 
samples, our data suggest that samples should be processed as soon as possible to increase the 
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chance of M. ulcerans recovery (Chapter 5). Despite the lack of diagnostic value, culturing 
does remain very important for studies that require clinical isolates. Such research includes 
for example investigations into the genetic diversity of M. ulcerans (Appendix 1). PCR, 
which has become the gold standard of BU diagnosis [22], is fast and highly specific if 
performed correctly in a quality controlled setting. Particularly RT-PCR, a method that was 
first applied to M. ulcerans detection by Rondini et al. in 2003 [23], achieves highly sensitive 
BU diagnosis. Although, the possibility of false negative PCR results cannot be fully 
excluded [24], it is likely quite low, at least if patients are sampled multiple times and 
specimens processed by experienced technicians. For correct sampling, samples collected by 
cotton swabs should be taken from all round the undermined edges to increase the chance of 
retrieving M. ulcerans DNA. Despite its advantages, PCR has limitations for use in very rural 
areas since it requires a sophisticated laboratory setup such as the “three room principal” to 
separate the individual steps of the process and is prone to contamination and false positive 
results. In many settings cases of BU are therefore currently only diagnosed retrospectively by 
PCR at a national reference laboratory. Furthermore, National BU Control Programs are 
struggling with the financial burden of having to pay for the analysis of the samples. In 
addition to the research value of laboratory diagnosis, it is also of great importance for public 
health purposes. All centres in Cameroon should therefore be given access to this type of 
diagnosis. In addition to fulfilling the requirements of the WHO (see below), staff at the 
centres could then also get feedback on the accuracy of their diagnosis. Finally histopathology 
has limited diagnostic value, since the focally distributed AFB are not necessarily detected in 
the part of the lesion being investigated. However like for culturing, histopathological studies 
are of great importance to improve our understanding of the pathology of BU and the immune 
response against M. ulcerans. Histopathology can for example aid in clinical decision making 
with respect to debridement by providing an insight into the extent of tissue damage or 
prolongation of antibiotic treatment by detecting the presence of clusters of intact AFBs after 
eight weeks of antibiotic treatment [25]. 
For confirmation of clinically diagnosed BU cases, the WHO highly recommends the 
use of PCR. Recommendations from the 2013 WHO BU meeting in Geneva demand that at 
least 70% of the BU cases reported by the endemic countries to the WHO should be PCR 
tested. Control programs are also asked to no longer report cases that tested PCR negative. 
WHO recommendations further suggest that countries should “strengthen laboratory 
capacities” to achieve the desired PCR test coverage rates. To achieve the proposed high rate 
of PCR confirmation, the financing of the test should further be discussed and the WHO 
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should provide support in the form of expertise to set-up and quality control the laboratories 
that are to conduct the tests. 
Despite the recommendation of the WHO for more laboratory diagnosis cases of BU 
in the remote BU endemic areas of Cameroon are still diagnosed on clinical grounds only. 
Clinical diagnosis can achieve accuracies of about 95% if performed by highly experienced 
health care workers [26]. However routine clinical diagnosis as performed in the Mapé Basin, 
is much less accurate (Chapter 2). And even in other BU endemic areas, accuracies between 
30-70% are reported in the literature (Chapter 2 and 6). In our main cohort of patients, 88 of 
157 were laboratory confirmed reflecting a clinical diagnostic accuracy of 56%. According to 
WHO conditions such as tropical phagedenic ulcer, venous ulcer, diabetic ulcer, yaws, 
cutaneous tuberculosis, cutaneous leishmaniasis and malignant skin ulcer may be mistaken for 
BU lesions [27]. In Addition to these conditions, less experiences health care workers may 
also confuse common mycoses of the skin as BU lesions. A characteristic clinical feature of 
ulcerated BU lesions are the undermined edges, which are easily detectable by palpating the 
lesion or using a cotton swab. Cases of yaws, which often present with multiple lesions, and 
cases of venous or diabetic ulcers present with lesions that usually do not have undermined 
edges. As demonstrated in Chapter 6, lesions of patients suffering from cutaneous TB on the 
other hand do also present with undermined edges and it is more the location of the lesion that 
may be used to guide the differential diagnosis. For cutaneous leishmaniasis, local endemicity 
or a travel history of the patient will help to include or exclude this condition in the 
differential diagnosis. Systematic studies are required to further identify the conditions that 
are commonly mistaken for BU and to develop a list of key criteria that can be evaluated to 
reduce the risk of misdiagnosis. A study aiming to accurately diagnose all skin lesions 
observed in a BU endemic health district of Ghana has found that already basic clinical 
diagnosis can in many cases exclude BU and that simple wound dressing and re-examination 
of lesions after a few days may help to clarify the diagnosis of non-BU cases (T. Junghanss, 
personal communication). Such a wait-and-see approach is also applied in the differential 
diagnosis of leprosy [28]. However in rural communities, such as in the Bankim area, such a 
strategy may bear the considerable risk of the patient not returning for follow-up visits 
because they deem the treatment as being insufficient. If another bacterial infection is 
included in the differential diagnosis, combining wound care with a short course of antibiotic 
treatment may reduce the risk of loosing the patient to follow-up. In addition to taking into 
account clinical features in the differential diagnosis, it is also important to consider the 
history of the lesion by asking the patient questions such as how and when it started and how 
149  
 
Martin W. Bratschi BU Epidemiology in the Mapé Basin of Cameroon 
it has been treated by other health care professionals or traditional healers. Without any 
information from the patient, even trauma from motorcycle or machete accidents, cases of 
child abuse or snake bites may wrongfully be diagnosed as BU. It is however also true that 
caution must be taken when considering the information provided by the patients. Particularly 
with information obtained during a first questioning, when the patient just arrived at the 
treatment facility and local staff have not yet gained the trust of the patient, there is a 
considerable risk of getting wrong information. Patients may initially provide the answers 
they think the health care worker expects / wants to hear. Patients may further be unwilling to 
admit that they have consulted a traditional healer before coming to the formal health care 
facility or the patients may even be ashamed to admit how long they waited before presenting 
their lesion to a health care professional. In terms of their origin, patients may also be initially 
reluctant to tell the health care worker where they are from. It may further be truly difficult 
for patients to recall when the disease started and how it evolved over time. With this recall 
bias it must be considered that many of the patients live in villages where there are no daily 
newspapers and the day of the month may not be important to know. Patients may therefore 
not remember, if the lesion started 4, 6 or 8 weeks ago. On the other hand it is also very 
important how questions are asked and that sufficient time is given to the patient or a family 
member to answer. Especially if a possible answer is provided with the question, it is unlikely 
that the true opinion of the patient will be heard. Based on our experience, it can be helpful 
that patients are interviewed on several occasions and even by different people that during the 
patient’s hospital stay have gained their trust. With this approach it is likely that information 
useful for the differential diagnosis can be obtained from the patient although in the end it is 
up to the health care professional to judge if the provided information is reasonable and 
trustworthy. 
The high rate of false BU clinical diagnosis has implications for the patients, the 
public health system as well as for BU research. The most important implication for the 
patients is that they are denied the treatment they would actually require for an additional 
eight weeks. This implies a substantial opportunity cost, for example for a patient with 
ulcerative skin cancer who is deprived of the appropriate care she/he needs and instead 
receives a treatment that will not have any impact on the disease they are really suffering 
from. On the other hand, patients with a machete wound or yaws would only require good 
wound care or a single injection of benzathine penicillin respectively and the their wound 
would be treated correctly whereas instead they receive eight weeks of unnecessary and 
potentially harmful antibiotics. For the health care system, false positive diagnosis of up to 
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50% means that substantial unnecessary costs occur. Finally for the researchers in the field, 
laboratory results may not be available at the time of conducting the work which implies that 
substantial efforts must be invested to study “patients” which then retrospectively have to be 
excluded from the analysis. To address this, clinical diagnosis should be improved and it may 
be helpful to observe patients in different endemic settings to better distinguish between noise 
and valuable information and allow for the discovery of parallels between the different 
settings (Chapter 3). Overall it is of great importance that all research is performed on PCR 
confirmed cases only so as to ensure the accuracy of the science being conducted. 
To prevent all of these negative impacts of the falsely diagnosed BU cases, there is a 
great need to further train front line health care workers to better diagnose suspected cases of 
BU. Such training must be offered repeatedly to train new staff and re-fresh the knowledge of 
existing personnel. Further the training must be practical and should involve examination of 
current suspected cases or recently diagnosed ones. Once trained, the work of the diagnostic 
staff must be regularly supervised to ensure that there is an iterative learning process, in 
which front line medical staff can profit from the medical knowledge and diagnostic expertise 
of regional BU experts and laboratory results. Through the regular sharing of a short clinical 
description and images of the new patients, it can be made possible for experts at the central 
level to provide valuable input into the clinical diagnosis of BU in remote endemic areas. 
Using modern information technology and mobile internet connections, which today reach 
even extremely remote areas, such an exchange can be implemented. Given the necessary 
tools, efforts required from the front line health care worker as well as the central experts are 
minimal. We have set up such a system in the Mapé Basin and such a system for medical 
feedback is currently also being developed by the WHO (https://who.telederm.org/). As 
illustrated by our experience in Bankim, feedback to the periphery, supervision and guidelines 
on how the feedback is to be used, will be crucial for the success of the system. In addition to 
improving clinical diagnosis, better local lab capacities could also help to raise diagnostic 
accuracy although the applied test will have to be simple and sufficiently sensitive and 
specific to merit an effect on treatment decisions. Serological markers have shown to be 
suitable to detect exposure to M. ulcerans but are not suitable to detect active disease (Chapter 
3). The development of a simple routine method to detect the M. ulcerans specific toxin 
mycolactone, is hampered by technical limitations, e.g. difficulties to produce sufficiently 
sensitive antibodies against the lipid structure. On the other hand diagnostic tests that detect 
M. ulcerans protein antigens in lesions by ELISA and eventually lateral flow assays look 
much more promising and may be available for field testing in the next few months (K. 
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Röltgen, personal communication). If high sensitivity and specificity can be achieved, such a 
rapid diagnostic test could greatly support differential diagnosis and be used to indicate to 
health care professionals if alternatives to the BU diagnosis need to be considered or if the 
clinical diagnosis of BU was correct. 
Finally, in addition to improving BU diagnosis, the much more difficult to address 
issue will be to provide primary health care facilities with the necessary skills and capacity to 
care for patients suffering from the other diseases, i.e. cases that turn out not to be BU. 
Differential diagnoses, such as cancer, may require lengthy, complicated and expensive 
treatments that are not available in peripheral health care facilities. The welcome fact that BU 
treatment comes at no cost for the patient, may here even create some wrong incentives for 
health care providers causing them to offer this treatment to poor patients although in reality 
they would require an expensive treatment only available in a faraway referral hospital which 
is not assessable to them. Only broad range health system strengthening, with local capacity 
building and a functioning referral systems, would be able to address this concern. 
 
7.4 Reservoir of M. ulcerans in the environment and site of BU transmission 
Despite more than half a century of research, both the environmental reservoir and the 
mode of transmission of M. ulcerans remain to be identified. In fact, these two crucial 
elements of BU epidemiology are arguably the biggest mysteries of BU that remain to be 
resolved. Studies dating as far back as the early 1970’s concluded that human-to-human 
spread of M. ulcerans was improbable and transmission from an environmental source much 
more likely [4,29,30]. A landmark study in the early 1970’s by the Uganda Buruli Group 
further showed that BU transmission is very focalized and areas with high and low incidence 
can be just a few km apart [4]. To elucidate BU transmission it is therefore essential to have a 
very detailed understanding of the distribution of BU cases in an area to be able to identify 
foci of infection. Through detailed investigations in the Mapé Basin, we have been able to 
describe such areas of high disease incidence. Specifically, we have identified small 
communities along the Mbam River with several cases which may represent suitable locations 
to study BU transmission (Chapter 2). In our analysis the village of Bankim also appeared to 
be a focus of BU transmission. However many of the BU patients from there travelled 
considerable distances to their farms (Chapter 4) and could have gotten infected in these much 
more rural areas. In addition to realizing that BU transmission is very focalize, investigation 
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by the Uganda Buruli Group and other researchers showed that close proximity to slow 
flowing or stagnant water and contact with open water sources are risk factors for BU [4,29]. 
Investigations in various BU endemic regions have repeatedly re-confirmed this risk factor 
[31]. Poor wound care and failure to wear protective clothing have also been confirmed as 
risk factors for BU in several studies but other than that no conclusive information could be 
obtained from case-control studies [31]. Analysing the age range of people most affected by 
BU (see below), including sufficient numbers of patients and only including laboratory 
confirmed patients may help to identify new risk factors for BU in the future. 
There is evidence that man-made alterations of the environment may increase the 
incidence of BU [32]. Based on the distribution of cases in the Mapé Basin, the reservoir 
associated with the Mapé Dam does not appear to play a major direct role in BU transmission 
in the region. We found that patients were more likely to be oriented towards the Mbam River 
as opposed to the Mapé Dam reservoir for their agricultural activities (Chapter 4). Further, 
there are only few cases of BU originating from the villages on the shore of the Mapé Dam in 
the central and northern part of the Bankim HD. On the other hand, there are patients living in 
the very small settlements located along the Mbam River (Chapter 2). For the risk of BU 
associated with water bodies, it must be noted that that proximity but not direct contact with 
the water appears to increase risk [29]. It is therefore possible that BU transmission takes 
place at water bodies much smaller than the Mbam River or the Mapé Dam close to the 
villages [29]. Overall, the collection of detailed geographic information of the origin of 
patients is a first step towards the tracing of BU transmission. Results help to decide where 
more targeted research should take place and which communities should be included in risk 
factor studies. With regards to risk factors of BU, it is also worth noting that given the fact 
that inhabitants of BU endemic village all live in very similar environments and perform 
similar work, it is likely that human genetic host factors also play a role in determining the 
susceptibility of an individual for BU. To date one host genetic risk factor study has 
investigated the role of a marker that has been associated with tuberculosis and leprosy. The 
study found that the SLC11A1 gene, which codes for the natural resistance-associated 
macrophage protein, plays a role in the susceptibility of an individual to develop BU [33]. A 
further such study to identify host genetic risk factors of BU in Ghana has been initiated and 
samples are currently being processed for analysis (G. Pluschke, personal communication). 
In addition to identifying foci of transmission in the Mapé Basin, our detailed 
epidemiological investigation has also reconfirmed that most BU cases are between 5 and 15 
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years old (Chapter 2). Specifically 46.6% of the 88 patients studied were in this age rage with 
12.5% being younger and 40.9% being older. Based on the population age distribution which 
we determined in the exhaustive survey, we were able to calculate the age adjusted 
cumulative BU incidence rate for the cases that lived in the Bankim HD (Chapter 2). The 
distribution of this cumulative incidence rate revealed that the age adjusted cumulative 
incidence rate of BU was lowest among the zero to less than 4 year-olds with only 5.7% of the 
cases being in this age range. This is astonishing given that roughly 10’600 small children 
below the age of four, which represented 22.3% of the entire population, were living in the 
Bankim HD in early 2010 (Chapter 2). A similar underrepresentation of below 5 year-olds 
among BU cases was already reported in the early 1970’s for cases from Uganda [4] and in a 
large scale study with 268 laboratory confirmed cases of BU from Ghana in 2009 [34]. 
However both of these studies do not go on to discuss this observation any further and even 
reviews commonly focus on the fact that BU affects mostly children between the age of 5 to 
15 without any further considerations on why below 5 year-olds are less affected by the 
disease [35]. However, the population-adjusted age distribution of BU cases may in fact 
provide hints as to how and where transmission of the disease takes place. The age 
distribution appears to indicate that most below 5 year-olds do not engage in activities that 
expose an individual to the risk of contracting BU. Very young children are likely to stay 
closer to their homes and have reduced direct contact with the environment away from home, 
since they are carried to cover larger distances. Once children are more than four to five years 
old, they seem to be exposed much more intensely to M. ulcerans and start to contract the 
disease. Differences in the behaviour of below and above 4-5 year-olds may explain the 
difference in incidence of BU. A transition in behaviour around this age includes starting to 
walk around the villages and further away from home, going to the family farm to help with 
some basic activities and going to the village water sites to collect water for household use. 
Further studies are required to investigate to which extend the movement radius between 
children less than 4-5 years old is different from that of older ones and how this is increasing 
the risk of contracting BU. 
Approaching the issue of exposure to BU from an immunological angle, Diaz et al. in 
our laboratory have previously been able to show that, although an antibody response specific 
for the M. ulcerans 18kDa small heat shock protein (shsp) cannot be used for diagnostic 
purposes, antibody titres against this antigen can be used to identify individuals or 
communities that have been exposed to the pathogen [36,37]. In the course of the work 
presented here, we have expanded, for the first time, the testing of sera to children below the 
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age of five and in addition to collecting sera from several hundred patients and controls from 
Ghana we also collected sera from multiple individuals living in the village of Mbandji 2, 
which is located in the Bankim Rural Health Area of the Bankim HD (Chapter 3). When sera 
were tested for anti-18kDa shsp antibody responses, similar to the age distribution of BU 
cases, children under the age of 6 were much less likely to be seropositive. This trend applied 
across both the Ghanaian and the Cameroonian endemic sites, indicating that there could be a 
similar behavioural transition between the very young and the older children in both BU 
endemic settings leading to seroconversion above a certain age (Chapter 3). Correlating the 
movement radius to the serological status of young children growing up in BU endemic areas 
may help to identify the activities that lead to increased exposure to M. ulcerans. 
With the potential of BU transmission taking place away from the homes of the 
patients and at sites of environmental contact, we set out to study such sites in detail (Chapter 
4). Specifically we visited and sampled the farms as well as the village and farm water sites of 
laboratory confirmed BU cases and attempted to detect M. ulcerans at these locations. 
Alongside the ability to culture M. ulcerans from the wounds of patients, attempts have been 
made to culture the pathogen from the environment to study its distribution in nature. These 
efforts remained unsuccessful until very recently when for the first time an environmental 
isolate of M. ulcerans could be cultured from an aquatic Hemiptera from Benin, by passaging 
through mice [38]. Unfortunately this approach is not suitable for routine use and because of 
these difficulties our current understanding of the distribution of M. ulcerans in the 
environment is based on the detection of M. ulcerans specific gene sequences by PCR. 
Although very sensitive, PCR has several caveats that need to be considered when 
interpreting the results. Firstly, the detection of M. ulcerans DNA in a sample does not 
necessarily mean that the corresponding sampled contained viable bacteria. Even in the 
complex matrix of environmental samples, DNA is stable and may persist after the bacteria 
have died [39]. Secondly, there is a great risk of cross-contamination between samples, 
especially if many samples are processed, all steps of the processing are conducted in the 
same room or if conventional as opposed to real-time PCR is used. This risk has been 
highlighted in a study on the distribution M. ulcerans DNA in the environment which in 
contrast to earlier studies [40] only found few M. ulcerans positive sites [41]. The risk of 
contamination when analysing M. ulcerans samples was further raised by a quality control 
trial testing the accuracy of laboratories analysing environmental and clinical samples for the 
presence of IS2404 (M. Eddyani et al., PLoSOne, submitted). An additional issue that has to 
be considered when interpreting environmental PCR results and that has not been sufficiently 
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addressed in the past, is the fact that there are microorganisms other than M. ulcerans that are 
IS2404 positive [42]. Only through the additional detection of the KR and IS2606 gene 
sequences and a specific difference between the multiplicity of IS2404 and IS2606 sequences 
can one conclude that the environment contains DNA originating from the ecovar of M. 
ulcerans that causes human disease [42,43]. Applying stringent conditions to ensure reliability 
of the RT-PCR results, we identified three M. ulcerans DNA positive village water sites used 
by laboratory confirmed BU patients in the Mapé Basin (Chapter 4). Further we found one 
positive duck faecal sample. From these findings we decided to study one of the positive 
village water sites as well as a close by negative site in great detail and over time. In doing so 
we identified detritus at the positive permanent village water site which may represent an 
environmental reservoir of M. ulcerans (Chapter 4). Interestingly an early BU transmission 
study on tsetse fly control workers showed that the use of small permanent water bodies to 
obtain water for household purposes increased the risk of getting BU [29]. Given the very 
focal distribution of M. ulcerans DNA in the environment that we have observed (Chapter 4), 
it is possible that we missed some positive sites and it may be valuable to examine further 
village water sites in villages that have recently reported cases as well as close by villages that 
have not reported any cases. If the role of village water sites is further confirmed, it would be 
interesting to examine the contact patterns of children of different ages with these sites. The 
positive waterfowl faecal sample raises the possibility of an animal reservoir of M. ulcerans, 
which unlike in Australia [44] has thus for not been identified in Africa [45], and also merits 
further investigation (Chapter 4). 
By phylogeographic analysis of M. ulcerans isolates it may be possible to further 
narrow down the environment in which patient acquired their infection and to elucidate 
transmission networks of BU. Röltgen et al. have previously shown that even in a BU 
endemic area of less than 1000 km2, strains of M. ulcerans can be differentiated based on 
single nucleotide polymorphism (SNP) typing [46]. From a total of 33 patients from the Mapé 
Basin we have isolated M. ulcerans and whole genome sequenced the isolates. Genomic data 
will allow for detailed phylogeographic strain-typing (Appendix 1). Of the same patients, we 
also collected detailed information on where they lived and worked for the year before the 
onset of BU symptoms (Appendix 1). Analysis of the strains is still on-going and we expect 
the phylogeographic analysis to further elucidate transmission by identifying groups of 
patients infected by the same haplotype. This may reveal whether patients are more likely 
infected around their homes or at their place of work (Appendix 1). Having typed the clinical 
isolates circulating in the Mapé Dam area, it would be of great interest to investigate if the M. 
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ulcerans in the environment, which we detected by RT-PCR (Chapter 4), have the same 
haplotype as the clinical isolates. As mentioned above, such investigations are however 
hampered by the fact that the routine culturing of M. ulcerans from the environment is an 
unsolved problem. Attempts to recover M. ulcerans from PCR positive environmental 
samples are on-going and with the right decontamination method and quick processing of the 
samples, this may be possible. As an alternative, next-generation DNA sequencing and 
metagenomic analysis could also be an option to type M. ulcerans strains in the environment 
[47,48]. However working with soil as a matrix for such analysis is not trivial and specific 
measures must be taken to ensure efficient analysis [49]. Comparative analysis of M. ulcerans 
positive and negative samples may further provide interesting insights on which types of 
bacteria or other organism share the specific ecological niche that M. ulcerans has adapted to. 
In addition to the unknown environmental reservoir of M. ulcerans, the mode of 
transmission of the pathogen to humans also remains to be identified. Initial studies believed 
that small injuries likely play a major role in getting the pathogen into the skin of the patients 
[2,4,50,51]. However, since the hypothesis of contracting BU through skin trauma could not 
be fully established, speculations on the mode of transmission of BU continued. However, 
because of the long incubation period, estimated to be several months, patients may not 
remember having had small skin injuries at the site of their BU lesion. Interestingly, M. 
marinum, the closest relative and ancestor of M. ulcerans, occasionally causes human 
infection by inoculation through small skin lesions which are often not remembered by the 
patient [52]. In 1999, Portaels et al. were the first to suggest that insects could be involved in 
the transmission of BU. Specifically they tested plants and water bugs from BU endemic areas 
from Benin and Ghana and found all plants to be PCR negative but some water bugs were 
positive. Based on these findings they suggested that the water bugs could be involved in the 
transmission of BU by being passive reservoirs for the pathogen or by transferring M. 
ulcerans to human patients by bites or by contaminating trauma at skin sites with their faeces 
[53]. Several follow-up studies have argued for a direct implication of water bugs in BU 
transmission [54–56]. However their role has also repeatedly been questioned and a key role 
of water bugs in transmission of M. ulcerans seems rather unlikely [31,57]. More recently, 
mosquitos have been suggested to play a role in the transmission of M. ulcerans in Southern 
Australia [58]. However, certain insects may just accumulate M. ulcerans from the 
environment [53] and the detection of M. ulcerans DNA in insects may therefore simply be a 
proxy for contact with a close-by positive environmental site and not necessarily imply that 
the insects are involved in human inoculation with M. ulcerans. In addition to trying to 
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directly identify the vector of M. ulcerans, epidemiological data have also been used to 
narrow down the mode of transmission of BU. Similar to an epidemiological study in Kinyara 
in 1971 in Uganda [4], we attempted to contribute to the understanding of BU transmission by 
analysing the distribution of BU lesions on the body of the patients (Chapter 2). For this 
purpose we developed a novel tool for the analysis of lesion distribution by methods usually 
used for geographic mapping. Having both the option of direct inoculation into the skin and 
transmission by insect vectors in mind, we compared the observed lesion distribution with the 
distribution of small skin injuries in children and the biting sites of insects. Neither of the 
distributions clearly matched the BU lesion distribution we observed. Interestingly however 
there was a difference in the distribution of the lesions in children compared to adults with 
lesion in adults being more focused on the lower legs (Chapter 2). A similar trend was also 
observed by the Uganda Buruli Group in 1971 in male patients. In this study, which included 
220 patients, however researchers also found a striking difference between male and female 
patients which they attribute to variations in the activities performed by the two genders [4]. 
In contrast, in our study of a smaller cohort of patients, we did not observe a significant 
difference between male and female patients (Chapter 2). Based on our findings, and as also 
suggested by other studies [31,53], we concluded that there may be multiple modes of 
transmission of BU. Further, in view of the difference in the onset of immune responses 
against M. ulcerans and P. falciparum that we observed in young children (Chapter 3), it 
appears that a potential insect vector for BU would be less commonly associated with the 
houses of patients compared to the malaria transmitting mosquitoes. The focal transmission 
pattern observed by Röltgen et al. [46] furthermore indicates that BU transmitting insects 
would need to be travelling only short distances. The role of water bugs has also been put into 
question based on the fact that these insects do not normally bite humans and bites are quite 
painful [31]. However, current evidence cannot exclude the role of insects in BU transmission 
and studies identify biting insects close to PCR positive environmental contact sites of BU 
patients may further help to explain the biggest mystery in BU research. Similar to the study 
conducted by Labbé and Caouette [59] on the distribution of small skin injuries in Canadian 
children, it would be interesting to monitor the distribution of skin injuries in individuals of 
all ages living in BU endemic areas. Given the differences in clothing worn and activities 
performed, the distribution of skin injuries in BU endemic areas is likely to be strikingly 
different from that of inhabitants of the developed world and the northern hemisphere. 
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7.5 Conclusion 
Prevalence of BU, even in highly endemic communities, is far below the 30% or even 
over 50% reported for malaria and soil-transmitted helminths in communities similar to those 
affected by BU [60–62]. However the impact of a BU infection on an individual patients and 
their family is devastating. Even small BU lesions require lengthy treatment, especially large 
wounds often lead to permanent disabilities and all lesion types inevitably lead to some 
disruption in the productivity of the patient and possibly a caretaker. Although current 
antibiotic treatment can cure the M. ulcerans infection, wound management including the 
often required skin transplantations represents a major challenge and burden for the health 
system in rural Africa. To reduce the burden of BU on the individual patients and the affected 
communities, sensitization efforts are needed to promote early case reporting, capacities of 
treatment facilities such as their diagnostic capacity and the quality of care they provide, need 
to be strengthened. Further, research is required to elucidate the mode of transmission of BU 
so that populations living in endemic areas can be educated on how to prevent infection. 
In this thesis, aspects of BU control and transmission were investigated in the Mapé 
Basin of Cameroon. Specifically, by investigating the age distribution of BU cases, we found 
that the number of cases in under five-year-olds is disproportionately low. In accordance with 
this we were further able to show that children below the age of six are less likely to have 
antibodies raised against M. ulcerans antigens compared to older children in the same 
communities. These findings indicate that transmission of BU takes place at locations away 
from home and beyond the small movement radius of very young children. Furthermore, close 
environmental contact may be required for transmission; something small children, that are 
being carried to get further away from their homes, are also experiencing less than older 
children. Indeed, we have identified three village water sites where M. ulcerans appeared to 
be present. Furthermore at one of these sites, which we studied in detail, we found that DNA 
of the pathogen persists over a period of more than two years. The RT-PCR positive detritus 
identified at this location may therefore represent an ecological niche and reservoir of M. 
ulcerans. On-going genetic analysis of the M. ulcerans strain circulating in the Mapé Basin 
will help to further elucidate transmission pathways and provide hints as to where the patients 
may have acquired the infection. In addition to studying these epidemiological and 
environmental aspects of BU, the work of this thesis highlighted the importance of correct 
differential diagnosis by reporting on a case of cutaneous tuberculosis that was initially 
misdiagnosed as BU. Further by large scale culturing effort we have been able to optimize 
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procedures for the primary isolation of M. ulcerans from human lesions and thereby facilitate 
the creation of strain collections that will enable further research on BU transmission and M. 
ulcerans pathogenicity. 
Overall the research conducted in the course of this thesis, has increased our 
understanding of BU epidemiology and provides a solid basis for more targeted investigations 
into the transmission of M. ulcerans in the African context. Multicentre, comparative and 
interdisciplinary studies with large patient numbers stand the highest chance of resolving the 
remaining mysteries of BU. 
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Appendix 1. M. ulcerans genetic diversity in the Mapé Basin 
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A1.1 Project Summary and Plan 
Buruli ulcer (BU) is a neglected tropical disease caused by Mycobacterium ulcerans 
that has been reported from over 30 countries with most cases originating from West Africa. 
The necrotising disease of the skin and subcutaneous tissue presents with a wide range of 
clinical forms including non-ulcerative and ulcerative lesions. Studies on the transmission of 
BU conclude that M. ulcerans is an environmental pathogen, human-to-human transmission is 
unlikely (1) and transmission may occur by an insect vector (2) or by direct inoculation of the 
pathogen into small skin wounds (3). However, despite years of investigations in numerous 
endemic areas, both the exact mode of transmission and the environmental reservoir of the 
pathogen remain to be identified and parallel modes of transmission may be possible (4, 5). 
Various results of our studies on BU patients in the Mapé Basin of Cameroon provide 
further clues towards the identification of the environmental reservoir of M. ulcerans. Firstly, 
by comparing the age distribution of 88 RT-PCR confirmed cases with the age distribution of 
the local population, we found that children below the age of 4 are vastly underrepresented 
among BU cases (5). Similar trends in the age distribution of BU cases have also been 
observed in Ghana (6). Further, in a sero-epidemiological study of young children living in 
the Mapé Basin and a BU endemic area in Ghana we have found that children below the age 
of 6 are less likely to have an antibody response towards M. ulcerans compared to older aged 
children (K. Röltgen et al., in preparation). Together these findings indicate that very young 
children are less exposed to risk factors of BU and that transmission likely takes place outside 
of the small motion radius of these very young children. Further transmission appears to 
require close contact with the environment, something very small children that are being 
carried to go further away from their homes would not experience. To investigate this 
hypothesis, we studied locations of regular environmental contact of laboratory confirmed BU 
patients and examined these locations for the presence of M. ulcerans DNA. We found that 
the soil around three permanent village water sites in the Bankim Health District (HD) were 
positive and at one longitudinally studied village water site, we identified underwater detritus 
as the potential reservoir of M. ulcerans (M. Bratschi et al., in preparation). In the course of 
the same study, we also investigated where BU patients have their homes and farms and 
found that patients are fairly mobile, travel up to 15km to get from their home to their farm 
and at times spend several months living at their farms (M. Bratschi et al., in preparation). 
With this wide motion radius of the patients there are several potential places where they 
could have contracted the infection. 
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The study described here, aims at further elucidating transmission of BU in the Mapé 
Basin by genomic analysis of the circulating M. ulcerans strains. Similar to a recent study 
conducted in Ghana, which showed that single nucleotide polymorphism (SNP) typing of M. 
ulcerans can be used for geographic clustering in an area of less than 1000km2 (7), we plan to 
phylogeographically cluster strains and attempt to determine where the patients are most 
likely to have been infected. For the analysis, we isolated and whole genome sequenced a 
total of 86 M. ulcerans strains from 45 patients. In addition to strains from 33 patients from 
the Mapé Basin, this collection also included isolates from one patient from the Foumban HD 
which is located to the South East of the Mapé Basin and strains from 11 BU patients from 
two endemic areas in the South of Cameroon (Figure A1.1). For the cases from the Mapé 
Basin we also identified their exact place of residence and for 31 of these patients we mapped 
the location of the farms where they worked (Figure A1.2). 
Whole genome sequencing of the strains has recently been finished and bioinformatic 
data analysis has been initiated. Methods that can be used to elucidate transmission networks 
of environmental pathogens will be used to performed detailed phylogeographic analysis of 
the strains isolated from the Mapé Basin. Further, comparisons between the strains from the 
Mapé Basin and those from Southern Cameroon will help to further our knowledge of M. 
ulcerans genetic diversity in the West African country. In addition to the strains that can be 
used for in-depth phylogeographic analysis, the sequenced isolates also include strains that 
were collected from two distant lesions from one patient and isolates obtained from a single 
patient over a period of more than a year. These strains allow us to investigate if patients with 
multiple BU lesions were infected multiple times or if a single infection can lead to multiple 
lesions. Further these strains may help to determine the in vivo mutation rate of M. ulcerans in 
the course of a human infection. 
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A1.2 Figures 
 
Figure A1.1: M. ulcerans strains per district. 
To study M. ulcerans diversity in Cameroon, we collected 86 strains from 44 patients from various 
parts of the country. Districts of origin of the patients from whom strains were isolated are shown. 
 
 
Figure A1.2: Geographic origin of patients from whom M. ulcerans strains were isolated. 
Map shows the homes (black points) of the 33 patients from the Mapé Basin BU endemic area from which M. 
ulcerans strains were isolated for phylogeographic analysis. Locations of the farms (green points) of 31 of the 
patients were also mapped. Homes and farms of the same patient are connected. Locations of the 6 health centres 
and the Bankim district hospital are depicted with red crosses. 
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